WO2021078132A1 - Inhibitors of mtor-mediated induction of autophagy - Google Patents
Inhibitors of mtor-mediated induction of autophagy Download PDFInfo
- Publication number
- WO2021078132A1 WO2021078132A1 PCT/CN2020/122341 CN2020122341W WO2021078132A1 WO 2021078132 A1 WO2021078132 A1 WO 2021078132A1 CN 2020122341 W CN2020122341 W CN 2020122341W WO 2021078132 A1 WO2021078132 A1 WO 2021078132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mass
- pyrrolidin
- yield
- triazaspiro
- Prior art date
Links
- 230000004900 autophagic degradation Effects 0.000 title claims abstract description 32
- 230000006698 induction Effects 0.000 title claims abstract description 20
- 230000001404 mediated effect Effects 0.000 title claims abstract description 14
- 239000003112 inhibitor Substances 0.000 title description 4
- 101150097381 Mtor gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 532
- 238000000034 method Methods 0.000 claims abstract description 222
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 230000006907 apoptotic process Effects 0.000 claims abstract description 38
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
- 230000010410 reperfusion Effects 0.000 claims abstract description 14
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 12
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 12
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000036541 health Effects 0.000 claims abstract description 4
- 230000006872 improvement Effects 0.000 claims abstract description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract 4
- -1 2, 3-dihydro-indenyl Chemical group 0.000 claims description 88
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 45
- 229940124530 sulfonamide Drugs 0.000 abstract description 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 204
- 238000005160 1H NMR spectroscopy Methods 0.000 description 193
- 239000007787 solid Substances 0.000 description 142
- 239000000843 powder Substances 0.000 description 83
- SJOFNNGTPDWPCJ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=NC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=NC=CC=C1)=O SJOFNNGTPDWPCJ-UHFFFAOYSA-N 0.000 description 68
- 239000011541 reaction mixture Substances 0.000 description 65
- 239000000243 solution Substances 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000012043 crude product Substances 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 26
- 239000012267 brine Substances 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000004698 Polyethylene Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000006676 mitochondrial damage Effects 0.000 description 11
- 230000002438 mitochondrial effect Effects 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 108700000707 bcl-2-Associated X Proteins 0.000 description 9
- 102000055102 bcl-2-Associated X Human genes 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- DATXHLPRESKQJK-UHFFFAOYSA-N 4-pyrrolidin-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCCC1 DATXHLPRESKQJK-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 101100325747 Mus musculus Bak1 gene Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 7
- 108700039689 bcl-2 Homologous Antagonist-Killer Proteins 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 5
- GMKMRTJMAYMLBK-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N(C)C)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N(C)C)CC)=O GMKMRTJMAYMLBK-UHFFFAOYSA-N 0.000 description 5
- ITQTVFOUWHRQKV-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1OCC)C#N)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1OCC)C#N)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O ITQTVFOUWHRQKV-UHFFFAOYSA-N 0.000 description 5
- 102100030497 Cytochrome c Human genes 0.000 description 5
- 108010075031 Cytochromes c Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- IQFNVMUMVPHNSL-UHFFFAOYSA-N 8-benzyl-3-(2,3-dihydro-1h-inden-2-yl)-1-ethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CCN1C(=O)N(C2CC3=CC=CC=C3C2)C(=O)C1(CC1)CCN1CC1=CC=CC=C1 IQFNVMUMVPHNSL-UHFFFAOYSA-N 0.000 description 4
- KRBSXJCHGHCJNO-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=C(C=C1)C1=CC(=CC=C1)C#N)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=C(C=C1)C1=CC(=CC=C1)C#N)OC)=O KRBSXJCHGHCJNO-UHFFFAOYSA-N 0.000 description 4
- GDGQSEXBMYGBMN-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC2=CC=CC=C2C=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC2=CC=CC=C2C=C1)=O GDGQSEXBMYGBMN-UHFFFAOYSA-N 0.000 description 4
- XUOLDAYHNDEINU-UHFFFAOYSA-N C1(=CC=C(C=C1)CN1CCC2(C(N(C(N2CC)=O)C2CC3=CC=CC=C3C2)=O)CC1)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)CN1CCC2(C(N(C(N2CC)=O)C2CC3=CC=CC=C3C2)=O)CC1)C1=CC=CC=C1 XUOLDAYHNDEINU-UHFFFAOYSA-N 0.000 description 4
- BTLJUFYTBULUHO-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCO)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCO)=O BTLJUFYTBULUHO-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- WGDUBDZBWQNSSA-UHFFFAOYSA-N ClC1=C(C=CC(=N1)C=1C=C(C#N)C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=N1)C=1C=C(C#N)C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O WGDUBDZBWQNSSA-UHFFFAOYSA-N 0.000 description 4
- MJTZCYCTKQGEJO-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC=C1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O MJTZCYCTKQGEJO-UHFFFAOYSA-N 0.000 description 4
- KTVGQSAAKHZJAT-UHFFFAOYSA-N ClC1=CC(=NC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C(=CC(=C(C#N)C=1)F)OCC Chemical compound ClC1=CC(=NC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C(=CC(=C(C#N)C=1)F)OCC KTVGQSAAKHZJAT-UHFFFAOYSA-N 0.000 description 4
- KXQUTDLOQZGPMO-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C=1C=C(C#N)C=CN=1)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C=1C=C(C#N)C=CN=1)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O KXQUTDLOQZGPMO-UHFFFAOYSA-N 0.000 description 4
- QFXNKRCYVOKQSP-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OC(C)C Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OC(C)C QFXNKRCYVOKQSP-UHFFFAOYSA-N 0.000 description 4
- WMZDEDUVHBLKHE-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1)OC)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1)OC)C#N WMZDEDUVHBLKHE-UHFFFAOYSA-N 0.000 description 4
- DNADOGOXFAWKTK-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)OCC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)OCC DNADOGOXFAWKTK-UHFFFAOYSA-N 0.000 description 4
- PKMIJZRQQCFUEP-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC(=N1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC(=N1)C#N PKMIJZRQQCFUEP-UHFFFAOYSA-N 0.000 description 4
- HXHBWEKWPFDQQQ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=NC=C(C#N)C=1 Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=NC=C(C#N)C=1 HXHBWEKWPFDQQQ-UHFFFAOYSA-N 0.000 description 4
- JEUYZXWEOMVGKQ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CCC(CC1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CCC(CC1)C#N JEUYZXWEOMVGKQ-UHFFFAOYSA-N 0.000 description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011278 co-treatment Methods 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- RDDNGEWEYVTDBP-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-2-yl)-1-ethyl-8-[(4-pyrrolidin-1-ylphenyl)methyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CCN1C(=O)N(C2CC3=CC=CC=C3C2)C(=O)C1(CC1)CCN1CC(C=C1)=CC=C1N1CCCC1 RDDNGEWEYVTDBP-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZKNVYUDDVNIHHU-UHFFFAOYSA-N C(C)(=O)C=1C=C(C=CC=1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound C(C)(=O)C=1C=C(C=CC=1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl ZKNVYUDDVNIHHU-UHFFFAOYSA-N 0.000 description 3
- YOYDXNNLGDJXBU-UHFFFAOYSA-N C(C)(=O)NC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound C(C)(=O)NC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl YOYDXNNLGDJXBU-UHFFFAOYSA-N 0.000 description 3
- RRGHQMLWSLQICK-UHFFFAOYSA-N C(C)(C)(C)C=1C=C(C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound C(C)(C)(C)C=1C=C(C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O RRGHQMLWSLQICK-UHFFFAOYSA-N 0.000 description 3
- BGEKERGTGALIMD-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)C#N)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)C#N)=O BGEKERGTGALIMD-UHFFFAOYSA-N 0.000 description 3
- SVDZSIPFTFACRX-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)C)=O SVDZSIPFTFACRX-UHFFFAOYSA-N 0.000 description 3
- YKADNEAWFABYKL-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)F)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)F)=O YKADNEAWFABYKL-UHFFFAOYSA-N 0.000 description 3
- OZGACANWWMQAJG-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1)C1=CC(=CC=C1)C#N)OC)=O OZGACANWWMQAJG-UHFFFAOYSA-N 0.000 description 3
- MVCIJPZAPKLIIV-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1F)C1=CC(=CC=C1)C#N)F)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=C(C=C1F)C1=CC(=CC=C1)C#N)F)=O MVCIJPZAPKLIIV-UHFFFAOYSA-N 0.000 description 3
- LHLWBIZCEBPNPZ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=CC(=C1)OC)C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C=CC(=C1)OC)C)=O LHLWBIZCEBPNPZ-UHFFFAOYSA-N 0.000 description 3
- DUFCQJWICANNEG-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=C(C=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=C(C=CC=C1)OC)=O DUFCQJWICANNEG-UHFFFAOYSA-N 0.000 description 3
- ILSNQVXHJUTDDD-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)C(=O)N)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)C(=O)N)=O ILSNQVXHJUTDDD-UHFFFAOYSA-N 0.000 description 3
- IJVZIAAJHRMLPC-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)OC)=O IJVZIAAJHRMLPC-UHFFFAOYSA-N 0.000 description 3
- RVKFOBHXHRZKOM-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C)=O RVKFOBHXHRZKOM-UHFFFAOYSA-N 0.000 description 3
- SOHIFMWOUXPPIM-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)OC)=O SOHIFMWOUXPPIM-UHFFFAOYSA-N 0.000 description 3
- MEKMINSWZYQLKA-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=NC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=NC=C1)=O MEKMINSWZYQLKA-UHFFFAOYSA-N 0.000 description 3
- ZMRWBWRKHCQPDV-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=NC=CC=N1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=NC=CC=N1)=O ZMRWBWRKHCQPDV-UHFFFAOYSA-N 0.000 description 3
- PMRBRYSTBRWHIU-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1C(=CC=CC=1)C#N)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1C(=CC=CC=1)C#N)=O PMRBRYSTBRWHIU-UHFFFAOYSA-N 0.000 description 3
- LCUYPBITHKXZKA-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1C=NC=CC=1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1C=NC=CC=1)=O LCUYPBITHKXZKA-UHFFFAOYSA-N 0.000 description 3
- WIMQNTPOTKVXKZ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1C(C1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1C(C1)C1=CC=CC=C1)=O WIMQNTPOTKVXKZ-UHFFFAOYSA-N 0.000 description 3
- PWKVOLMCINYKIE-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC=C(C=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC=C(C=C1)OC)=O PWKVOLMCINYKIE-UHFFFAOYSA-N 0.000 description 3
- NYKYHFAWCRLQOF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CCC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CCC1)C1=CC=CC=C1)=O NYKYHFAWCRLQOF-UHFFFAOYSA-N 0.000 description 3
- ZHFDFGWGCUQNRL-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=C(C#N)C=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=C(C#N)C=CC=C1)=O ZHFDFGWGCUQNRL-UHFFFAOYSA-N 0.000 description 3
- VQQUWEHATYRUPD-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=C(C=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=C(C=CC=C1)OC)=O VQQUWEHATYRUPD-UHFFFAOYSA-N 0.000 description 3
- MWHZXEIAFVSEPU-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=CC=C(C#N)C=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=CC=C(C#N)C=C1)=O MWHZXEIAFVSEPU-UHFFFAOYSA-N 0.000 description 3
- AHANINUJWBSZNJ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C=1C=C(C#N)C=CC=1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C=1C=C(C#N)C=CC=1)=O AHANINUJWBSZNJ-UHFFFAOYSA-N 0.000 description 3
- LTHBMFAKXTXWFR-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)CCC1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)CCC1=CC=CC=C1)=O LTHBMFAKXTXWFR-UHFFFAOYSA-N 0.000 description 3
- LZFMMFIWAFUKCI-UHFFFAOYSA-N C1(=CCCC1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound C1(=CCCC1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O LZFMMFIWAFUKCI-UHFFFAOYSA-N 0.000 description 3
- QPLDJAQDRLJHSD-UHFFFAOYSA-N C1(CC1)C(=O)NC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound C1(CC1)C(=O)NC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl QPLDJAQDRLJHSD-UHFFFAOYSA-N 0.000 description 3
- RPHONWRGBRCNEZ-UHFFFAOYSA-N C1(CCCC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C1(CCCC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O RPHONWRGBRCNEZ-UHFFFAOYSA-N 0.000 description 3
- RMNYVTKZAKYKRF-UHFFFAOYSA-N C1=C(C=CC=2C3=CC=CC=C3CC1=2)CN1CCC2(C(N(C(N2CC)=O)C2CC3=CC=CC=C3C2)=O)CC1 Chemical compound C1=C(C=CC=2C3=CC=CC=C3CC1=2)CN1CCC2(C(N(C(N2CC)=O)C2CC3=CC=CC=C3C2)=O)CC1 RMNYVTKZAKYKRF-UHFFFAOYSA-N 0.000 description 3
- MYNJGKLMASHUTR-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C#N)C=C1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C#N)C=C1)CC)=O MYNJGKLMASHUTR-UHFFFAOYSA-N 0.000 description 3
- GSUIETBVYWUMJD-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCOC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCOC)=O GSUIETBVYWUMJD-UHFFFAOYSA-N 0.000 description 3
- XUNKESBIAHGXJE-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCOC1OCCCC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCOC1OCCCC1)=O XUNKESBIAHGXJE-UHFFFAOYSA-N 0.000 description 3
- HDVNAEILJYAIDY-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCCC1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCCC1)CC)=O HDVNAEILJYAIDY-UHFFFAOYSA-N 0.000 description 3
- NTZVXPGLZBIJNY-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=C(C=1)F)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=C(C=1)F)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O NTZVXPGLZBIJNY-UHFFFAOYSA-N 0.000 description 3
- CXQHKFCERGAOAF-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=CC=1)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=CC=1)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O CXQHKFCERGAOAF-UHFFFAOYSA-N 0.000 description 3
- GQYAJJWSKRYIAX-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=CC=1OCC)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=C(C(=N1)C=1C=C(C#N)C=CC=1OCC)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O GQYAJJWSKRYIAX-UHFFFAOYSA-N 0.000 description 3
- QUSNVXOPPIQELX-UHFFFAOYSA-N ClC1=C(C=C(C(=N1)C=1C=CC(=C(C#N)C=1)F)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=C(C(=N1)C=1C=CC(=C(C#N)C=1)F)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O QUSNVXOPPIQELX-UHFFFAOYSA-N 0.000 description 3
- JUMVYZWWEITTQG-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1C=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=C1)N1C=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O JUMVYZWWEITTQG-UHFFFAOYSA-N 0.000 description 3
- UGPKNMFYNFZNRO-UHFFFAOYSA-N ClC1=C(C=CC(=C1Cl)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 Chemical compound ClC1=C(C=CC(=C1Cl)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 UGPKNMFYNFZNRO-UHFFFAOYSA-N 0.000 description 3
- AWNDFYYQRVLEEH-UHFFFAOYSA-N ClC1=C(C=CC(=N1)C=1C(=CC(=C(C#N)C=1)F)OCC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=N1)C=1C(=CC(=C(C#N)C=1)F)OCC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O AWNDFYYQRVLEEH-UHFFFAOYSA-N 0.000 description 3
- MBPGBPPGGNOLRF-UHFFFAOYSA-N ClC1=C(C=CC(=N1)C=1C=C(C#N)C=C(C=1OCC)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=N1)C=1C=C(C#N)C=C(C=1OCC)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O MBPGBPPGGNOLRF-UHFFFAOYSA-N 0.000 description 3
- GKMDUFFVXPLPSW-UHFFFAOYSA-N ClC1=C(C=CC(=N1)C=1C=CC(=C(C#N)C=1)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=N1)C=1C=CC(=C(C#N)C=1)F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O GKMDUFFVXPLPSW-UHFFFAOYSA-N 0.000 description 3
- OBASGRKADJDYHG-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound ClC1=C(C=CC=C1)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl OBASGRKADJDYHG-UHFFFAOYSA-N 0.000 description 3
- QWLWTZSBYBQBBD-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1CC(CC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC=C1)C1CC(CC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O QWLWTZSBYBQBBD-UHFFFAOYSA-N 0.000 description 3
- WBSCHOOJUBZDOH-UHFFFAOYSA-N ClC1=C(C=CC=C1)N1CC(CC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC=C1)N1CC(CC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O WBSCHOOJUBZDOH-UHFFFAOYSA-N 0.000 description 3
- HNBAZULYWLLVSW-UHFFFAOYSA-N ClC1=C(C=CC=C1OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC=C1OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O HNBAZULYWLLVSW-UHFFFAOYSA-N 0.000 description 3
- CPUSVMLBFSIYDV-UHFFFAOYSA-N ClC1=CC(=NC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CC=1OCC Chemical compound ClC1=CC(=NC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CC=1OCC CPUSVMLBFSIYDV-UHFFFAOYSA-N 0.000 description 3
- IEXKDUNGFXBYGN-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=CC(=C1)F)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=CC(=C1)F)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O IEXKDUNGFXBYGN-UHFFFAOYSA-N 0.000 description 3
- TULYKDAKCGKVCL-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O TULYKDAKCGKVCL-UHFFFAOYSA-N 0.000 description 3
- YMYVASQAKXMJPL-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=NC=C1)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=NC=C1)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O YMYVASQAKXMJPL-UHFFFAOYSA-N 0.000 description 3
- YKCJNLKDXCJQNC-UHFFFAOYSA-N ClC=1C=C(C=C(C=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C)C1=CC(=CC=C1)C#N Chemical compound ClC=1C=C(C=C(C=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C)C1=CC(=CC=C1)C#N YKCJNLKDXCJQNC-UHFFFAOYSA-N 0.000 description 3
- PLSWWNUEJXXJJS-UHFFFAOYSA-N ClC=1C=C(C=C(C=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC=CC=C1 Chemical compound ClC=1C=C(C=C(C=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC=CC=C1 PLSWWNUEJXXJJS-UHFFFAOYSA-N 0.000 description 3
- QIAJFPCCOQSEAU-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C(=CC=C1)C#N)OC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C(=CC=C1)C#N)OC QIAJFPCCOQSEAU-UHFFFAOYSA-N 0.000 description 3
- ZPYRBAQENHYPLO-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)C Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)C ZPYRBAQENHYPLO-UHFFFAOYSA-N 0.000 description 3
- BQLVBIFQDVPUJM-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)C(F)(F)F Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)C(F)(F)F BQLVBIFQDVPUJM-UHFFFAOYSA-N 0.000 description 3
- XXRICUHJAKZTFH-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)F Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)F XXRICUHJAKZTFH-UHFFFAOYSA-N 0.000 description 3
- ZXPDRUYPRSJOLZ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OC ZXPDRUYPRSJOLZ-UHFFFAOYSA-N 0.000 description 3
- ZFSDCUQJNMYUOB-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=C(C=C1OCC)F)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=C(C=C1OCC)F)C#N ZFSDCUQJNMYUOB-UHFFFAOYSA-N 0.000 description 3
- HKUWBCKNYRJOLM-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1)F)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1)F)C#N HKUWBCKNYRJOLM-UHFFFAOYSA-N 0.000 description 3
- FKLVCUMDYUFDLP-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1OCC)F)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC(=C1OCC)F)C#N FKLVCUMDYUFDLP-UHFFFAOYSA-N 0.000 description 3
- OEZGSULSYJFGAZ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C#C Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C#C OEZGSULSYJFGAZ-UHFFFAOYSA-N 0.000 description 3
- SPJLPDBRLPUZAC-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C#N SPJLPDBRLPUZAC-UHFFFAOYSA-N 0.000 description 3
- YFXFBDLBOYAVBI-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C1CC1 Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)C1CC1 YFXFBDLBOYAVBI-UHFFFAOYSA-N 0.000 description 3
- GZVLVVJMWGANCJ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)S(=O)(=O)C Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1)S(=O)(=O)C GZVLVVJMWGANCJ-UHFFFAOYSA-N 0.000 description 3
- FAOBIDHAYVAGTH-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1OC)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1OC)C#N FAOBIDHAYVAGTH-UHFFFAOYSA-N 0.000 description 3
- WFZCBRMQSBMFTJ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=NC=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=NC=C1)C#N WFZCBRMQSBMFTJ-UHFFFAOYSA-N 0.000 description 3
- VHMFPOORVRUBPI-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=C(C=C1)C(=O)OC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=C(C=C1)C(=O)OC VHMFPOORVRUBPI-UHFFFAOYSA-N 0.000 description 3
- GGBQHTVQIKMXHG-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 GGBQHTVQIKMXHG-UHFFFAOYSA-N 0.000 description 3
- BJOONJMOMNABIM-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CN=1 Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CN=1 BJOONJMOMNABIM-UHFFFAOYSA-N 0.000 description 3
- HQOFPTVAYKGRGA-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C(=CC=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C(=CC=C1)C#N HQOFPTVAYKGRGA-UHFFFAOYSA-N 0.000 description 3
- OZYZGFAHQUCBGR-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C=C(C=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C=C(C=C1)C#N OZYZGFAHQUCBGR-UHFFFAOYSA-N 0.000 description 3
- LWQUQHAEVWWXMR-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C=NC(=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1C=NC(=C1)C#N LWQUQHAEVWWXMR-UHFFFAOYSA-N 0.000 description 3
- YHTWRIVZFDYFFQ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CC(CC1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CC(CC1)C#N YHTWRIVZFDYFFQ-UHFFFAOYSA-N 0.000 description 3
- RXDULVXDPVCYPS-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CC(CCC1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1CC(CCC1)C#N RXDULVXDPVCYPS-UHFFFAOYSA-N 0.000 description 3
- VPYKSDGRMIYUTJ-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1N=CC(=C1)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)N1N=CC(=C1)C#N VPYKSDGRMIYUTJ-UHFFFAOYSA-N 0.000 description 3
- FYXKQRBZTYGDCD-UHFFFAOYSA-N ClC=1C=C(C=NC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CC=1 Chemical compound ClC=1C=C(C=NC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=1C=C(C#N)C=CC=1 FYXKQRBZTYGDCD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QECQFLIWRVLSKA-UHFFFAOYSA-N FC=1C=C2CC(CC2=CC=1F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound FC=1C=C2CC(CC2=CC=1F)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O QECQFLIWRVLSKA-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- FEGGVCGPTGRYNO-UHFFFAOYSA-N N1(N=CC=C1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 Chemical compound N1(N=CC=C1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 FEGGVCGPTGRYNO-UHFFFAOYSA-N 0.000 description 3
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 3
- KLFWETIEVZBZAK-UHFFFAOYSA-N S1C2=C(C(=C1)N1C(N(C3(C1=O)CCN(CC3)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=CC=C2 Chemical compound S1C2=C(C(=C1)N1C(N(C3(C1=O)CCN(CC3)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=CC=C2 KLFWETIEVZBZAK-UHFFFAOYSA-N 0.000 description 3
- BLUCPNWIHYUUAI-UHFFFAOYSA-N S1C2=C(C=C1N1C(N(C3(C1=O)CCN(CC3)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=CC=C2 Chemical compound S1C2=C(C=C1N1C(N(C3(C1=O)CCN(CC3)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C=CC=C2 BLUCPNWIHYUUAI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940125436 dual inhibitor Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- QIMMUPPBPVKWKM-UHFFFAOYSA-N 2-methylnaphthalene Chemical compound C1=CC=CC2=CC(C)=CC=C21 QIMMUPPBPVKWKM-UHFFFAOYSA-N 0.000 description 2
- CRYXOKSQDKLMQU-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-2-yl)-1-ethyl-8-[(4-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CCN1C(=O)N(C2CC3=CC=CC=C3C2)C(=O)C1(CC1)CCN1CC1=CC=C(OC)C=C1 CRYXOKSQDKLMQU-UHFFFAOYSA-N 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CIIHNQPSVFOAIP-UHFFFAOYSA-N BrC=1C=C(C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound BrC=1C=C(C=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O CIIHNQPSVFOAIP-UHFFFAOYSA-N 0.000 description 2
- LEROIKWGNYLBEA-UHFFFAOYSA-N C(#C)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O Chemical compound C(#C)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O LEROIKWGNYLBEA-UHFFFAOYSA-N 0.000 description 2
- GNYZTMQVEGKFAN-LJAQVGFWSA-N C(#C)C=1C=C2C[C@H](CC2=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O Chemical compound C(#C)C=1C=C2C[C@H](CC2=CC=1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O GNYZTMQVEGKFAN-LJAQVGFWSA-N 0.000 description 2
- PJIZSBKOWFYJPU-UHFFFAOYSA-N C(C)(=O)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C(C)(=O)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O PJIZSBKOWFYJPU-UHFFFAOYSA-N 0.000 description 2
- VDZPRCONYWZTLK-UHFFFAOYSA-N C(C)(=O)NC1=C(C=C(C=C1)C#N)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound C(C)(=O)NC1=C(C=C(C=C1)C#N)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl VDZPRCONYWZTLK-UHFFFAOYSA-N 0.000 description 2
- TUEQMARUBPVYDM-UHFFFAOYSA-N C(C)(=O)NC1=C(C=CC=C1C#N)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl Chemical compound C(C)(=O)NC1=C(C=CC=C1C#N)C1=CC(=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl TUEQMARUBPVYDM-UHFFFAOYSA-N 0.000 description 2
- YSBAWHHDNRVLQF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C2=CC=CC=C2C=C1)C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=C(C2=CC=CC=C2C=C1)C)=O YSBAWHHDNRVLQF-UHFFFAOYSA-N 0.000 description 2
- OBJKUWKVESHBFO-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=C(C=C1)C)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=C(C=C1)C)OC)=O OBJKUWKVESHBFO-UHFFFAOYSA-N 0.000 description 2
- XZFUXOXQUQDTRK-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)N1CCOCC1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)N1CCOCC1)=O XZFUXOXQUQDTRK-UHFFFAOYSA-N 0.000 description 2
- HHOGORYLLJBUJK-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC(C)C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC(C)C)=O HHOGORYLLJBUJK-UHFFFAOYSA-N 0.000 description 2
- XJFVHMUBVOXEON-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC)=O XJFVHMUBVOXEON-UHFFFAOYSA-N 0.000 description 2
- JQAPTRBUVGWQBY-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC(=CC=C1)OC1=CC=CC=C1)=O JQAPTRBUVGWQBY-UHFFFAOYSA-N 0.000 description 2
- USAAFJBVIAHQIT-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C#N)C=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C#N)C=C1)=O USAAFJBVIAHQIT-UHFFFAOYSA-N 0.000 description 2
- CJGCSPXGZFBJJZ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C#C)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C#C)=O CJGCSPXGZFBJJZ-UHFFFAOYSA-N 0.000 description 2
- UFZRSIFZMOQDHF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=C(C=CC=C1)F)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=C(C=CC=C1)F)=O UFZRSIFZMOQDHF-UHFFFAOYSA-N 0.000 description 2
- UGAAVLNJAQVYLM-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)C#N)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC(=CC=C1)C#N)=O UGAAVLNJAQVYLM-UHFFFAOYSA-N 0.000 description 2
- WFTNLCGOGVZUFY-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C#N)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C#N)=O WFTNLCGOGVZUFY-UHFFFAOYSA-N 0.000 description 2
- FJBQQCGGQWYQRF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1SC=CN=1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)C=1SC=CN=1)=O FJBQQCGGQWYQRF-UHFFFAOYSA-N 0.000 description 2
- DXDZMBJWEWLCGV-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)N1CCCC1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=C(C=C1)N1CCCC1)=O DXDZMBJWEWLCGV-UHFFFAOYSA-N 0.000 description 2
- PKCBVGPMNXFOHF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=CC2=CC=CC=C12)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=CC2=CC=CC=C12)=O PKCBVGPMNXFOHF-UHFFFAOYSA-N 0.000 description 2
- KOUMTTGKGXAOJL-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1=CC=CC=C1)=O KOUMTTGKGXAOJL-UHFFFAOYSA-N 0.000 description 2
- NIQXZTHBXJENOF-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(C1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(C1)C1=CC=CC=C1)=O NIQXZTHBXJENOF-UHFFFAOYSA-N 0.000 description 2
- ZLQWAZXHHZVZAG-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=C(C=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=C(C=CC=C1)OC)=O ZLQWAZXHHZVZAG-UHFFFAOYSA-N 0.000 description 2
- IUGJSKXREQEPDQ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC(=CC=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC(=CC=C1)OC)=O IUGJSKXREQEPDQ-UHFFFAOYSA-N 0.000 description 2
- KEHOLPWZJWKUHI-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC(CC1)C1=CC=CC=C1)=O KEHOLPWZJWKUHI-UHFFFAOYSA-N 0.000 description 2
- YOHNWTATQBREMR-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=C(C=C2C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=C(C=C2C1)OC)=O YOHNWTATQBREMR-UHFFFAOYSA-N 0.000 description 2
- FJQGPXFRRKKAON-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC(=C2C1)F)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC(=C2C1)F)=O FJQGPXFRRKKAON-UHFFFAOYSA-N 0.000 description 2
- ZCQLMPGDMULNHE-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC(=C2C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC(=C2C1)OC)=O ZCQLMPGDMULNHE-UHFFFAOYSA-N 0.000 description 2
- ABWTURNVVGSIMJ-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2CC1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2CC1)=O ABWTURNVVGSIMJ-UHFFFAOYSA-N 0.000 description 2
- JMINJIXKNNCXOG-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCC(CC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCC(CC1)C1=CC=CC=C1)=O JMINJIXKNNCXOG-UHFFFAOYSA-N 0.000 description 2
- PJNPGMGNIAKHIB-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCCC2=CC=CC=C12)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCCC2=CC=CC=C12)=O PJNPGMGNIAKHIB-UHFFFAOYSA-N 0.000 description 2
- LGIZNDLPSSTAEY-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CCN(CC1)C1=CC=CC=C1)=O LGIZNDLPSSTAEY-UHFFFAOYSA-N 0.000 description 2
- GFWSIQASNCSXTB-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(C1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(C1)C1=CC=CC=C1)=O GFWSIQASNCSXTB-UHFFFAOYSA-N 0.000 description 2
- XFSXGZHYEMUNEI-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(CC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(CC1)C1=CC=CC=C1)=O XFSXGZHYEMUNEI-UHFFFAOYSA-N 0.000 description 2
- WHZKHKIQLMPAIX-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(CCC1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CN(CCC1)C1=CC=CC=C1)=O WHZKHKIQLMPAIX-UHFFFAOYSA-N 0.000 description 2
- PMYJTTYDAJEINU-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C=1SC(=CC=1)C1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C=1SC(=CC=1)C1=CC=CC=C1)=O PMYJTTYDAJEINU-UHFFFAOYSA-N 0.000 description 2
- PODYIOODODXRCN-UHFFFAOYSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)CC1=CC=C(C=C1)OC)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)CC1=CC=C(C=C1)OC)=O PODYIOODODXRCN-UHFFFAOYSA-N 0.000 description 2
- NYQYBWINDWYFSW-XCZPVHLTSA-N C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)[C@@H]1C[C@H](CC1)OC1=CC=CC=C1)=O Chemical compound C(C)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)[C@@H]1C[C@H](CC1)OC1=CC=CC=C1)=O NYQYBWINDWYFSW-XCZPVHLTSA-N 0.000 description 2
- HXBYBTAXQXKVBM-UHFFFAOYSA-N C(C)N1C(NC(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)=O Chemical compound C(C)N1C(NC(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)=O HXBYBTAXQXKVBM-UHFFFAOYSA-N 0.000 description 2
- NNLOUCPPFFBUHW-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#C)=O Chemical compound C(C1=CC=CC=C1)(=O)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#C)=O NNLOUCPPFFBUHW-UHFFFAOYSA-N 0.000 description 2
- IKOAUVNKMQEMCT-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C(C1=CC=CC=C1)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O IKOAUVNKMQEMCT-UHFFFAOYSA-N 0.000 description 2
- LMYFNZKNJZYKHL-UHFFFAOYSA-N C(CCC)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C(CCC)N1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O LMYFNZKNJZYKHL-UHFFFAOYSA-N 0.000 description 2
- OLSAPQKGSUZRDL-UHFFFAOYSA-N C1(=C(C=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 Chemical compound C1(=C(C=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 OLSAPQKGSUZRDL-UHFFFAOYSA-N 0.000 description 2
- KHMALFHLAVFMFK-UHFFFAOYSA-N C1(=CC(=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 Chemical compound C1(=CC(=CC=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 KHMALFHLAVFMFK-UHFFFAOYSA-N 0.000 description 2
- BFLGQDXZMKKNJL-UHFFFAOYSA-N C1(=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC=CC=C1 BFLGQDXZMKKNJL-UHFFFAOYSA-N 0.000 description 2
- MFVRVFBBJWSGSL-UHFFFAOYSA-N C1(CC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C1(CC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O MFVRVFBBJWSGSL-UHFFFAOYSA-N 0.000 description 2
- ZXFALPNCZGYMHZ-UHFFFAOYSA-N C1(CCC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C1(CCC1)CN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O ZXFALPNCZGYMHZ-UHFFFAOYSA-N 0.000 description 2
- IIOZFKHGWBTRJJ-UHFFFAOYSA-N C1(CCC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound C1(CCC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O IIOZFKHGWBTRJJ-UHFFFAOYSA-N 0.000 description 2
- YWEKSMJEQXQSMJ-UHFFFAOYSA-N C1(CCCC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound C1(CCCC1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O YWEKSMJEQXQSMJ-UHFFFAOYSA-N 0.000 description 2
- WWYOJPYQPJUIHM-UHFFFAOYSA-N C1(CCCCC1)CCN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O Chemical compound C1(CCCCC1)CCN1C(N(C(C11CCN(CC1)CC1=CC=C(C=C1)N1CCCC1)=O)C1CC2=CC=CC=C2C1)=O WWYOJPYQPJUIHM-UHFFFAOYSA-N 0.000 description 2
- YCVXZTNOMJBVHS-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=C(C=C(C=C1)N1CCCC1)F)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=C(C=C(C=C1)N1CCCC1)F)CC)=O YCVXZTNOMJBVHS-UHFFFAOYSA-N 0.000 description 2
- FBNCPVVWVGOINH-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=C(C=C(C=C1)N1CCCC1)OC)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=C(C=C(C=C1)N1CCCC1)OC)CC)=O FBNCPVVWVGOINH-UHFFFAOYSA-N 0.000 description 2
- KGQFGXBLNLXTSE-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=C(C=C1)N1CCCC1)F)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=C(C=C1)N1CCCC1)F)CC)=O KGQFGXBLNLXTSE-UHFFFAOYSA-N 0.000 description 2
- XLHVJYKDBHDGAG-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=C(C=C1)N1CCCC1)OC)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=C(C=C1)N1CCCC1)OC)CC)=O XLHVJYKDBHDGAG-UHFFFAOYSA-N 0.000 description 2
- KHRIJBNROQBVOD-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=CC=C1)N1CCCC1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC(=CC=C1)N1CCCC1)CC)=O KHRIJBNROQBVOD-UHFFFAOYSA-N 0.000 description 2
- OBEZQYIDFNTIAT-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)C#C)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)C#C)CC)=O OBEZQYIDFNTIAT-UHFFFAOYSA-N 0.000 description 2
- QNFORHUHBNSXKU-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)C(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)C(C)C)=O QNFORHUHBNSXKU-UHFFFAOYSA-N 0.000 description 2
- NJJFQQAWFLOURQ-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)C)=O NJJFQQAWFLOURQ-UHFFFAOYSA-N 0.000 description 2
- QDCQZFGUWWXFIG-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#C)=O QDCQZFGUWWXFIG-UHFFFAOYSA-N 0.000 description 2
- CHCBKCBLUGSYPY-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#N)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC#N)=O CHCBKCBLUGSYPY-UHFFFAOYSA-N 0.000 description 2
- SCVHZGNUOGAEAS-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC(C)(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC(C)(C)C)=O SCVHZGNUOGAEAS-UHFFFAOYSA-N 0.000 description 2
- CGKVTOMCDNROBB-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC(C)C)=O CGKVTOMCDNROBB-UHFFFAOYSA-N 0.000 description 2
- URLNMNOKHKGZKB-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1(OC1)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1(OC1)C)=O URLNMNOKHKGZKB-UHFFFAOYSA-N 0.000 description 2
- CPSVGKQIKZNWQZ-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1=CSC=C1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1=CSC=C1)=O CPSVGKQIKZNWQZ-UHFFFAOYSA-N 0.000 description 2
- NIMKLVVRPNGJPI-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1OC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC1OC1)=O NIMKLVVRPNGJPI-UHFFFAOYSA-N 0.000 description 2
- GUZOMDZKSRICDA-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC(C)(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC(C)(C)C)=O GUZOMDZKSRICDA-UHFFFAOYSA-N 0.000 description 2
- BJVDGJDMGOCASO-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC(C)C)=O BJVDGJDMGOCASO-UHFFFAOYSA-N 0.000 description 2
- PPVDRGWVNHJITJ-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC)=O PPVDRGWVNHJITJ-UHFFFAOYSA-N 0.000 description 2
- AWHZRJFDKJDVTF-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O AWHZRJFDKJDVTF-UHFFFAOYSA-N 0.000 description 2
- ZEUFIIJAUUFAPL-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN(C)C)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN(C)C)=O ZEUFIIJAUUFAPL-UHFFFAOYSA-N 0.000 description 2
- NTOJGXCNKVYMOE-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCCC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCCC1)=O NTOJGXCNKVYMOE-UHFFFAOYSA-N 0.000 description 2
- JSLSBHDMDYROSS-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCCCC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCCCC1)=O JSLSBHDMDYROSS-UHFFFAOYSA-N 0.000 description 2
- LOTPQAGQLNLJPV-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCOCC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCN1CCOCC1)=O LOTPQAGQLNLJPV-UHFFFAOYSA-N 0.000 description 2
- QDTHTQPVXRHULU-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)COC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)COC)=O QDTHTQPVXRHULU-UHFFFAOYSA-N 0.000 description 2
- SYWIVGQRYDYGKA-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=NC=C(C=C1)N1CCCC1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=NC=C(C=C1)N1CCCC1)CC)=O SYWIVGQRYDYGKA-UHFFFAOYSA-N 0.000 description 2
- QABLHLFIGILFMH-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC=1C=C2CCNC2=CC=1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC=1C=C2CCNC2=CC=1)CC)=O QABLHLFIGILFMH-UHFFFAOYSA-N 0.000 description 2
- HLSWXMUAKCPIJK-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC=1C=NC(=CC=1)N1CCCC1)CC)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC=1C=NC(=CC=1)N1CCCC1)CC)=O HLSWXMUAKCPIJK-UHFFFAOYSA-N 0.000 description 2
- LAHGDUPRZGMIIK-UHFFFAOYSA-N C1C(CC2=CC=CC=C12)N1C(NC2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)=O Chemical compound C1C(CC2=CC=CC=C12)N1C(NC2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)=O LAHGDUPRZGMIIK-UHFFFAOYSA-N 0.000 description 2
- LXKIITMVOKYKLO-UHFFFAOYSA-N C1CCC2=CC(=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound C1CCC2=CC(=CC=C12)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O LXKIITMVOKYKLO-UHFFFAOYSA-N 0.000 description 2
- FINWZCIQIJTJOW-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound COC=1C=C(C=CC=1OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O FINWZCIQIJTJOW-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- UOQXRYHIOVIAIG-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC(=CC=C1)C#N Chemical compound ClC1=C(C=C(C(=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC(=CC=C1)C#N UOQXRYHIOVIAIG-UHFFFAOYSA-N 0.000 description 2
- FLQAFHKYIXCWJT-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)Cl)C1=CC=CC=C1 FLQAFHKYIXCWJT-UHFFFAOYSA-N 0.000 description 2
- RBKWIHPKUCUTQV-UHFFFAOYSA-N ClC1=C(C=CC(=C1)C=1N(C(C=CC=1)=O)C)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=C1)C=1N(C(C=CC=1)=O)C)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O RBKWIHPKUCUTQV-UHFFFAOYSA-N 0.000 description 2
- DFQUWFMPNCCAAB-UHFFFAOYSA-N ClC1=C(C=CC(=C1)N1CC(CC1)O)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=C1)N1CC(CC1)O)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O DFQUWFMPNCCAAB-UHFFFAOYSA-N 0.000 description 2
- BDMRSSXYHNQIQR-UHFFFAOYSA-N ClC1=C(C=CC(=N1)C=1C=C(C#N)C=CC=1OCC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC1=C(C=CC(=N1)C=1C=C(C#N)C=CC=1OCC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O BDMRSSXYHNQIQR-UHFFFAOYSA-N 0.000 description 2
- QCXCZCNEDDSKSY-UHFFFAOYSA-N ClC1=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=CC(=C1)N1CCCC1 Chemical compound ClC1=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=CC(=C1)N1CCCC1 QCXCZCNEDDSKSY-UHFFFAOYSA-N 0.000 description 2
- QZQVJFHILRKTKQ-UHFFFAOYSA-N ClC1=NC(=CC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OCC Chemical compound ClC1=NC(=CC=C1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OCC QZQVJFHILRKTKQ-UHFFFAOYSA-N 0.000 description 2
- WYTYVJZALIFGME-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=C(C=C1)F)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=C(C=C1)F)C#N)OC)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O WYTYVJZALIFGME-UHFFFAOYSA-N 0.000 description 2
- RCLUALKXVBPSCQ-UHFFFAOYSA-N ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1OCC)C#N)C#C)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O Chemical compound ClC=1C(=CC(=C(C=1)C1=CC(=CC=C1OCC)C#N)C#C)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CCC1(N=N1)C)=O RCLUALKXVBPSCQ-UHFFFAOYSA-N 0.000 description 2
- PPVOTUOUGQTNKI-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C(=CC=C1)C#N)OCC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C(=CC=C1)C#N)OCC PPVOTUOUGQTNKI-UHFFFAOYSA-N 0.000 description 2
- HABLIULTHDKFNH-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OCC Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=C(C=CC=C1)OCC HABLIULTHDKFNH-UHFFFAOYSA-N 0.000 description 2
- HOUZJABDCSCEKK-UHFFFAOYSA-N ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1OCC)C#N Chemical compound ClC=1C=C(C=CC=1N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O)C1=CC(=CC=C1OCC)C#N HOUZJABDCSCEKK-UHFFFAOYSA-N 0.000 description 2
- QBYRKLIQFWXWPS-UHFFFAOYSA-N ClC=1C=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=CC=1N1CCCC1 Chemical compound ClC=1C=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=CC=1N1CCCC1 QBYRKLIQFWXWPS-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- JDZLOGGYQSTWSQ-UHFFFAOYSA-N N1(C=CC=C1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O Chemical compound N1(C=CC=C1)C1=CC=C(C=C1)N1C(N(C2(C1=O)CCN(CC2)CC1=CC=C(C=C1)N1CCCC1)CC)=O JDZLOGGYQSTWSQ-UHFFFAOYSA-N 0.000 description 2
- VZXVKTTWJHRKII-UHFFFAOYSA-N N1(C=CC=C1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 Chemical compound N1(C=CC=C1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 VZXVKTTWJHRKII-UHFFFAOYSA-N 0.000 description 2
- NOKRIQSBCLHTTF-UHFFFAOYSA-N N1(CC1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 Chemical compound N1(CC1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 NOKRIQSBCLHTTF-UHFFFAOYSA-N 0.000 description 2
- YNFTWMYTTJTUTP-UHFFFAOYSA-N N1(CCC1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 Chemical compound N1(CCC1)C1=CC=C(CN2CCC3(C(N(C(N3CC)=O)C3CC4=CC=CC=C4C3)=O)CC2)C=C1 YNFTWMYTTJTUTP-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000012822 autophagy inhibitor Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 201000008247 brain infarction Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000006667 mitochondrial pathway Effects 0.000 description 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 2
- 229950004847 navitoclax Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- 0 *CN(CC1)CCC1(C(N1*)=O)N(*)C1=O Chemical compound *CN(CC1)CCC1(C(N1*)=O)N(*)C1=O 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- SAVGSSSLZPLNLG-UHFFFAOYSA-N 1-(2-bromoethyl)pyrrolidine Chemical compound BrCCN1CCCC1 SAVGSSSLZPLNLG-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- RGZKCDYNLOHIOC-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-5-[2-methylsulfonyl-6-(trifluoromethyl)pyrimidin-4-yl]pyridin-2-one Chemical compound COC=1C=C(CN2C(C=CC(=C2)C2=NC(=NC(=C2)C(F)(F)F)S(=O)(=O)C)=O)C=CC=1OC RGZKCDYNLOHIOC-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- XPPUOZUUOFQHKD-UHFFFAOYSA-N 1-benzothiophen-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2SC(N)=CC2=C1 XPPUOZUUOFQHKD-UHFFFAOYSA-N 0.000 description 1
- DDITYYPIADDMFF-UHFFFAOYSA-N 1-benzothiophen-3-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=CSC2=C1 DDITYYPIADDMFF-UHFFFAOYSA-N 0.000 description 1
- LTLVZQZDXQWLHU-UHFFFAOYSA-N 1-bromo-4-ethynylbenzene Chemical compound BrC1=CC=C(C#C)C=C1 LTLVZQZDXQWLHU-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- NPPQHNGXMKRUDG-UHFFFAOYSA-N 2,6-dichloro-4-phenylaniline Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1C1=CC=CC=C1 NPPQHNGXMKRUDG-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- GYZRFKCNMIPTEI-UHFFFAOYSA-N 2-bromoethylcyclopentane Chemical compound BrCCC1CCCC1 GYZRFKCNMIPTEI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- JQASBXWRZKSMBV-UHFFFAOYSA-N 2-chloro-4-(2-ethoxyphenyl)aniline Chemical compound CCOc1ccccc1-c1ccc(N)c(Cl)c1 JQASBXWRZKSMBV-UHFFFAOYSA-N 0.000 description 1
- RBJUGYSOVYKIEO-UHFFFAOYSA-N 2-chloro-4-(2-fluorophenyl)aniline Chemical compound Nc1ccc(cc1Cl)-c1ccccc1F RBJUGYSOVYKIEO-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- CUCCSOOMJXROTJ-UHFFFAOYSA-N 3-(4-amino-3-chlorophenyl)benzonitrile Chemical compound C1=C(Cl)C(N)=CC=C1C1=CC=CC(C#N)=C1 CUCCSOOMJXROTJ-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- IHPRVZKJZGXTBQ-UHFFFAOYSA-N 3-chloropropan-1-amine;hydron;chloride Chemical compound Cl.NCCCCl IHPRVZKJZGXTBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- VJXKVDLXKYYYBX-UHFFFAOYSA-N 3-phenylcyclobutan-1-amine Chemical compound C1C(N)CC1C1=CC=CC=C1 VJXKVDLXKYYYBX-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- DLGZLIXYVSQGOX-UHFFFAOYSA-N 4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=COC(C(N)=O)=C1 DLGZLIXYVSQGOX-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- YNHLVALLAURVJF-UHFFFAOYSA-N 4-amino-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(N)(C(O)=O)CC1 YNHLVALLAURVJF-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- ISDBWOPVZKNQDW-UHFFFAOYSA-N 4-phenylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=C1 ISDBWOPVZKNQDW-UHFFFAOYSA-N 0.000 description 1
- ILJVPSVCFVQUAD-UHFFFAOYSA-N 4-piperidin-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1CCCCC1 ILJVPSVCFVQUAD-UHFFFAOYSA-N 0.000 description 1
- PPGRDLZPSDHBIC-UHFFFAOYSA-N 4-pyrazol-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1N=CC=C1 PPGRDLZPSDHBIC-UHFFFAOYSA-N 0.000 description 1
- BXYRAPNURYRQSP-UHFFFAOYSA-N 4-pyridin-2-ylaniline Chemical compound C1=CC(N)=CC=C1C1=CC=CC=N1 BXYRAPNURYRQSP-UHFFFAOYSA-N 0.000 description 1
- GKVYVZSNXXTOMQ-UHFFFAOYSA-N 4-pyridin-4-ylaniline Chemical compound C1=CC(N)=CC=C1C1=CC=NC=C1 GKVYVZSNXXTOMQ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VMNADOXDGZJTBJ-UHFFFAOYSA-N 4-pyrrol-1-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1N1C=CC=C1 VMNADOXDGZJTBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- MNQGEQSXFDKAPY-UHFFFAOYSA-N 9h-fluorene-2-carbaldehyde Chemical compound C1=CC=C2C3=CC=C(C=O)C=C3CC2=C1 MNQGEQSXFDKAPY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 1
- 102000055105 BH3 Interacting Domain Death Agonist Human genes 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 102100021589 Bcl-2-like protein 11 Human genes 0.000 description 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- IYNQFSZKKRBNQV-UHFFFAOYSA-N CCN(C1(CCN(Cc(cc2)ccc2N2CCCC2)CC1)C(N1c(c(C)c2)cnc2-c(cc(c(F)c2)C#N)c2OCC)=O)C1=O Chemical compound CCN(C1(CCN(Cc(cc2)ccc2N2CCCC2)CC1)C(N1c(c(C)c2)cnc2-c(cc(c(F)c2)C#N)c2OCC)=O)C1=O IYNQFSZKKRBNQV-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000971078 Homo sapiens Bcl-2-like protein 11 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100026639 MICOS complex subunit MIC60 Human genes 0.000 description 1
- 101710128942 MICOS complex subunit MIC60 Proteins 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100035548 Protein Bop Human genes 0.000 description 1
- 108050008794 Protein Bop Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000004705 aldimines Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical group N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 230000006739 dopaminergic cell death Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005067 haloformyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000003606 oligomerizing effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NFOKCUQWYHRJGR-UHFFFAOYSA-N phosphonosulfanylphosphonic acid Chemical compound OP(O)(=O)SP(O)(O)=O NFOKCUQWYHRJGR-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- cellular assays that mimic the activation of mitochondrial apoptosis pathway, we screened out a novel small molecule that blocks apoptosis by protecting mitochondrial integrity and function.
- Compound R6 prevents apoptosis by activating autophagy through mTOR inhibition; it also confers significant, dose-dependent neuro-protective effects in a rat cerebral ischemia/reperfusion injury model.
- SAR to develop a class of pharmaceutically active inhibitors of mTOR-mediated induction of autophagy, with particular applications for treating cerebral ischemia/reperfusion and neurodegenerative diseases.
- the invention provides compounds that inhibit of apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, and prodrugs thereof, which are hydrolyzed, typically in the gut or blood, to yield the corresponding compounds/inhibitors.
- the invention provides a compound of formula I, or a salt, hydrate or stereosomer thereof:
- R1 is C3-C14 cyclic or hetero-cyclic moiety, particularly substituted or unsubstituted, 0-3 heteroatom C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl; or substituted or unsubstituted, 0-3 heteroatom C5-C14 aryl;
- R2 is optionally substituted phenyl
- R3 is H, substituted or unsubstituted, 0-3 heteroatom hydrocarbyl.
- R1 is optionally substituted phenyl, biphenyl or 2, 3-dihydro-indenyl
- R2 is 4- (pyrrolidin-1-yl) phenyl
- R3 is optionally substituted ethyl.
- the compound has a structure disclosed herein, optionally excluding hit compound 6.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound for formula I (supra) in predetermined, unit dosage form and one or more pharmaceutically acceptable excipients.
- the invention provides use of a compound or composition disclosed herein in the manufacture of a medicament to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof.
- the invention provides a compound or composition disclosed herein to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof, or in the manufacture of a medicament thereof in a person in need thereof.
- the invention provides a method of using a compound or composition disclosed herein to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, and optionally detecting a resultant improvement in the person’s health or condition.
- the invention encompasses all combination of the particular embodiments recited herein, as if each combination had been laboriously recited.
- alkyl′′ refers to a hydrocarbon group selected from linear and branched saturated hydrocarbon groups of 1-18, or 1-12, or 1-6 carbon atoms.
- alkyl group include methyl, ethyl, 1-propyl or n-propyl ( ′′n-Pr′′ ) , 2-propyl or isopropyl ( ′′i-Pr′′ ) , 1-butyl or n-butyl ( ′′n-Bu′′ ) , 2-methyl-1-propyl or isobutyl ( ′′i-Bu′′ ) , 1-methylpropyl or s-butyl ( ′′s-Bu′′ ) , and 1, 1-dimethylethyl or t-butyl ( ′′t-Bu′′ ) .
- alkyl group examples include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2, 3-dimethyl-2-butyl and 3, 3-dimethyl-2-butyl groups.
- Lower alkyl means 1-8, preferably 1-6, more preferably 1-4 carbon atoms; lower alkenyl or alkynyl means 2-8, 2-6 or 2-4 carbon atoms.
- alkenyl group may be selected from ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1, 3-dienyl, 2-methylbuta-1, 3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1, 3-dienyl groups.
- alkynyl′′ refers to a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C ⁇ C triple bond and of 2-18, or 2-12, or 2-6 carbon atoms.
- alkynyl group include ethynyl, 1-propynyl, 2-propynyl (propargyl) , 1-butynyl, 2-butynyl, and 3-butynyl groups.
- cycloalkyl′′ refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups.
- the cycloalkyl group may be of 3-12, or 3-8, or 3-6 carbon atoms. Even further for example, the cycloalkyl group may be a monocyclic group of 3-12, or 3-8, or 3-6 carbon atoms.
- Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups.
- bicyclic cycloalkyl groups include those having 7-12 ring atoms arranged as a bicycle ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems, or as a bridged bicyclic ring selected from bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, and bicyclo [3.2.2] nonane.
- the ring may be saturated or have at least one double bond (i.e. partially unsaturated) , but is not fully conjugated, and is not aromatic, as aromatic is defined herein.
- aryl herein refers to a group selected from: 5-and 6-membered carbocyclic aromatic rings, for example, phenyl; bicyclic ring systems such as 7-12 membered bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, selected, for example, from naphthalene, indane, and 1, 2, 3, 4-tetrahydroquinoline; and tricyclic ring systems such as 10-15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
- the aryl group is selected from 5-and 6-membered carbocyclic aromatic rings fused to a 5-to 7-membered cycloalkyl or heterocyclic ring optionally comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring when the carbocyclic aromatic ring is fused with a heterocyclic ring, and the point of attachment can be at the carbocyclic aromatic ring or at the cycloalkyl group when the carbocyclic aromatic ring is fused with a cycloalkyl group.
- Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
- Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in ′′-yl′′ by removal of one hydrogen atom from the carbon atom with the free valence are named by adding ′′-idene′′ to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
- halogen′′ or halo refers to F, Cl, Br or I.
- heteroalkyl refers to alkyl comprising at least one heteroatom.
- heteroaryl′′ refers to a group selected from:
- 5-to 7-membered aromatic, monocyclic rings comprising 1, 2, 3 or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon;
- 8-to 12-membered bicyclic rings comprising 1, 2, 3 or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring;
- 11-to 14-membered tricyclic rings comprising 1, 2, 3 or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
- the heteroaryl group includes a 5-to 7-membered heterocyclic aromatic ring fused to a 5-to 7-membered cycloalkyl ring.
- the point of attachment may be at the heteroaromatic ring or at the cycloalkyl ring.
- the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
- heteroaryl group examples include, but are not limited to, (as numbered from the linkage position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl) , cinnolinyl, pyrazinyl, 2, 4-pyrimidinyl, 3, 5-pyrimidinyl, 2, 4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furyl, benzofuryl, benzoimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl,
- heterocyclic′′ or ′′heterocycle′′ or ′′heterocyclyl′′ refers to a ring selected from 4-to 12-membered monocyclic, bicyclic and tricyclic, saturated and partially unsaturated rings comprising at least one carbon atoms in addition to 1, 2, 3 or 4 heteroatoms, selected from oxygen, sulfur, and nitrogen.
- Heterocycle also refers to a 5-to 7-membered heterocyclic ring comprising at least one heteroatom selected from N, O, and S fused with 5-, 6-, and/or 7-membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring when the heterocyclic ring is fused with a carbocyclic aromatic or a heteroaromatic ring, and that the point of attachment can be at the cycloalkyl or heterocyclic ring when the heterocyclic ring is fused with cycloalkyl.
- Heterocycle also refers to an aliphatic spirocyclic ring comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring.
- the rings may be saturated or have at least one double bond (i.e. partially unsaturated) .
- the heterocycle may be substituted with oxo.
- the point of the attachment may be carbon or heteroatom in the heterocyclic ring.
- a heterocyle is not a heteroaryl as defined herein.
- heterocycle examples include, but not limited to, (as numbered from the linkage position assigned priority 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2, 4-imidazolidinyl, 2, 3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2, 5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1, 2-dithietanyl, 1, 3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, 1,
- Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1, 1-dioxo-1-thiomorpholinyl.
- oxo moieties such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1, 1-dioxo-1-thiomorpholinyl.
- fused rings refers to a polycyclic ring system, e.g., a bicyclic or tricyclic ring system, in which two rings share only two ring atoms and one bond in common.
- fused rings may comprise a fused bicyclic cycloalkyl ring such as those having from 7 to 12 ring atoms arranged as a bicyclic ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems as mentioned above; a fused bicylclic aryl ring such as 7 to 12 membered bicyclic aryl ring systems as mentioned above, a fused tricyclic aryl ring such as 10 to 15 membered tricyclic aryl ring systems mentioned above; a fused bicyclic heteroaryl ring such as 8-to 12-membered bicyclic heteroaryl rings as mentioned above, a fused tricyclic heteroaryl ring such as
- substituents are selected from optionally substituted heteroatom and optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl, particularly wherein the optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl is optionally-substituted, optionally hetero-, optionally cyclic alkyl, alkenyl or alkynyl, or optionally-substituted, optionally hetero-aryl; and/or the optionally substituted heteroatom is halogen, optionally substituted hydroxyl (such as alkoxy, aryloxy) , optionally substituted acyl (such as formyl, alkanoyl, carbamoyl, carboxyl, amido) , optionally substituted amino (such as amino, alkylamino, dialkylamino, amido, sulfamidyl) , optionally substituted thiol (such as mercapto, alkylthiol, aryl
- R′, R′′ and R′′′ each independently refer to hydrogen, unsubstituted (C1-C8) alkyl and heteroalkyl, (C1- C8) alkyl and heteroalkyl substituted with one to three halogens, unsubstituted aryl, aryl substituted with one to three halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl- (C1-C4) alkyl groups.
- R′and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-or 7-membered ring.
- -NR′R′′ includes 1-pyrrolidinyl and 4-morpholinyl
- ′′alkyl includes groups such as trihaloalkyl (e.g., -CF3 and -CH2CF3) , and when the aryl group is 1, 2, 3, 4-tetrahydronaphthalene, it may be substituted with a substituted or unsubstituted (C3-C7) spirocycloalkyl group.
- the (C3-C7) spirocycloalkyl group may be substituted in the same manner as defined herein for ′′cycloalkyl′′ .
- substituents are disclosed herein and exemplified in the tables, structures, examples, and claims, and may be applied across different compounds of the invention, i.e. substituents of any given compound may be combinatorially used with other compounds.
- applicable substituents are independently substituted or unsubstituted heteroatom, substituted or unsubstituted, 0-3 heteroatom C1-C6 alkyl, substituted or unsubstituted, 0-3 heteroatom C2-C6 alkenyl, substituted or unsubstituted, 0-3 heteroatom C2-C6 alkynyl, or substituted or unsubstituted, 0-3 heteroatom C6-C14 aryl, wherein each heteroatom is independently oxygen, phosphorus, sulfur or nitrogen.
- applicable substituents are independently aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkyloxy, alkyl, amine, azo, halogens, carbamoyl, carbonyl, carboxamido, carboxyl, cyanyl, ester, halo, haloformyl, hydroperoxyl, hydroxyl, imine, isocyanide, iscyante, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, sulfide, sulfonyl, sulfo, sulfhydryl, thiol, thiocyanyl, trifluoromethyl or trifluromethyl ether (OCF3) .
- OCF3 trifluoromethyl or trifluromethyl ether
- the compounds may contain an asymmetric center and may thus exist as enantiomers. Where the compounds possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
- the term “substantially pure” means that the target stereoisomer contains no more than 35%, such as no more than 30%, further such as no more than 25%, even further such as no more than 20%, by weight of any other stereoisomer (s) . In some embodiments, the term “substantially pure” means that the target stereoisomer contains no more than 10%, for example, no more than 5%, such as no more than 1%, by weight of any other stereoisomer (s) .
- keto and enol forms are also intended to be included where applicable.
- reaction products from one another and/or from starting materials.
- the desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art.
- separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography.
- Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ( ′′SMB′′ ) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
- ′′SMB′′ simulated moving bed
- preparative thin or thick layer chromatography as well as techniques of small scale thin layer and flash chromatography.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher′s acid chloride) , separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher′s acid chloride
- Enantiomers can also be separated by use of a chiral HPLC column.
- a single stereoisomer e.g., a substantially pure enantiomer
- Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
- “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, selected, for example, from hydrochlorates, phosphates, diphosphates, hydrobromates, sulfates, sulfinates, and nitrates; as well as salts with organic acids, selected, for example, from malates, maleates, fumarates, tartrates, succinates, citrates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, alkanoates such as acetate, and salts with HOOC- (CH 2 ) n-COOH, wherein n is selected from 0 to 4.
- examples of pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
- Treating, ” “treat, ” or ′′treatment′′ refers to administering at least one compound and/or at least one stereoisomer thereof, and/or at least one pharmaceutically acceptable salt thereof to a subject in recognized need thereof.
- An ′′effective amount′′ refers to an amount of at least one compound and/or at least one stereoisomer thereof, and/or at least one pharmaceutically acceptable salt thereof effective to ′′treat′′ a disease or disorder in a subject, and that will elicit, to some significant extent, the biological or medical response of a tissue, system, animal or human that is being sought, such as when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated.
- the therapeutically effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- ′′at least one substituent′′ includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents.
- ′′at least one substituent R 16 ′′ herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents selected from the list of R 16 as described herein.
- the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may be employed alone or in combination with at least one other therapeutic agent for treatment.
- the compounds, stereoisomers thereof, and pharmaceutically acceptable salts thereof can be used in combination with at least one additional therapeutic agent.
- the compound and/or one pharmaceutically acceptable salt disclosed herein may be administered with the at least one other therapeutic agent in a single dosage form or as a separate dosage form.
- the at least one other therapeutic agent may be administered prior to, at the same time as, or following administration of the compound and/or one pharmaceutically acceptable salt disclosed herein.
- composition comprising a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
- compositions comprising a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof can be administered in various known manners, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implanted reservoir, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- the compositions disclosed herein may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art.
- the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragées, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions.
- the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions.
- dosages forms that can also be used to administer the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
- powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegr
- Liquid dosage forms for oral administration can further comprise at least one agent selected from coloring and flavoring agents to increase patient acceptance.
- parenteral solutions can comprise a water soluble salt of the at least one compound describe herein, at least one suitable stabilizing agent, and if necessary, at least one buffer substance.
- Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, can be examples of suitable stabilizing agents.
- Citric acid and its salts and sodium EDTA can also be used as examples of suitable stabilizing agents.
- parenteral solutions can further comprise at least one preservative, selected, for example, from benzalkonium chloride, methyl-and propylparaben, and chlorobutanol.
- a pharmaceutically acceptable carrier is, for example, selected from carriers that are compatible with active ingredients of the composition (and in some embodiments, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated.
- solubilizing agents such as cyclodextrins (which can form specific, more soluble complexes with the at least one compound and/or at least one pharmaceutically acceptable salt disclosed herein)
- examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow # 10.
- Suitable pharmaceutically acceptable carriers are described in Remington′s Pharmaceutical Sciences, A. Osol, a standard reference text in the art.
- the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
- the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may also be delivered as powders, which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
- One exemplary delivery system for inhalation can be metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein in at least one suitable propellant, selected, for example, from fluorocarbons and hydrocarbons.
- MDI metered dose inhalation
- an ophthalmic preparation may be formulated with an appropriate weight percentage of a solution or suspension of the subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof in an appropriate ophthalmic vehicle, such that the subject compound and stereoisomers thereof, and at least one pharmaceutically acceptable salts thereof is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
- Useful pharmaceutical dosage-forms for administration of the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
- the dosage administered will be dependent on factors, such as the age, health and weight of the recipient, the extent of disease, type of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- a daily dosage of the active ingredient can vary, for example, from 0.1 to 2000 milligrams per day. For example, 10-500 milligrams once or multiple times per day may be effective to obtain the desired results.
- a large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with, for example, 100 milligrams of the subject compound and stereoisomers thereof, and pharmaceutically acceptable salt thereof disclosed herein in powder, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
- a mixture of the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.
- a large number of tablets can be prepared by conventional procedures so that the dosage unit comprises, for example, 100 milligrams of the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
- Appropriate coatings may be applied to increase palatability or delay absorption.
- a parenteral composition suitable for administration by injection can be prepared by stirring 1.5%by weight of the compound and/or at least an enantiomer, a diastereomer, or pharmaceutically acceptable salt thereof disclosed herein in 10%by volume propylene glycol. The solution is made to the expected volume with water for injection and sterilized.
- an aqueous suspension can be prepared for oral administration.
- an aqueous suspension comprising 100 milligrams of finely divided compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin can be used.
- the same dosage forms can generally be used when the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof are administered stepwise or in conjunction with at least one other therapeutic agent.
- the dosage form and administration route should be selected depending on the compatibility of the combined drugs.
- coadministration is understood to include the administration of at least two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the at least two active components.
- the compounds, stereoisomers thereof, and pharmaceutically acceptable salt thereof disclosed herein can be administered as the sole active ingredient or in combination with at least one second active ingredient.
- compositions or formulations will contain pharmaceutically acceptable diluents and/or carriers, i.e. diluents or carriers that are physiologically compatible and substantially free from pathogenic impurities.
- Suitable excipients or carriers and methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in more detail in such publications as Remington′s Pharmaceutical Science, Mack Publishing Co, NJ (1991) .
- the compositions may also be in the form of controlled release or sustained release compositions as known in the art. For many applications the subject compounds are administered for morning/daytime dosing, with off period at night.
- the subject compounds may be used per se, or in the form of their pharmaceutically acceptable salts, such as hydrochlorides, hydrobromides, acetates, sulfates, citrates, carbonates, trifluoroacetates and the like.
- salts can be obtained by addition of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or the like.
- salts can be obtained by addition of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al, “Pharmaceutical Salts” , Journal of Pharmaceutical Science, 1977, 66, 1-19) .
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of this invention.
- this invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be more bioavailable by oral administration than the parent drug.
- the prodrug may also have improved solubility in pharmacological compositions over the parent drug.
- prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
- An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the ′′prodrug′′ ) , but then is metabolically hydrolyzed to the carboxylic acid, the active entity.
- Certain compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the invention.
- the compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds, such as deuterium, e.g. -CD 3 , CD 2 H or CDH 2 in place of methyl.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H) , iodine-125 ( 125 I) or carbon-14 ( 14 C) . All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
- the compounds are generally administered in a ′′therapeutically effective amount′′ , i.e. the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- a ′′therapeutically effective amount′′ includes that amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated.
- the therapeutically effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- the contacting is generally effected by administering to the subject an effective amount of one or more compounds having the general formula I (supra) , including the various embodiments described above.
- administration is adjusted to achieve a therapeutic dosage of about 0.1 to 50, preferably 0.5 to 10, more preferably 1 to 10 mg/kg, though optimal dosages are compound specific, and generally empirically determined for each compound.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules, lozenges or the like in the case of solid compositions.
- the mimetic is usually a minor component (from about 0.1 to about 50%by weight or preferably from about 1 to about 40%by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
- Unit dosage formulations are preferably about of 5, 10, 25, 50, 100, 250, 500, or 1,000 mg per unit.
- unit dosage forms are packaged in a multipack adapted for sequential use, such as blisterpack comprising sheets of at least 6, 9 or 12 unit dosage forms.
- compositions may also be coformulated and/or coadministered with a different compound to treat applicable indications.
- Active compounds were demonstrated to inhibit Bim-induced intrinsic apoptosis.
- Representative active compounds where also demonstrated to inhibit apoptosis by inhibiting mTOR and activating autophagy, to inhibit intrinsic apoptosis specifically induced by serum withdrawal plus a Bcl-2/Bcl-xL dual inhibitor, and to protect against neuronal injury in a rat model of transient focal cerebral ischemia/reperfusion injury; methods all herein.
- Step 2 The solution of 1-03 (132mg, 0.34mmol) in DMF was cooled to 0°C, then 60%NaH (41.2mg, 1.03mmol) was added to it. The reaction mixture was stirred at 0°C for 30min, followed by addition of CH 3 CH 2 I (160mg, 1.03mmol) . The reaction mixture was warmed to room temperature and stirred for 4h. The reaction was quenched by H 2 O, and the aqueous layer was extracted by EA for 3 times. The organic layers were combined, washed with H 2 O, brine, dried over Na 2 SO 4 , filtrated and evaporated to give 156mg 1-04 as light brown solid which was used without further purification. Mass (m/z) : 414.48 [M+H] + .
- Step 3 The 1-04 (0.34mmol) was dissolved in hydrogen chloride (1N in ethanol) , the reaction mixture was heated to 50°C, and then stirred for 2h. The reaction mixture was evaporated to remove ethanol to give 1-05 as light yellow solid, which was used without further purification. Mass (m/z) : 314.36 [M+H] + .
- the title compound 2 (9.8mg) was prepared in a yield of 30.6%as light yellow powder from 1-05 (25mg, 0.072mmol) and 4- (dimethylamino) benzaldehyde (12mg, 0.080mmol) according to the procedure for compound 1.
- Step 1 The 1-01 (180mg, 0.67mmol) , 3-01 (126mg, 0.61mmol) , Cu 2 O (54mg, 0.73mmol) , K 2 CO 3 (185mg, 1.34mmol) and N 1 , N 2 -dimethylethane-1, 2-diamine (118mg, 1.34mmol) were mixed in DMF (5mL) .
- the reaction mixture was reacted in microwave at 150°C for 1h.
- the reaction mixture was diluted by water, and the aqueous was extracted by EA for several times. The organic layers were combined, washed with water, brine in turn, dried over Na 2 SO 4 .
- Step 3 The 3-04 (144mg) was prepared as yellow powder from 3-03 (160mg, 0.38mmol) according to the procedure for 1-05. Mass (m/z) : 325.38 [M+H] + .
- Step 4 The compound 3 (29mg) was prepared as white solid in a yield of 35.4%from 3-04 (55mg, 0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (33mg, 0.19mmol) according to the procedure for compound 1.
- 1 HNMR 400 MHz, CDCl 3 ) ⁇ 7.92-7.87 (m.
- the title compound 4 (22.4mg) was prepared in a yield of 63.3%as light yellow powder from 1-05 (25mg, 0.072mmol) and 9H-fluorene-2-carbaldehyde (16mg, 0.080mmol) according to the procedure for compound 1.
- the title compound 8 (8.7mg) was prepared in a yield of 25.5%as light yellow powder from 1-05 (23mg, 0.07mmol) and 4- (piperidin-1-yl) benzaldehyde (15mg, 0.078mmol) according to the procedure for compound 1.
- Step 2 The 1N HCl was added to the solution of 10-02 in THF at room temperature. Then the reaction mixture was stirred at room temperature for 2h. The reaction mixture was concentrated under reduce pressure to give crude product 10-03. The crude product was used without further purification. Mass (m/z) : 176.16 [M+H] + .
- Step 3 The title compound 10 (15.0mg) was prepared in a yield of 63.6% (2 steps) as light yellow powder from 1-05 (15mg, 0.043mmol) and 10-03 (0.11mmol) according to the procedure for compound 1.
- Step 2 The 12-01 (141mg, 0.42mmol) was dissolved in DMF. The solvent was cooled under 0°C, 60%NaH (50.2mg, 1.25mmol) was added to the solution in batches. The reaction mixture was reacted at 0°C for 1h, and then EtI (196mg, 1.25mmol) was added to the reaction mixture, then stirred at room temperature for 2h. The reaction was quenched by cold water, and the aqueous layer was extracted by EA for several times. The organic layers was combined, washed with water and brine in turn, dried over Na 2 SO 4 , filtrated and evaporated to give crude product 12-02, which was used without further purification. Mass (m/z) : 336.34 [M+H] + .
- Step 3 The 12-03 (201mg) was prepared as yellow powder from 12-02 (198mg) according to the procedure for 1-05. Mass (m/z) : 266.23 [M+H] + .
- Step 4 The title compound 12 (45.8mg) was prepared as yellow solid in a yield of 65.1%from 12-03 (50mg, 0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (34mg, 0.18mmol) according to the procedure for compound 1. Mass (m/z) : 425.36 [M+H] + .
- the 2-Methylnaphthalene (711mg, 5mmol) was suspended in water in flask which covered with aluminum foil to create a dark environment. 48%HBr (0.57mL, 5mmol) and 30%H 2 O 2 (1.02mL, 10mmol) were added to the solution. Then the reaction mixture was stirred at room temperature for 48h. The reaction was quenched by NaHCO 3 aqueous, which was extracted by EA for several times. The organic layers was combined, washed with brine, dried over Na 2 SO 4 , filtrated and concentrated to give 1.07g yellow oil of 14-02 as crude product which was used without further purification.
- Step 1 The 1-01 (100mg, 0.37mmol) , 3-Phenylpropyl Bromide 15-01 (68.5mg, 0.37mmol) and K 2 CO 3 (105mg, 0.74mmol) were dissolved in DMF. The reaction mixture was stirred at 50°C for 4h. The reaction mixture was diluted by water, and the aqueous layer was extracted by EA for several times. The organic layers was combined, washed with H 2 O and brine in turn, dried over Na 2 SO 4 , filtrated and evaporated to give 15-02 as 230mg colorless crystal as crude product, which was used without further purification. Mass (m/z) : 374.22 [M+H] + .
- Step 2 to 4 The compound 15 (34.4mg) was prepared in a yield of 42.9% (4 steps) as yellow powder from 15-02 (200mg, 0.54mmol) according to the procedure for compound 3.
- Step 1 To the solution of 3-Chloropropylamine hydrochloride 16-03 (1.30g, 10mmol) in DCM was added TEA (1.67mL, 12mmol) dropwise, and the resulting solution was stirred for 15min. Then a solution of Boc 2 O in DCM was added dropwise to the solution over a period of 1h, and the resulting mixture was stirred overnight at room temperature. The reaction mixture was diluted with DCM, which was washed sequentially with 1N HCl, water, saturated aqueous NaHCO 3 , and brine. The organic layer was separated, dried over Na 2 SO4, and concentrated under reduce pressure to give compound 16-04 as colorless oil, which was used without further purification.
- Step 2 The compound 16-04 was dissolved in ACN and treated with DMAP (559mg, 4.56mmol) at room temperature, and the resulting mixture was stirred for 10min. A solution of Boc 2 O (3.32g, 15.25mmol) in 15mL THF was added to the reaction mixture, and the resulting mixture was stirred overnight at room temperature. The reaction was quenched by the addition of water, and the aqueous phase was extracted by EA for several times. The organic layer was combined, washed with 1N HCl and brine in turn, dried over Na 2 SO 4 , filtrated and evaporated to give crude product.
- Step 1 The compound 16-06 (16mg, 0.042mmol) was dissolved in 1N HCl (in EtOH) , the reaction mixture was stirred at 50°C for 2h. The reaction mixture was evaporated to remove the solvent to give 32.9mg 16-07 crude product which was use for the next step without further purification. Mass (m/z) : 286.07 [M+H] + .
- Step 2 The compound 16-08 (14mg) was prepared in a yield of 31.5% (2 steps) as light yellow powder from 16-07 (32.9mg, 0.10mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (21.3mg, 0.11mmol) according to the procedure for compound 1. Mass (m/z) : 445.29 [M+H] + .
- Step 3 The compound 16-08 (14mg, 0.032mmol) was dissolved in DMF, and the solution cooled to 0°C, followed by addition of 60%NaH (1.9mg, 0.047mmol) slowly. The reaction mixture was stirred at 0°C for 30min followed by addition of compound 16-05 (13.8mg, 0.047mmol) . Then the reaction mixture was heated to 50°C and stirred overnight. The reaction was quenched by water, extracted by EA for several time. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give 34mg 16-09 crude product which was used for the next step without further purification. Mass (m/z) : 702.64 [M+H] + .
- Step 4 The compound 16-09 (34mg) was dissolved in 1N HCl (in EtOH) , the reaction mixture was stirred at 50°C for 3h. The reaction mixture was evaporated to remove the solvent to give 32.3mg 16-10 crude product which was use for the next step without further purification. Mass (m/z) : 502.43 [M+H] + .
- Step 5 To a solution of 16-10 (32.3mg, 0.06mmol) in DMF was added TEA (15.2mg, 0.15mmol) . The reaction mixture was stirred at room temperature for 20min, followed by addition of 16-02 (22.6mg, 0.06mmol) . Then the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with water, which extracted by EA for several times. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give crude product. The crude product was purified with pre-HPLC to give 3.8mg compound 16 as white solid in a yield of 16.6% (3 steps) . Mass (m/z) : 728.72 [M+H] + .
- Step 1 The compound 17-02 (100mg) was prepared from 1-01 (200mg, 0.74mmol) and 17-01 (180mg, 0.68mmol) in a yield of 29.96%according to the procedure for compound 3-02. Mass (m/z) : 450.28 [M+H] + .
- Step 2 The compound 17-02 (100mg, 0.22mmol) , 3-bromoprop-1-yne (78mg, 0.66mmol) and K 2 CO 3 (91mg, 066mmol) were mixed in the DMF. The reaction mixture was stirred at 50°C overnight. The reaction mixture was diluted by water, extracted by EA for several times. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give 155mg crude product of 17-03, which was used without further purification. Mass (m/z) : 488.19 [M+H] + .
- Step 3 to 4 The title compound 17 (47.5mg) was prepared as yellow powder in a yield of 39.01% (3 steps) from compound 17-03 (155mg, 0.32mmol) according to the procedure for compound 1. Mass (m/z) : 547.33 [M+H] + .
- Step 1 The compound 1-01 (50mg, 0.19mmol) , Boc 2 O (40mg, 0.19mmol) and DMAP (catalyst amount) were dissolved in DCM. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted by DCM, washed by H 2 O and brine in turn. The organic phase was dried over Na 2 SO 4 , filtrated and evaporated to give compound 18-01, which was used without further purification. Mass (m/z) : 370.16 [M+H] + .
- Step 2 to 4 The title compound 18 (18.9mg) was prepared in a yield of 20.8% (4 steps) as yellow powder from 18-01 (86mg, 0.23mmol) according to the procedure for compound 1. Mass (m/z) : 357.29 [M+H] + .
- Step 1 A solution of 19-01 (890mg, 4.05mmol) , (CH 2 OH) 2 (271uL, 4.87mmol) , TsOH H 2 O(25mg, 0.11mmol) and molecular sieve in Toluene was reflux for 24h followed by cooled to room temperature. The reaction mixture was diluted with EA, washed with 1N NaOH, H 2 O and brine in turn, then dried over Na 2 SO 4 , filtrated and evaporated to give crude product of 19-02 as light yellow solid, which was used without further purification. Mass (m/z) : 262.96, 264.95 [M+H] + .
- Step 2 The compound 19-02 (1.063g, 2.0mmol) and pyrrolidine (142mg, 2.0mmol) were dissolved in Toluene, followed by addition of Pd 2 (dba) 3 (37mg, 0.04mmol) , BINAP (25mg, 0.04mmol) and t-BuONa (288mg, 3.0mmol) in the solution.
- Pd 2 (dba) 3 37mg, 0.04mmol
- BINAP 25mg, 0.04mmol
- t-BuONa 288mg, 3.0mmol
- Step 3 The compound 19-03 was dissolved in THF, followed by addition of 1N HCl (1mL) in it. The reaction mixture was stirred at room temperature for 2h. Then the solvent was removed by evaporation to give crude product 19-04 which was used without further purification. Mass (m/z) : 210.09, 212.04 [M+H] + .
- Step 4 The title compound 19 (19.5mg) was prepared as light yellow solid in a yield of 26.9%from 1-05 (50mg, 0.16mmol) and 19-04 (36mg, 0.17mmol) according to the procedure of compound 1.
- Step 1 The compound 1-03 (2.0g, 5.2mmol) was dissolved in HCl (1N in EtOH) , the reaction mixture was stirred at 50°C for 2h. The solvent was removed by evaporation to give crude product 21-01 which was used without further purification. Mass (m/z) : 286.13 [M+H] + .
- Step 2 The title compound 21 (1.85g) was prepared in a yield of 80.1% (2 steps) as yellow powder from 21-01 (5.2mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (1.08g, 5.7mmol) according to the procedure for compound 1.
- Step 1 The compound 36-01 (62.7mg) was prepared in a yield of 9.1%from 1-01 (500mg, 1.86mmol) and 1-bromo-4-ethynylbenzene (306mg, 1.69mmol) according to the procedure of 3-02. Mass (m/z) : 370.26 [M+H] + .
- Step 2 The compound 36-02 was prepared from 36-01 (62.4mg, 0.17mmol) according to the procedure for 1-05. Mass (m/z) : 270.22 [M+H] + .
- Step 3 The compound 36-03 (25mg) was prepared in a yield of 34.7% (2 steps) as yellow powder from 36-02 (0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (35mg, 0.19mmol) according to the procedure for compound 1. Mass (m/z) : 429.34 [M+H] + .
- Step 1 The mixture of 49-01 (2.37g, 0.014mol) and water was stirred and heated to 58-60°C to obtain a solution. To the resulting solution was added Br 2 (2.4g, 0.015mol) dropwise while maintaining an internal temperature of 58-60°C. And then the mixture was stirred at an internal temperature 60-62°C for an additional 1h.
- Step 2 DIEA (2.2g, 17.14mmol) was added dropwise to a stirred solution of 49-03 (2.0g, 4.29mmol) and 49-02 (1.38g, 4.72mmol) in CAN (100mL) containing PyBOP (3.35g, 6.43mmol) at r. t. under N 2 .
- Mass (m/z) 660.41, 662.51 [M+H] + .
- Step 3 Et 2 NH (5.9g, 80.73mmol) was added to the solution of 49-04 (2.66g, 4.04mmol) in DCM at r. t. The reaction mixture was stirred at r. t. for 4h. Evaporated in vacuo to remove the solvent and Et 2 NH to give crude 49-05 as light yellow oil, which was used without further purification. Mass (m/z) : 438.26, 440.23 [M+H] + .
- Step 4 Pyridine (4.79g, 60.6mmol) was added dropwise to the solution of BTC (600mg, 2.02mmol) in anhydrous DCM under 0°C. The reaction mixture became clear, and then became slurry. The solution of 49-05 (4.04mmol) in anhydrous DCM was added dropwise to the reaction mixture under 0°C, followed by the reaction mixture became red and clear. After stirred at 0°C for 2h, the reaction mixture was heated to 40°C and stirred overnight. The reaction was quenched by sat. NH 4 Cl, the organic layer was washed with H 2 O and brine in turn, dried over Na 2 SO 4 . Evaporated in vacuo to remove the solvent to give crude product.
- Step 5 The compound 49-06 (500mg, 1.08mmol) , ethynyltrimethylsilane (127mg, 1.29mmol) , CuI (20.5mg, 0.108mmol) , Pd (PPh 3 ) 2 Cl 2 ( 76mg, 0.108mmol) and TEA (164mg, 1.62mmol) were mixed in the DMF. The reaction mixture was stirred at 70°C overnight. And then the reaction mixture was diluted by water, extracted by EA for several times. The organic phase was combined and washed by water and brine in turn, dried over Na 2 SO 4 , evaporated to give crude product.
- Step 6 The mixture of 49-07 and 49-08 (500mg, ⁇ 1.04mmol) was dissolved in MeOH, followed by addition of K 2 CO 3 (359mg, 2.6mmol) in it. The reaction mixture was stirred at room temperature for 4h. After 4h, the reaction mixture became clear, and evaporated to remove the solvent. The residue was diluted by DCM, filtrated to remove K 2 CO 3 , and the filter was evaporated removing DCM to give crude product 49-08, which was used without further purification. Mass (m/z) : 408.21 [M+H] + .
- Step 7 The compound 49-09 was prepared from 49-08 (1.04mmol) according to the procedure for 1-05. Mass (m/z) : 310.11 [M+H] + .
- Step 8 The compound 49-10 (mixture, 211mg) was prepared as a yellow powder from 49-09 (mixture, 1.04mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (215mg, 1.14mmol) according to the procedure for compound 1. Mass (m/z) : 469.57 [M+H] + .
- Step 9 The title compound 49 (27mg) was prepared as a yellow powder from 49-10 (mixture, 200mg, 0.43mmol) and 24-01 (108mg, 0.43mmol) according to the procedure for 24.
- Mass (m/z) 551.57 [M+H] + .
- the title compound 78 was prepared in a yield of 6.04%as white powder from compound 13-01 according to the procedure for compound 1-04.
- Step 2 Preparation of 1N HCl in MeOH: 36 mL of AcCl was added slowly to anhydrous MeOH (500 mL) in ice bath at 0°C, which was stirred for another 1hrs. A solution of 97-02 (54.5 g, 0.12 mol) in MeOH (200 mL) was added to the above 1 N HCl solution in MeOH, the reaction mixture was heated to 60°C for 24 hrs. Concentrated the solvent and the residue was used directly for the next step. Mass (m/z) : 381.46, [M+H] +
- Step 3 97-03 (41.7 g, 0.1 mol) , 4- (pyrrolidin-1-yl) benzaldehyde (19.1 g, 0.11 mol) was dissolved in DCE (500 mL) , NaBH (AcO) 3 (63 g, 0.3 mol) and catalytic Ti (Oi-Pr) 4 (2 mL) was added subsequently to the above system, the reaction mixture was stirred at room temperature overnight.
- DCE 500 mL
- NaBH (AcO) 3 63 g, 0.3 mol
- catalytic Ti (Oi-Pr) 4 2 mL
- Step 5 The 4- (pyridin-2-yl) aniline 97-06 (59mg, 0.35mmol) in THF was added BTC (37mg, 0.12mmol) and Et 3 N (64 mg, 0.63mmol) at rt under nitrogen protection. 10 min later, 28-05 (100 mg, 0.32mmol) and another Et 3 N (64mg, 0.63mmol) was added. The mixture was stirred at rt for 2 h. The reaction mixture was diluted by H 2 O, extracted with EA for 3 times. The organic layers were combined, washed by brine, dried over Na 2 SO 4 , filtrated and evaporated to give 160 mg 97-07 which was used without further purification.
- Step 6 160 mg 97-07 in DMF was added tBuOK (178mg, 1.58mmol) , The mixture was stirred at 50°C for 2 h. The resulting solution was diluted by H 2 O, extracted with EA for 3 times. The organic layers were combined, washed by brine, dried over Na 2 SO 4 , filtrated and evaporated to give 150 mg 97-08 which was used without further purification.
- Step 7 The title compound 97 (7mg, 4.4%for 3 steps) was prepared as white solid from compound 97-08 (150mg, crude product) and CH 3 CH 2 I (75mg, 0.47mmol) according to the procedure for 1-04.
- the title compound 106 (11mg) was prepared in a yield of 7.1%for three steps as white solid from 97-05 (100mg, 0.32mmol) and benzo [b] thiophen-2-amine hydrochloride (64mg, 0.34mmol) according to the procedure for 97.
- the title compound 107 (19mg) was prepared in a yield of 12.3%for three steps as white solid from 97-05 (100mg, 0.32mmol) and benzo [b] thiophen-3-amine hydrochloride (64mg, 0.34mmol) according to the procedure for 97.
- the title compound 108 (18mg) was prepared in a yield of 12.3%for three steps as white solid from (50mg, 0.16mmol) and 3, 5-dichloro- [1, 1′-biphenyl] -4-amine (41mg, 0.17mmol) according to the procedure for 97.
- the title compound 126 (16mg) was prepared in a yield of 17.9%for three steps as white solid from 4′-amino-3′-chloro- [1, 1′-biphenyl] -3-carbonitrile (50mg, 0.16mmol) and 97-05 (43mg, 0.19mmol) according to the procedure for compound 97.
- Step1 To a solution of compound 97-05 (1g) in super dry dichloromethane (10 mL) , compound 135-01 (150 mg, 1.1 equivs) and Titanium (IV) isopropoxide (one drops) was added at room temperature. The mixture was stirred for further 30 minutes at the same temperature. Sodium triacetoxyborohydride (1g, 1.5 equivs) was added at 0°C with ice-water bath. The resulting mixture was stirred for 2 hours. The reaction was quenched with sat.
- Step2 The tittle compound 135 (48.2mg) was prepared in a yield of 50%as white solid from 135-02 (60mg, 0.17mmol) and compound 135-03 (40.5mg, 0.19mmol) according to the procedure for compound 97-08.
- the title compound 139 (24mg) was prepared in a yield of 28.2%for three steps as white solid from 3-chloro-2′-ethoxy- [1, 1′-biphenyl] -4-amine (50mg, 0.14mmol) and 97-05 (39mg, 0.16mmol) according to the procedure for compound 97.
- the title compound 160 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
- the title compound 165 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
- Apoptosis activation by cytochrome c release from mitochondria to cytosol is a normal cellular response to mitochondrial damage.
- small molecule apoptosis inhibitors that protect cells from mitochondrial damage.
- Compound A which blocks dopaminergic neuron death in a rat model of Parkinson’s disease through targeting succinate dehydrogenase subunit B (SDHB) of complex II to protect the integrity of the mitochondrial respiratory chain.
- SDHB succinate dehydrogenase subunit B
- Compound R6 which saves cells from apoptosis via mTOR-mediated induction of autophagy.
- Compound R6 protects mitochondrial integrity and respiration after induction of the intrinsic apoptosis pathway.
- PK pharmacokinetics
- IV intravenous
- IP intraperitoneal
- Compound R6 confers significant neuro-protective effects on a rat cerebral ischemia/reperfusion model, demonstrating its potential as a promising drug candidate for neurodegenerative diseases.
- Mitochondria in mammalian cells play many functional roles in maintaining the well being of the organism, acting as the major bio-energy source, as well as a signaling compartment that can trigger apoptosis and inflammation (1, 2) .
- apoptosis and inflammation (1, 2) .
- intermembrane proteins are released into the cytosol.
- One such protein, cytochrome c is able to initiate an apoptotic caspase-9/3 activation cascade, causing apoptotic cell death (3, 4) .
- cytochrome c during apoptosis is controlled by the Bcl-2 family of proteins that come in three known flavors: the mitochondrial outer membrane gate-keepers Bax and Bak; the anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1 hetero-dimerize with Bax or Bak, and prevent them from forming oligomers on the mitochondria and altering mitochondrial outer membrane permeability; and the so-called BH-3-only proteins like Bim or tBid, which free Bax/Bak from Bcl-2/Bcl-xL/Mcl-1 by competitively binding to them (5, 6) .
- the mitochondrial outer membrane gate-keepers Bax and Bak the anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1 hetero-dimerize with Bax or Bak, and prevent them from forming oligomers on the mitochondria and altering mitochondrial outer membrane permeability
- the so-called BH-3-only proteins like Bim or
- mitochondrial inner membrane protein OpaI a dynamin-related GTPase for which loss of function mutations cause optical nerve atrophy
- mitochondrial inner membrane protease OmaI which cleaves OpaI upon Bax/Bak oligomerization, are important mediators of apoptosis that cause the mitochondrial cristae dilation to facilitate the release of cytochrome c from mitochondria.
- this compound is not a covalent modifier; it blocks apoptosis through mTOR-mediated induction of autophagy. Moreover, this compound shows significant neuro-protective effects in a rat cerebral ischemia/reperfusion model, and together with its ability to pass the blood brain barrier and accumulate in the brain via both IV and IP administration, provides a promising treatment for neurodegenerative diseases.
- a small molecule blocks Bim-induced intrinsic apoptosis
- the U2OS_Bim cell line that we previously established responds to the addition of doxycycline (Dox) by undergoing apoptosis within a few hours (7) .
- Dox doxycycline
- the addition of Dox induces the expression of Bim (henceforth Bim is referred to as BimEL, unless otherwise stated) , which subsequently activates the intrinsic apoptosis pathway in this cell line.
- BimEL doxycycline
- a chemical library of ⁇ 50,000 compounds was screened for hits that could inhibit Dox-induced apoptosis in these U2OS_Bim cells.
- Compound R6 had a half-maximal inhibitory concentration (IC50) around 207.6nM.
- IC50 half-maximal inhibitory concentration
- Compound R6 when present in the culture medium alongside Dox, blocked the release of cytochrome c from mitochondria and the subsequent activation of caspase-9, which is the well-characterized initiator caspase of the intrinsic apoptosis pathway.
- Compound R6 prevented the Bax protein from oligomerizing on the mitochondrial outer membrane, as analyzed by blue native gel electrophoresis. This result clearly indicates that Compound R6 functions upstream of any mitochondrial damage. Similar to Compound A, this compound protected the normal function of the mitochondria respiratory chain as measured by oxygen consumption.
- Compound R6 Another similarity with compound A is that the presence of Compound R6 also enabled Dox-treated cells to continue to proliferate.
- This capacity of Compound R6 to preserve cell proliferation contrasts with the well-known pan-caspase inhibitor z-VAD-FMK (zVAD) , which acts downstream of mitochondrial damage and cannot prevent cells from eventual death even the apoptotic morphological changes were abolished.
- Compound R6′s preservation of long-term cell viability was further confirmed in colony-formation assays.
- U2OS_Bim cells readily formed cell colonies on the culture dish after one week of culture with continuous co-treatment of Compound R6 and Dox, whereas hardly any colonies formed in cells with co-treatment of DMSO or zVAD and Dox. All of these results indicate that Compound R6 functions upstream of mitochondrial damage after Bim-induction.
- Compound R6 prevents apoptosis by inhibiting mTOR and activating autophagy
- Compound R6 also inhibits intrinsic apoptosis specifically induced by serum withdrawal plus a Bcl-2/Bcl-xL dual inhibitor
- Compound R6 also protected cells from apoptosis through autophagy induction by mTOR inhibition in this condition: Compound R6 could decrease the phosphorylation of S6K and increase the accumulation of LC3-II, and we observed that autophagy inhibitor 3-MA or CQ could diminish this protective effect from Compound R6. Moreover, there are 4 compounds which share structural similarity with Compound R6 that also showed apoptosis inhibition ability during the initial compound screen:
- Compound R6 has protective effect against neuronal injury in a rat model of transient focal cerebral ischemia/reperfusion injury
- ischemia cerebral ischemia followed by reperfusion, which is caused by the loss of available oxygen resulting from temporary blockage of blood flow to certain parts of the brain.
- the exceptional pharmacological properties of Compound R6 allowed us to test its effect in a rat ischemic/reperfusion model wherein ischemia is caused by occlusion of the rat’s left-side middle cerebral artery (MCA) using a nylon suture; the subsequent reperfusion results from removal of the suture 1 hour later (19-21) .
- MCA left-side middle cerebral artery
- This ischemia/reperfusion injury caused severe damage to the left side of the rats’ brain, as shown by the infarct area in the control group.
- Transient focal cerebral ischemia/reperfusion injury We modified the procedure described in ref. 20. Briefly, male Sprague Dawley rats (weight 230-250 g) were given Compound R6 by IP injection and then anesthetized with 2%isoflurane. The left common, external, and internal carotid arteries (CCA, ECA, and ICA) were exposed. A 4-0 monofilament nylon suture with a silicon-coated tip was introduced through an incision of the ECA into the ICA to occlude the origin of the middle cerebral artery for 1 hr. Animals were sacrificed 24 hr later. Brains were removed and sliced into sections of 2 mm thickness. Infarct size was examined via staining with 1.5 %2, 3, 5-triphenyltetrazolium chloride (TTC) at 37°C for 10min.
- TTC 5-triphenyltetrazolium chloride
- a compound blocks the mitochondrial pathway of apoptosis by inhibiting mTOR
- Compound R6 possesses unusual and potentially highly attractive pharmacological properties. In addition to its good pharmacodynamics properties, it passes the blood brain barrier readily and accumulates in the brain tissue after both IV and IP administration. Compound R6 showed significant protective effects by decreasing the brain infarct volume in a rat cerebral ischemia/reperfusion injury model. Mitochondrial damage is known to increase during the normal aging process and is also a common feature of many neurodegenerative diseases. R6, and its analogs provide therapeutic benefits for such diseases and for aging-related effects.
- RAFT1 a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides amides that inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
Description
Introduction
Mitochondrial damage and ensuring cell death underline many neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and cerebral ischemia/reperfusion injury. Using cellular assays that mimic the activation of mitochondrial apoptosis pathway, we screened out a novel small molecule that blocks apoptosis by protecting mitochondrial integrity and function. Specifically, Compound R6 prevents apoptosis by activating autophagy through mTOR inhibition; it also confers significant, dose-dependent neuro-protective effects in a rat cerebral ischemia/reperfusion injury model. We use SAR to develop a class of pharmaceutically active inhibitors of mTOR-mediated induction of autophagy, with particular applications for treating cerebral ischemia/reperfusion and neurodegenerative diseases.
Summary of the Invention
The invention provides compounds that inhibit of apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, and prodrugs thereof, which are hydrolyzed, typically in the gut or blood, to yield the corresponding compounds/inhibitors.
In an aspect the invention provides a compound of formula I, or a salt, hydrate or stereosomer thereof:
wherein:
R1 is C3-C14 cyclic or hetero-cyclic moiety, particularly substituted or unsubstituted, 0-3 heteroatom C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl; or substituted or unsubstituted, 0-3 heteroatom C5-C14 aryl;
R2 is optionally substituted phenyl; and
R3 is H, substituted or unsubstituted, 0-3 heteroatom hydrocarbyl.
In embodiments:
R1 is optionally substituted phenyl, biphenyl or 2, 3-dihydro-indenyl;
R2 is 4- (pyrrolidin-1-yl) phenyl; and/or
R3 is optionally substituted ethyl.
the compound has a structure disclosed herein, optionally excluding hit compound 6.
In an aspect the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound for formula I (supra) in predetermined, unit dosage form and one or more pharmaceutically acceptable excipients.
In an aspect the invention provides use of a compound or composition disclosed herein in the manufacture of a medicament to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof.
In an aspect the invention provides a compound or composition disclosed herein to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof, or in the manufacture of a medicament thereof in a person in need thereof.
In an aspect the invention provides a method of using a compound or composition disclosed herein to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, and optionally detecting a resultant improvement in the person’s health or condition.
The invention encompasses all combination of the particular embodiments recited herein, as if each combination had been laboriously recited.
Figs. 1A-1F. Exemplary substitutions.
Description of particular embodiments of the invention
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
The term ″alkyl″ refers to a hydrocarbon group selected from linear and branched saturated hydrocarbon groups of 1-18, or 1-12, or 1-6 carbon atoms. Examples of the alkyl group include methyl, ethyl, 1-propyl or n-propyl ( ″n-Pr″ ) , 2-propyl or isopropyl ( ″i-Pr″ ) , 1-butyl or n-butyl ( ″n-Bu″ ) , 2-methyl-1-propyl or isobutyl ( ″i-Bu″ ) , 1-methylpropyl or s-butyl ( ″s-Bu″ ) , and 1, 1-dimethylethyl or t-butyl ( ″t-Bu″ ) . Other examples of the alkyl group include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2, 3-dimethyl-2-butyl and 3, 3-dimethyl-2-butyl groups.
Lower alkyl means 1-8, preferably 1-6, more preferably 1-4 carbon atoms; lower alkenyl or alkynyl means 2-8, 2-6 or 2-4 carbon atoms.
The term ″alkenyl″ refers to a hydrocarbon group selected from linear and branched hydrocarbon groups comprising at least one C=C double bond and of 2-18, or 2-12, or 2-6 carbon atoms. Examples of the alkenyl group may be selected from ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1, 3-dienyl, 2-methylbuta-1, 3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1, 3-dienyl groups.
The term ″alkynyl″ refers to a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C≡C triple bond and of 2-18, or 2-12, or 2-6 carbon atoms. Examples of the alkynyl group include ethynyl, 1-propynyl, 2-propynyl (propargyl) , 1-butynyl, 2-butynyl, and 3-butynyl groups.
The term ″cycloalkyl″ refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups. For example, the cycloalkyl group may be of 3-12, or 3-8, or 3-6 carbon atoms. Even further for example, the cycloalkyl group may be a monocyclic group of 3-12, or 3-8, or 3-6 carbon atoms. Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. Examples of the bicyclic cycloalkyl groups include those having 7-12 ring atoms arranged as a bicycle ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems, or as a bridged bicyclic ring selected from bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, and bicyclo [3.2.2] nonane. The ring may be saturated or have at least one double bond (i.e. partially unsaturated) , but is not fully conjugated, and is not aromatic, as aromatic is defined herein.
The term “aryl” herein refers to a group selected from: 5-and 6-membered carbocyclic aromatic rings, for example, phenyl; bicyclic ring systems such as 7-12 membered bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, selected, for example, from naphthalene, indane, and 1, 2, 3, 4-tetrahydroquinoline; and tricyclic ring systems such as 10-15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
For example, the aryl group is selected from 5-and 6-membered carbocyclic aromatic rings fused to a 5-to 7-membered cycloalkyl or heterocyclic ring optionally comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring when the carbocyclic aromatic ring is fused with a heterocyclic ring, and the point of attachment can be at the carbocyclic aromatic ring or at the cycloalkyl group when the carbocyclic aromatic ring is fused with a cycloalkyl group. Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in ″-yl″ by removal of one hydrogen atom from the carbon atom with the free valence are named by adding ″-idene″ to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
The term ″halogen″ or “halo” refers to F, Cl, Br or I.
The term ″heteroalkyl″ refers to alkyl comprising at least one heteroatom.
The term ″heteroaryl″ refers to a group selected from:
5-to 7-membered aromatic, monocyclic rings comprising 1, 2, 3 or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon;
8-to 12-membered bicyclic rings comprising 1, 2, 3 or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and
11-to 14-membered tricyclic rings comprising 1, 2, 3 or 4 heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
For example, the heteroaryl group includes a 5-to 7-membered heterocyclic aromatic ring fused to a 5-to 7-membered cycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings comprises at least one heteroatom, the point of attachment may be at the heteroaromatic ring or at the cycloalkyl ring.
When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
Examples of the heteroaryl group include, but are not limited to, (as numbered from the linkage position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl) , cinnolinyl, pyrazinyl, 2, 4-pyrimidinyl, 3, 5-pyrimidinyl, 2, 4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furyl, benzofuryl, benzoimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl (such as 1H-pyrrolo [2, 3-b] pyridin-5-yl) , pyrazolopyridinyl (such as1H-pyrazolo [3, 4-b] pyridin-5-yl) , benzoxazolyl (such as benzo [d] oxazol-6-yl) , pteridinyl, purinyl, 1-oxa-2, 3-diazolyl, 1-oxa-2, 4-diazolyl, 1-oxa-2, 5-diazolyl, 1-oxa-3, 4-diazolyl, 1-thia-2, 3-diazolyl, 1-thia-2, 4-diazolyl, 1-thia-2, 5-diazolyl, 1-thia-3, 4-diazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (such as benzo [d] thiazol-6-yl) , indazolyl (such as 1H-indazol-5-yl) and 5, 6, 7, 8-tetrahydroisoquinoline.
The term ″heterocyclic″ or ″heterocycle″ or ″heterocyclyl″ refers to a ring selected from 4-to 12-membered monocyclic, bicyclic and tricyclic, saturated and partially unsaturated rings comprising at least one carbon atoms in addition to 1, 2, 3 or 4 heteroatoms, selected from oxygen, sulfur, and nitrogen. “Heterocycle” also refers to a 5-to 7-membered heterocyclic ring comprising at least one heteroatom selected from N, O, and S fused with 5-, 6-, and/or 7-membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring when the heterocyclic ring is fused with a carbocyclic aromatic or a heteroaromatic ring, and that the point of attachment can be at the cycloalkyl or heterocyclic ring when the heterocyclic ring is fused with cycloalkyl.
“Heterocycle” also refers to an aliphatic spirocyclic ring comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring. The rings may be saturated or have at least one double bond (i.e. partially unsaturated) . The heterocycle may be substituted with oxo. The point of the attachment may be carbon or heteroatom in the heterocyclic ring. A heterocyle is not a heteroaryl as defined herein.
Examples of the heterocycle include, but not limited to, (as numbered from the linkage position assigned priority 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2, 4-imidazolidinyl, 2, 3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2, 5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1, 2-dithietanyl, 1, 3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, 1, 4-oxathianyl, 1, 4-dioxepanyl, 1, 4-oxathiepanyl, 1, 4-oxaazepanyl, 1, 4-dithiepanyl, 1, 4-thiazepanyl and 1, 4-diazepane 1, 4-dithianyl, 1, 4-azathianyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, 1, 4-dioxanyl, 1, 3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinylimidazolinyl, pyrimidinonyl, 1, 1-dioxo-thiomorpholinyl, 3-azabicyco [3.1.0] hexanyl, 3-azabicyclo [4.1.0] heptanyl and azabicyclo [2.2.2] hexanyl. Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1, 1-dioxo-1-thiomorpholinyl.
The term ″fused ring″ herein refers to a polycyclic ring system, e.g., a bicyclic or tricyclic ring system, in which two rings share only two ring atoms and one bond in common. Examples of fused rings may comprise a fused bicyclic cycloalkyl ring such as those having from 7 to 12 ring atoms arranged as a bicyclic ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems as mentioned above; a fused bicylclic aryl ring such as 7 to 12 membered bicyclic aryl ring systems as mentioned above, a fused tricyclic aryl ring such as 10 to 15 membered tricyclic aryl ring systems mentioned above; a fused bicyclic heteroaryl ring such as 8-to 12-membered bicyclic heteroaryl rings as mentioned above, a fused tricyclic heteroaryl ring such as 11-to 14-membered tricyclic heteroaryl rings as mentioned above; and a fused bicyclic or tricyclic heterocyclyl ring as mentioned above.
In embodiments substituents are selected from optionally substituted heteroatom and optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl, particularly wherein the optionally substituted, optionally hetero-, optionally cyclic C1-C18 hydrocarbyl is optionally-substituted, optionally hetero-, optionally cyclic alkyl, alkenyl or alkynyl, or optionally-substituted, optionally hetero-aryl; and/or the optionally substituted heteroatom is halogen, optionally substituted hydroxyl (such as alkoxy, aryloxy) , optionally substituted acyl (such as formyl, alkanoyl, carbamoyl, carboxyl, amido) , optionally substituted amino (such as amino, alkylamino, dialkylamino, amido, sulfamidyl) , optionally substituted thiol (such as mercapto, alkylthiol, aryl thiol) , optionally substituted sulfinyl or sulfonyl (such as alkylsulfinyl, arylsulfinyl, alkyl sulfonyl, arylsulfonyl) , nitro, or cyano.
In embodiments, substituents are selected from: halogen, -R′, -OR′, =O, =NR′, =N-OR′, -NR′R″, -SR′, -SiR′R″R″′, -OC (O) R′, -C (O) R′, -CO2R′, -CONR′R″, -OC (O) NR′R″, -NR″C (O) R′, -NR′-C (O) NR″R″′, -NR′-SO2NR″′, -NR″CO2R′, -NH-C (NH2) =NH, -NR′C (NH2) =NH, -NH-C (NH2) =NR′, -S (O) R′, -SO2R′, -SO2NR′R″, -NR″SO2R, -CN and -NO2, -N3, -CH (Ph) 2, perfluoro (C1-C4) alkoxy and perfluoro (C1-C4) alkyl, in a number ranging from zero to three, with those groups having zero, one or two substituents being particularly preferred. R′, R″ and R″′ each independently refer to hydrogen, unsubstituted (C1-C8) alkyl and heteroalkyl, (C1- C8) alkyl and heteroalkyl substituted with one to three halogens, unsubstituted aryl, aryl substituted with one to three halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl- (C1-C4) alkyl groups. When R′and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-or 7-membered ring. Hence, -NR′R″ includes 1-pyrrolidinyl and 4-morpholinyl, ″alkyl” includes groups such as trihaloalkyl (e.g., -CF3 and -CH2CF3) , and when the aryl group is 1, 2, 3, 4-tetrahydronaphthalene, it may be substituted with a substituted or unsubstituted (C3-C7) spirocycloalkyl group. The (C3-C7) spirocycloalkyl group may be substituted in the same manner as defined herein for ″cycloalkyl″ .
Preferred substituents are selected from: halogen, -R′, -OR′, =O, -NR′R″, -SR′, -SiR′R″R″′, -OC (O) R′, -C (O) R′, -CO2R′, -CONR′R″, -OC (O) NR′R″, -NR″C (O) R′, -NR″CO2R′, -NR′-SO2NR″R″′, -S (O) R′, -SO2R′, -SO2NR′R″, -NR″SO2R, -CN and -NO2, perfluoro (C1-C4) alkoxy and perfluoro (C1-C4) alkyl, where R′and R″ are as defined above.
Preferred substituents are disclosed herein and exemplified in the tables, structures, examples, and claims, and may be applied across different compounds of the invention, i.e. substituents of any given compound may be combinatorially used with other compounds.
In particular embodiments applicable substituents are independently substituted or unsubstituted heteroatom, substituted or unsubstituted, 0-3 heteroatom C1-C6 alkyl, substituted or unsubstituted, 0-3 heteroatom C2-C6 alkenyl, substituted or unsubstituted, 0-3 heteroatom C2-C6 alkynyl, or substituted or unsubstituted, 0-3 heteroatom C6-C14 aryl, wherein each heteroatom is independently oxygen, phosphorus, sulfur or nitrogen.
In more particular embodiments, applicable substituents are independently aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkyloxy, alkyl, amine, azo, halogens, carbamoyl, carbonyl, carboxamido, carboxyl, cyanyl, ester, halo, haloformyl, hydroperoxyl, hydroxyl, imine, isocyanide, iscyante, N-tert-butoxycarbonyl, nitrate, nitrile, nitrite, nitro, nitroso, phosphate, phosphono, sulfide, sulfonyl, sulfo, sulfhydryl, thiol, thiocyanyl, trifluoromethyl or trifluromethyl ether (OCF3) .
The compounds may contain an asymmetric center and may thus exist as enantiomers. Where the compounds possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
The term “substantially pure” means that the target stereoisomer contains no more than 35%, such as no more than 30%, further such as no more than 25%, even further such as no more than 20%, by weight of any other stereoisomer (s) . In some embodiments, the term “substantially pure” means that the target stereoisomer contains no more than 10%, for example, no more than 5%, such as no more than 1%, by weight of any other stereoisomer (s) .
When compounds contain olefin double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers.
Some of the compounds may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl -CH
2C (O) -groups (keto forms) may undergo tautomerism to form hydroxyl -CH=C (OH) -groups (enol forms) . Both keto and enol forms, individually as well as mixtures thereof, are also intended to be included where applicable.
It may be advantageous to separate reaction products from one another and/or from starting materials. The desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ( ″SMB″ ) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography. One skilled in the art will apply techniques most likely to achieve the desired separation.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher′s acid chloride) , separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of a chiral HPLC column.
A single stereoisomer, e.g., a substantially pure enantiomer, may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents. Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
“Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, selected, for example, from hydrochlorates, phosphates, diphosphates, hydrobromates, sulfates, sulfinates, and nitrates; as well as salts with organic acids, selected, for example, from malates, maleates, fumarates, tartrates, succinates, citrates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, alkanoates such as acetate, and salts with HOOC- (CH
2) n-COOH, wherein n is selected from 0 to 4. Similarly, examples of pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
In addition, if a compound is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable addition salts.
“Treating, ” “treat, ” or ″treatment″ refers to administering at least one compound and/or at least one stereoisomer thereof, and/or at least one pharmaceutically acceptable salt thereof to a subject in recognized need thereof.
An ″effective amount″ refers to an amount of at least one compound and/or at least one stereoisomer thereof, and/or at least one pharmaceutically acceptable salt thereof effective to ″treat″ a disease or disorder in a subject, and that will elicit, to some significant extent, the biological or medical response of a tissue, system, animal or human that is being sought, such as when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
The term ″at least one substituent″ includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents. For example, ″at least one substituent R
16″ herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents selected from the list of R
16 as described herein.
The subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may be employed alone or in combination with at least one other therapeutic agent for treatment. In some embodiments, the compounds, stereoisomers thereof, and pharmaceutically acceptable salts thereof can be used in combination with at least one additional therapeutic agent. The compound and/or one pharmaceutically acceptable salt disclosed herein may be administered with the at least one other therapeutic agent in a single dosage form or as a separate dosage form. When administered as a separate dosage form, the at least one other therapeutic agent may be administered prior to, at the same time as, or following administration of the compound and/or one pharmaceutically acceptable salt disclosed herein.
Also provided is a composition comprising a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
The composition comprising a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof can be administered in various known manners, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implanted reservoir, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The compositions disclosed herein may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art.
The subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragées, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions. The subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosages forms that can also be used to administer the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
Gelatin capsules containing the compound and/or the at least one pharmaceutically acceptable salt thereof disclosed herein and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like, can also be used. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can further comprise at least one agent selected from coloring and flavoring agents to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene gycols can be examples of suitable carriers for parenteral solutions. Solutions for parenteral administration may comprise a water soluble salt of the at least one compound describe herein, at least one suitable stabilizing agent, and if necessary, at least one buffer substance. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, can be examples of suitable stabilizing agents. Citric acid and its salts and sodium EDTA can also be used as examples of suitable stabilizing agents. In addition, parenteral solutions can further comprise at least one preservative, selected, for example, from benzalkonium chloride, methyl-and propylparaben, and chlorobutanol.
A pharmaceutically acceptable carrier is, for example, selected from carriers that are compatible with active ingredients of the composition (and in some embodiments, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated. For example, solubilizing agents, such as cyclodextrins (which can form specific, more soluble complexes with the at least one compound and/or at least one pharmaceutically acceptable salt disclosed herein) , can be utilized as pharmaceutical excipients for delivery of the active ingredients. Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow # 10. Suitable pharmaceutically acceptable carriers are described in Remington′s Pharmaceutical Sciences, A. Osol, a standard reference text in the art.
For administration by inhalation, the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof may also be delivered as powders, which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. One exemplary delivery system for inhalation can be metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein in at least one suitable propellant, selected, for example, from fluorocarbons and hydrocarbons.
For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percentage of a solution or suspension of the subject compound and stereoisomers thereof, and pharmaceutically acceptable salts thereof in an appropriate ophthalmic vehicle, such that the subject compound and stereoisomers thereof, and at least one pharmaceutically acceptable salts thereof is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
Useful pharmaceutical dosage-forms for administration of the subject compounds and stereoisomers thereof, and pharmaceutically acceptable salts thereof disclosed herein include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
The dosage administered will be dependent on factors, such as the age, health and weight of the recipient, the extent of disease, type of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. In general, a daily dosage of the active ingredient can vary, for example, from 0.1 to 2000 milligrams per day. For example, 10-500 milligrams once or multiple times per day may be effective to obtain the desired results.
In some embodiments, a large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with, for example, 100 milligrams of the subject compound and stereoisomers thereof, and pharmaceutically acceptable salt thereof disclosed herein in powder, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
In some embodiments, a mixture of the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.
In some embodiments, a large number of tablets can be prepared by conventional procedures so that the dosage unit comprises, for example, 100 milligrams of the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
In some embodiments, a parenteral composition suitable for administration by injection can be prepared by stirring 1.5%by weight of the compound and/or at least an enantiomer, a diastereomer, or pharmaceutically acceptable salt thereof disclosed herein in 10%by volume propylene glycol. The solution is made to the expected volume with water for injection and sterilized.
In some embodiment, an aqueous suspension can be prepared for oral administration. For example, each 5 milliliters of an aqueous suspension comprising 100 milligrams of finely divided compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin can be used.
The same dosage forms can generally be used when the compound, stereoisomers thereof, and pharmaceutically acceptable salts thereof are administered stepwise or in conjunction with at least one other therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus the term coadministration is understood to include the administration of at least two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the at least two active components.
The compounds, stereoisomers thereof, and pharmaceutically acceptable salt thereof disclosed herein can be administered as the sole active ingredient or in combination with at least one second active ingredient.
The subject compounds are incorporated into pharmaceutical compositions or formulations. The compositions will contain pharmaceutically acceptable diluents and/or carriers, i.e. diluents or carriers that are physiologically compatible and substantially free from pathogenic impurities. Suitable excipients or carriers and methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in more detail in such publications as Remington′s Pharmaceutical Science, Mack Publishing Co, NJ (1991) . The compositions may also be in the form of controlled release or sustained release compositions as known in the art. For many applications the subject compounds are administered for morning/daytime dosing, with off period at night.
The subject compounds may be used per se, or in the form of their pharmaceutically acceptable salts, such as hydrochlorides, hydrobromides, acetates, sulfates, citrates, carbonates, trifluoroacetates and the like. When compounds contain relatively acidic functionalities, salts can be obtained by addition of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or the like. When compounds contain relatively basic functionalities, salts can be obtained by addition of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al, “Pharmaceutical Salts” , Journal of Pharmaceutical Science, 1977, 66, 1-19) .
The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of this invention.
In addition to salt forms, this invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be more bioavailable by oral administration than the parent drug. The prodrug may also have improved solubility in pharmacological compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the ″prodrug″ ) , but then is metabolically hydrolyzed to the carboxylic acid, the active entity.
Certain compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the invention.
Some of the subject compounds possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
The compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds, such as deuterium, e.g. -CD
3, CD
2H or CDH
2 in place of methyl. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (
3H) , iodine-125 (
125I) or carbon-14 (
14C) . All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
The compounds are generally administered in a ″therapeutically effective amount″ , i.e. the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. The term ″therapeutically effective amount″ includes that amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
The contacting is generally effected by administering to the subject an effective amount of one or more compounds having the general formula I (supra) , including the various embodiments described above. Generally administration is adjusted to achieve a therapeutic dosage of about 0.1 to 50, preferably 0.5 to 10, more preferably 1 to 10 mg/kg, though optimal dosages are compound specific, and generally empirically determined for each compound.
The term ″unit dosage forms″ refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules, lozenges or the like in the case of solid compositions. In such compositions, the mimetic is usually a minor component (from about 0.1 to about 50%by weight or preferably from about 1 to about 40%by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form. Unit dosage formulations are preferably about of 5, 10, 25, 50, 100, 250, 500, or 1,000 mg per unit. In a particular embodiment, unit dosage forms are packaged in a multipack adapted for sequential use, such as blisterpack comprising sheets of at least 6, 9 or 12 unit dosage forms.
The subject compositions may also be coformulated and/or coadministered with a different compound to treat applicable indications.
Table A: Active Compounds: Structures
Active compounds were demonstrated to inhibit Bim-induced intrinsic apoptosis. Representative active compounds where also demonstrated to inhibit apoptosis by inhibiting mTOR and activating autophagy, to inhibit intrinsic apoptosis specifically induced by serum withdrawal plus a Bcl-2/Bcl-xL dual inhibitor, and to protect against neuronal injury in a rat model of transient focal cerebral ischemia/reperfusion injury; methods all herein.
Table 1: Active compounds: Inhibition of Bim-induced apoptosis;
# | EC50 | # | EC50 | # | EC50 | # | EC50 |
1 | >10 uM | 52 | >10 uM | 103 | 1-1000 nM | 154 | 1-10 uM |
2 | >10 uM | 53 | 1-1000 nM | 104 | 1-1000 nM | 155 | 1-10 uM |
3 | 1-10 uM | 54 | 1-1000 nM | 105 | 1-1000 nM | 156 | 1-1000 nM |
4 | >10 uM | 55 | 1-1000 nM | 106 | 1-10 uM | 157 | 1-1000 nM |
5 | >10 uM | 56 | 1-1000 nM | 107 | 1-10 uM | 158 | 1-1000 nM |
6 | 1-1000 nM | 57 | 1-1000 nM | 108 | 1-1000 nM | 159 | 1-10 uM |
7 | >10 uM | 58 | 1-1000 nM | 109 | > 10 uM | 160 | 1-1000 nM |
8 | >10 uM | 59 | 1-1000 nM | 110 | 1-10 uM | 161 | 1-1000 nM |
9 | >10 uM | 60 | 1-1000 nM | 111 | 1-10 uM | 162 | 1-1000 nM |
10 | >10 uM | 61 | 1-1000 nM | 112 | 1-10 uM | 163 | 1-1000 nM |
11 | >10 uM | 62 | 1-1000 nM | 113 | 1-1000 nM | 164 | 1-1000 nM |
12 | 1-10 uM | 63 | 1-10 uM | 114 | > 10 uM | 165 | 1-1000 nM |
13 | 1-1000 nM | 64 | > 10 uM | 115 | 1-1000 nM | 166 | 1-1000 nM |
14 | 1-1000 nM | 65 | 1-1000 nM | 116 | 1-1000 nM | 167 | 1-1000 nM |
15 | >10 uM | 66 | 1-1000 nM | 117 | 1-1000 nM | 168 | 1-1000 nM |
16 | >10 uM | 67 | 1-10 uM | 118 | 1-10 uM | 169 | 1-1000 nM |
17 | >10 uM | 68 | 1-1000 nM | 119 | 1-1000 nM | 170 | 1-1000 nM |
18 | >10 uM | 69 | 1-1000 nM | 120 | > 10 uM | 171 | 1-1000 nM |
19 | >10 uM | 70 | 1-10 uM | 121 | 1-10 uM | 172 | 1-1000 nM |
20 | >10 uM | 71 | > 10 uM | 122 | 1-1000 nM | 173 | 1-1000 nM |
21 | >10 uM | 72 | 1-10 uM | 123 | 1-1000 nM | 174 | 1-1000 nM |
22 | 1-1000 nM | 73 | > 10 uM | 124 | 1-1000 nM | 175 | 1-1000 nM |
23 | 1-1000 nM | 74 | 1-10 uM | 125 | > 10 uM | 176 | 1-1000 nM |
24 | 1-1000 nM | 75 | 1-10 uM | 126 | 1-1000 nM | 177 | 1-1000 nM |
25 | 1-1000 nM | 76 | 1-10 uM | 127 | 1-10 uM | 178 | 1-1000 nM |
26 | > 10 uM | 77 | 1-1000 nM | 128 | 1-1000 nM | 179 | 1-1000 nM |
27 | > 10 uM | 78 | 1-1000 nM | 129 | 1-1000 nM | 180 | 1-1000 nM |
28 | 1-1000 nM | 79 | 1-1000 nM | 130 | 1-1000 nM | 181 | 1-1000 nM |
29 | > 10uM | 80 | > 10 uM | 131 | 1-1000 nM | 182 | 1-1000 nM |
30 | 1-10 uM | 81 | > 10 uM | 132 | 1-1000 nM | 183 | 1-1000 nM |
31 | 1-10 uM | 82 | 1-10 uM | 133 | 1-1000 nM | 184 | 1-1000 nM |
32 | 1-1000 nM | 83 | 1-1000 nM | 134 | 1-1000 nM | 185 | 1-1000 nM |
33 | > 10uM | 84 | > 10 uM | 135 | > 10 uM | 186 | 1-1000 nM |
34 | > 10uM | 85 | > 10 uM | 136 | 1-1000 nM | 187 | 1-1000 nM |
35 | > 10uM | 86 | 1-10 uM | 137 | 1-1000 nM | 188 | 1-1000 nM |
36 | 1-10 uM | 87 | 1-10 uM | 138 | 1-1000 nM | 189 | 1-1000 nM |
37 | 1-1000 nM | 88 | 1-1000 nM | 139 | 1-1000 nM | 190 | 1-1000 nM |
38 | 1-1000 nM | 89 | > 10 uM | 140 | 1-1000 nM | 191 | 1-1000 nM |
39 | 1-1000 nM | 90 | 1-10 uM | 141 | 1-1000 nM | 192 | 1-1000 nM |
40 | 1-1000 nM | 91 | 1-1000 nM | 142 | 1-1000 nM | 193 | 1-1000 nM |
41 | 1-1000 nM | 92 | > 10 uM | 143 | 1-1000 nM | 194 | 1-1000 nM |
42 | 1-1000 nM | 93 | > 10 uM | 144 | 1-1000 nM | 195 | 1-1000 nM |
43 | 1-1000 nM | 94 | 1-10 uM | 145 | 1-1000 nM | 196 | > 10 uM |
44 | > 10uM | 95 | 1-10 uM | 146 | 1-1000 nM | 197 | 1-1000 nM |
45 | 1-10 uM | 96 | > 10 uM | 147 | 1-10 uM | 198 | 1-1000 nM |
46 | > 10uM | 97 | 1-10 uM | 148 | 1-10 uM | 199 | 1-1000 nM |
47 | 1-1000 nM | 98 | > 10 uM | 149 | 1-1000 nM | 200 | 1-1000 nM |
48 | 1-10 uM | 99 | 1-10 uM | 150 | 1-10 uM | 201 | 1-1000 nM |
49 | 1-10 uM | 100 | 1-1000 nM | 151 | 1-1000 nM | ||
50 | > 10uM | 101 | 1-1000 nM | 152 | 1-1000 nM | ||
51 | 1-1000 nM | 102 | 1-1000 nM | 153 | 1-1000 nM |
Active Compounds: Representative Synthesis Preparation of 8- ( [1, 1′-biphenyl] -4-ylmethyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (1)
Step 1: The 1-01 (1g, 3.7mmol) , 1-02 (1.2g, 5.6mmol) and K
2CO
3 (1.1g, 7.4mmol) were added to DMF. Then the reaction mixture was reacted in microwave at 100℃ for 30min. The reaction mixture was diluted by H
2O, extracted with EA for 3 times. The organic layers were combined, washed by H
2O, brine, dried over Na
2SO
4, filtrated and evaporated to give crude product. The crude product was purified by silica gel column chromatography (PE: EA=3: 1 to 1: 2) to recycle 844mg 1-01 and to give 132mg 1-03 as white solid. Mass (m/z) : 386.17 [M+H]
+.
Step 2: The solution of 1-03 (132mg, 0.34mmol) in DMF was cooled to 0℃, then 60%NaH (41.2mg, 1.03mmol) was added to it. The reaction mixture was stirred at 0℃ for 30min, followed by addition of CH
3CH
2I (160mg, 1.03mmol) . The reaction mixture was warmed to room temperature and stirred for 4h. The reaction was quenched by H
2O, and the aqueous layer was extracted by EA for 3 times. The organic layers were combined, washed with H
2O, brine, dried over Na
2SO
4, filtrated and evaporated to give 156mg 1-04 as light brown solid which was used without further purification. Mass (m/z) : 414.48 [M+H]
+.
Step 3: The 1-04 (0.34mmol) was dissolved in hydrogen chloride (1N in ethanol) , the reaction mixture was heated to 50℃, and then stirred for 2h. The reaction mixture was evaporated to remove ethanol to give 1-05 as light yellow solid, which was used without further purification. Mass (m/z) : 314.36 [M+H]
+.
Step 4: The 1-05 (34mg, 0.097mmol) , biphenyl-4-carbaldehyde (20mg, 0.11mmol) , NaBH (AcO)
3 (42mg , 0.2mmol) and Ti (Oi-Pr)
4 (catalytic amount) were mixed in DCE. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduce pressure to give crude product. The crude product was purified with pre-TLC (PE: EA=1: 1) to give compound 1 as white solid (17.8mg, 44.7%for 3 steps) .
1HNMR (400 MHz, CDCl
3) δ 7.60-7.56 (m, 4H) , 7.46-7.42 (m, 4H) , 7.37-7.33 (m, 1H) , 7.20-7.15 (m, 4H) , 4.94 (p, J=9.0Hz, 1H) , 3.73 (s, 2H) , 3.56 (d, J=15.2Hz, 1H) , 3.53 (d, J=15.2Hz, 1H) , 3.35 (q, J=7.1Hz, 2H) , 3.15 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.96 (br, 4H) , 1.71 (d, J=13.4Hz, 2H) , 1.25 (t, J=7.2Hz, 3H) . Mass (m/z) : 480.43 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (dimethylamino) benzyl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (2)
The title compound 2 (9.8mg) was prepared in a yield of 30.6%as light yellow powder from 1-05 (25mg, 0.072mmol) and 4- (dimethylamino) benzaldehyde (12mg, 0.080mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.32 (d, J=8.4Hz, 2H) , 7.17 (m, J=8.8Hz, 2H) , 4.92 (p, J=9.0Hz, 1H) , 3.90 (s, 2H) , 3.51 (d, J=15.2Hz, 1H) , 3.48 (d, J=15.2Hz, 1H) , 3.39 (q, J=7.2Hz, 2H) , 3.14 (s, J=15.2Hz, 1H) , 3.11 (d, J=15.2Hz, 1H) , 2.95 (s, 6H) , 1.24 (t, J=7.2Hz, 3H) . Mass (m/z) : 447.38 [M+H]
+.
Preparation of 1-ethyl-3- (naphthalen-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (3)
Step 1: The 1-01 (180mg, 0.67mmol) , 3-01 (126mg, 0.61mmol) , Cu
2O (54mg, 0.73mmol) , K
2CO
3 (185mg, 1.34mmol) and N
1, N
2-dimethylethane-1, 2-diamine (118mg, 1.34mmol) were mixed in DMF (5mL) . The reaction mixture was reacted in microwave at 150℃ for 1h. The reaction mixture was diluted by water, and the aqueous was extracted by EA for several times. The organic layers were combined, washed with water, brine in turn, dried over Na
2SO
4. Filtrated and evaporated to remove solvent to give crude product, which was purified by silica gel chromatography (PE to PE: EA=2: 1) to give 147mg 3-02 as light pink powder in a yield of 61.8%. Mass (m/z) : 396.27 [M+H]
+.
Step 2: The 3-02 (110mg, 0.28mmol) and K
2CO
3 (115mg, 0.83mmol) were mixed in DMF (10mL) . EtI (130mg, 0.83mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at room temperature for 2 days. The reaction mixture was diluted by water, and the aqueous layer was extracted by EA for several times. The organic layers were combined, washed with water, brine in turn, dried over Na
2SO
4. Filtrated and evaporated to remove solvent to give crude product, which was purified by silica gel chromatography (PE: EA=3: 1) to give 163mg 3-03 as light yellow oil in a yield of 100%. Mass (m/z) : 424.35 [M+H]
+.
Step 3: The 3-04 (144mg) was prepared as yellow powder from 3-03 (160mg, 0.38mmol) according to the procedure for 1-05. Mass (m/z) : 325.38 [M+H]
+.
Step 4: The compound 3 (29mg) was prepared as white solid in a yield of 35.4%from 3-04 (55mg, 0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (33mg, 0.19mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.92-7.87 (m. 2H) , 7.86-7.83 (m, 2H) , 7.53-7.50 (m, 2H) , 7.47 (dd, J=8.8, 2.1Hz, 1H) , 7.35 (d, J=8.6Hz, 2H) , 6.53 (d, J=8.7Hz, 2H) , 4.01 (s, 2H) , 3.52 (q, J=7.1Hz, 2H) , 3.38-3.45 (m, 4H) , 3.26 (m, 4H) , 3.09 (m, 2H) , 1.99 (m, 4H) , 1.90 (d, J=14.5Hz, 2H) , 1.31 (t, J=7.1Hz, 3H) . Mass (m/z) : 483.52 [M+H]
+.
Preparation of 8- ( (9H-fluoren-2-yl) methyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (4)
The title compound 4 (22.4mg) was prepared in a yield of 63.3%as light yellow powder from 1-05 (25mg, 0.072mmol) and 9H-fluorene-2-carbaldehyde (16mg, 0.080mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.78-7.74 (m, 2H) , 7.58-7.53 (m, 2H) , 7.39-7.35 (m, 2H) , 7.32-7.28 (m, 1H) , 7.20-7.15 (m, 4H) , 7.94 (p, J=9.1Hz, 1H) , 3.90 (s, 2H) , 3.77 (br, 2H) , 3.55 (d, J=15.2Hz, 1H) , 3.52 (d, J=15.6Hz, 1H) , 3.35 (q, J=7.2Hz, 2H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.98 (br, 4H) , 1.71 (d, J=13.6Hz, 2H) , 1.25 (t, J=7.2Hz, 3H) . Mass (m/z) : 492.55 [M+H]
+.
Preparation of 8- (4- (1H-pyrrol-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (5)
The title compound 5 (12.4mg) was prepared in a yield of 36.8%as light yellow powder from 1-05 (25mg, 0.072mmol) and 4- (1H-pyrrol-1-yl) benzaldehyde (15mg, 0.080mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.42 (m, 2H) , 7.35 (m, 2H) , 7.19-7.15 (m, 4H) , 7.08 (t, J=2.2Hz, 2H) , 6.35 (t, J=2.2Hz, 2H) , 4.94 (p, J=9.1Hz, 1H) , 3.70 (br, 2H) , 3.55 (d, J=15.2Hz, 1H) , 3.52 (d, J=15.2Hz, 1H) , 3.35 (q, J=7.2Hz, 2H) , 3.15 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.93 (br, 4H) , 1.72 (d, J=12.8Hz, 2H) , 1.25 (t, J=7.2Hz, 3H) .
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione 6 (hit)
The title compound 6 (9.8mg) was prepared in a yield of 74.1%as light yellow powder from 1-05 (25mg, 0.072mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (14mg, 0.080mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.33 (d, J=8.4Hz, 2H) , 7.17 (m, 4H) , 6.52 (d, J=8.8Hz, 2H) , 4.91 (p, J=9.1Hz, 1H) , 4.00 (s, 2H) , 3.49 (d, J=15.2Hz, 1H) , 3.46 (d, J= J=15.2Hz, 1H) , 3.40 (q, J=7.2Hz, 2H) , 3.34-3.37 (m, 2H) , 3.26 (m, 4H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.91-2.96 (m, 2H) , 1.99 (m, 4H) , 1.74 (d, J=14.0Hz, 2H) , 1.24 (t, J=7.2Hz, 3H) . Mass (m/z) : 473.47 [M+H]
+.
Preparation of 8- (4- (1H-pyrazol-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (7)
The title compound 7 (3.2mg) was prepared in a yield of 14.8%as light yellow powder from 1-05 (15mg, 0.046mmol) and 4- (1H-pyrazol-1-yl) benzaldehyde (9mg, 0.051mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.93 (m, 1H) , 7.76-7.68 (m, 4H) , 7.60 (br, 1H) , 7.54-7.44 (m, 1H) , 7.20-7.15 (m, 3H) , 6.49-6.46 (m, 1H) , 4.93 (p, J=9.0Hz, 1H) , 3.52 (d, J+15.2Hz, 1H) , 3.49 (d, J=15.2Hz, 1H) , 3.39 (q, J=7.2Hz, 2H) , 3.15 (d, J=15.2Hz, 1H) , 3.13 (d, J=15.2Hz, 1H) , 2.09 (s, 2H) , 2.03-1.98 (m, 1H) , 1.77-1.60 (m, 4H) , 1.49-1.39 (m, 1H) , 1.33-1.29 (m, 2H) , 1.26 (t, J=7.2Hz, 3H) . Mass (m/z) : 470.46 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4- (piperidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (8)
The title compound 8 (8.7mg) was prepared in a yield of 25.5%as light yellow powder from 1-05 (23mg, 0.07mmol) and 4- (piperidin-1-yl) benzaldehyde (15mg, 0.078mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.34 (d, J=8.4Hz, 2H) , 7.15-7.20 (m, 4H) , 6.89 (d, J=8.8Hz, 2H) , 4.92 (p, J=9.0Hz, 1H) , 3.89 (s, 2H) , 3.50 (d, J=15.2Hz, 1H) , 3.48 (d, J=15.2Hz, 1H) , 3.39 (q, J=7.2Hz, 2H) , 3.25 (br, 4H) , 3.18 (t, J=5.2Hz, 4H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.77 (br, 2H) , 1.73 (d, J=15.6Hz, 2H) , 1.69-1.65 (m, 4H) , 1.61-1.56 (m, 2H) , 1.24 (t, J=7.2Hz, 3H) . Mass (m/z) : 487.48 [M+H]
+.
Preparation of 8-benzyl-3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (9)
The title compound 9 (10mg) was prepared in a yield of 49.7%as light yellow powder from 1-05 (15mg, 0.05mmol) and benzaldehyde (5mg, 0.05mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.47-7.48 (m, 2H) , 7.38-7.34 (m, 4H) , 7.21-7.15 (m, 3H) , 4.93 (p, J=9.0Hz, 1H) , 3.87 (s, 2H) , 3.52 (d, J=15.2Hz, 1H) , 3.50 (d, J=15.2Hz, 1H) , 3.36 (q, J=7.2Hz, 2H) , 3.19-3.3 (m, 6H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.47 (br, 2H) , 1.72 (d, J=14.4Hz, 2H) , 1.22 (t, J=7.2Hz, 3H) . Mass (m/z) : 404.34 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (3- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (10)
Step 1: To the solution of 10-01 (500mg, 2.18mmol) in toluene was added Pyrrolidine (155mg, 2.18mmol) , Pd
2 (dba)
3 (40mg, 0.04mmol) , BINAP (25mg, 0.04mmol) and t-BuONa (314mg, 3.27mmol) at room temperature. The reaction mixture was heated to 70℃ and stirred overnight. The reaction mixture was concentrated under reduce pressure, and then diluted by H
2O. The aqueous layer was extracted by EA for 3 times. The organic layers were combined, washed by H
2O, brine in turn, dried over Na
2SO
4, filtrated and evaporated to give crude product. The crude product was purified by silica gel column chromatography (PE: EA=15: 1) to give 10-02 as yellow oil (23.5mg, 4.95%) . Mass (m/z) : 220.49 [M+H]
+.
Step 2: The 1N HCl was added to the solution of 10-02 in THF at room temperature. Then the reaction mixture was stirred at room temperature for 2h. The reaction mixture was concentrated under reduce pressure to give crude product 10-03. The crude product was used without further purification. Mass (m/z) : 176.16 [M+H]
+.
Step 3: The title compound 10 (15.0mg) was prepared in a yield of 63.6% (2 steps) as light yellow powder from 1-05 (15mg, 0.043mmol) and 10-03 (0.11mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.20-7.15 (m, 5H) , 6.76 (br, 1H) , 6.62 (d, J=7.5Hz, 1H) , 6.52 (dd, J=8.2, 2.0Hz, 1H) , 4.92 (p, J=9.0Hz, 1H) , 3.86 (s, 2H) , 3.51 (d, J=15.2Hz, 1H) , 3.49 (d, J=15.6Hz, 1H) , 3.37 (q, J=6.8Hz, 2H) , 3.29 (m, 4H) , 3.22 (br, 2H) , 3.15 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 2.63 (br, 2H) , 1.99 (m, 4H) , 1.71 (d, J=14.4Hz, 2H) , 1.24 (t, J=7.2Hz, 3H) . Mass (m/z) : 473.41 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4-methoxybenzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (11)
The title compound 11 (11.4mg) was prepared in a yield of 59.4%as light yellow powder from 1-05 (15mg, 0.05mmol) and 4-methoxybenzaldehyde (7mg, 0.05mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.47-7.41 (m, 2H) , 7.20-7.15 (m, 4H) , 6.92 (d, J=8.8Hz, 2H) , 4.92 (p, J=9.0Hz, 1H) , 3.92 (s, 2H) , 3.80 (s, 3H) , 3.50 (d, J=15.2Hz, 1H) , 3.48 (d, J=15.6Hz, 1H) , 3.39 (q, J=6.8Hz, 2H) , 3.25 (br, 2H) , 3.15 (d, J=14.8Hz, 1H) , 3.13 (d, J=15.2Hz, 1H) , 2.77 (br, 2H) , 1.74 (d, J=13.9Hz, 2H) , 1.25 (t, J=7.2Hz, 3H) . Mass (m/z) : 434.38 [M+H]
+.
Preparation of 3-cyclopentyl-1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (12)
Step 1: The 1-01 (250mg, 0.93mmol) , Bromocyclopentane (414mg, 2.78mmol) and K
2CO
3 (512mg, 3.71mmol) were mixed in DMF. The reaction mixture was stirred at room temperature for 4h. The reaction mixture was diluted by water, extracted by EA for several times. The organic layers was combined, washed with water and brine in turn, dried over Na
2SO4, filtrated and evaporated to give crude product. The crude product was purified by silica gel chromatography (PE: EA=5: 1 to 2: 1) to give 151mg 12-01 as white solid in a yield of 48.2%. Mass (m/z) : 338.30 [M+H]
+.
Step 2: The 12-01 (141mg, 0.42mmol) was dissolved in DMF. The solvent was cooled under 0℃, 60%NaH (50.2mg, 1.25mmol) was added to the solution in batches. The reaction mixture was reacted at 0℃ for 1h, and then EtI (196mg, 1.25mmol) was added to the reaction mixture, then stirred at room temperature for 2h. The reaction was quenched by cold water, and the aqueous layer was extracted by EA for several times. The organic layers was combined, washed with water and brine in turn, dried over Na
2SO
4, filtrated and evaporated to give crude product 12-02, which was used without further purification. Mass (m/z) : 336.34 [M+H]
+.
Step 3: The 12-03 (201mg) was prepared as yellow powder from 12-02 (198mg) according to the procedure for 1-05. Mass (m/z) : 266.23 [M+H]
+.
Step 4: The title compound 12 (45.8mg) was prepared as yellow solid in a yield of 65.1%from 12-03 (50mg, 0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (34mg, 0.18mmol) according to the procedure for compound 1. Mass (m/z) : 425.36 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (prop-2-yn-1-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (13)
The title compound 13 (23.3mg) was prepared as light yellow solid in a yield of 58.7% (3 steps) from 13-01 (30mg, 0.08mmol) and 3-bromoprop-1-yne (28mg, 0.24mmol) according to the procedure for compound 1-04.
1HNMR (400 MHz, CDCl
3) δ 7.31 (d, J=8.5Hz, 2H) , 7.17 (m, 4H) , 6.52 (d, J=8.5Hz, 2H) , 4.93 (p, J=9.0Hz, 1H) , 4.18 (d, J=2.3Hz, 2H) , 3.92 (s, 2H) , 3.50 (d, J=15.6Hz, 1H) , 3.47 (d, J=15.2Hz, 1H) , 3.32 (d, J=7.8Hz, 4H) , 3.26 (m, 4H) , 3.15 (d, J=15.2Hz, 1H) , 3.13 (d, J=15.6Hz, 1H) , 3.00 (br, 2H) , 2.05 (s, 1H) , 1.99 (m, 4H) , 1.79 (d, J=14.6Hz, 2H) . Mass (m/z) : 483.37 [M+H]
+.
Preparation of 1-ethyl-3- (1-methylnaphthalen-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (14)
The 2-Methylnaphthalene (711mg, 5mmol) was suspended in water in flask which covered with aluminum foil to create a dark environment. 48%HBr (0.57mL, 5mmol) and 30%H
2O
2 (1.02mL, 10mmol) were added to the solution. Then the reaction mixture was stirred at room temperature for 48h. The reaction was quenched by NaHCO
3 aqueous, which was extracted by EA for several times. The organic layers was combined, washed with brine, dried over Na
2SO
4, filtrated and concentrated to give 1.07g yellow oil of 14-02 as crude product which was used without further purification.
1HNMR (400 MHz, CDCl
3) δ 8.29 (d, J=8.5Hz, 1H) , 8.00 (dd, J=12.5, 4.8Hz, 1H) , 7.69 (d, J=7.5Hz, 1H) , 7.60 (m, 2H) , 7.18 (d, J=7.5Hz, 1H) , 2.67 (s, 3H) .
The compound 14 (12.5mg) was prepared in a yield of 3.4% (4 steps) as light yellow solid from 1-01 and 14-03 according to the procedure for compound 3.
1HNMR (400 MHz, CDCl
3) δ 8.04 (m, 1H) , 7.54 (m, 2H) , 7.47 (m, 1H) , 7.38 (m, 1H) , 7.26 (m, 4H) , 6.51 (d, J=8.6Hz, 2H) , 3.89 (s, 2H) , 3.52 (m, 2H) , 3.26 (m, 8H) , 3.00-2.72 (br, 2H) , 2.72 (s, 3H) , 1.99 (m, 4H) , 1.34 (t, J = 7.1Hz, 3H) . Mass (m/z) : 497.37 [M+H]
+.
Preparation of 1-ethyl-3-phenethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (15)
Step 1: The 1-01 (100mg, 0.37mmol) , 3-Phenylpropyl Bromide 15-01 (68.5mg, 0.37mmol) and K
2CO
3 (105mg, 0.74mmol) were dissolved in DMF. The reaction mixture was stirred at 50℃ for 4h. The reaction mixture was diluted by water, and the aqueous layer was extracted by EA for several times. The organic layers was combined, washed with H
2O and brine in turn, dried over Na
2SO
4, filtrated and evaporated to give 15-02 as 230mg colorless crystal as crude product, which was used without further purification. Mass (m/z) : 374.22 [M+H]
+.
Step 2 to 4: The compound 15 (34.4mg) was prepared in a yield of 42.9% (4 steps) as yellow powder from 15-02 (200mg, 0.54mmol) according to the procedure for compound 3.
1HNMR (400 MHz, CDCl
3) δ 7.25 (m, 4H) , 7.18 (m, 3H) , 6.52 (d, J=8.7Hz, 2H) , 3.83 (s, 2H) , 3.73 (m, 2H) , 3.29 (m, 6H) , 3.11 (m, 4H) , 2.95 (t, J=7.2Hz, 2H) , 2.52 (br, 2H) , 2.00 (m, 4H) , 1.43 (d, J=14.5Hz, 2H) , 1.16 (t, J=7.1Hz, 3H) Mass (m/z) : 461.41 [M+H]
+.
Preparation of compound 16-02
The Biotin (2.0g, 8.2mmol) and 16-01 (942mg, 8.2mmol) were dissolved in DMF (60mL) , then the reaction mixture was stirred followed by addition of DCC (2.2g, 10.7mmol) in the solution. Then the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water, which was extracted by EA for several times. The organic layer was combined, washed with H
2O, brine in turn, dried over Na
2SO
4, filtrated and evaporated to give 3.14g 16-02 as white powder, which was used without further purification. Mass (m/z) : 342.17 [M+H]
+.
Preparation of compound 16-05
Step 1: To the solution of 3-Chloropropylamine hydrochloride 16-03 (1.30g, 10mmol) in DCM was added TEA (1.67mL, 12mmol) dropwise, and the resulting solution was stirred for 15min. Then a solution of Boc
2O in DCM was added dropwise to the solution over a period of 1h, and the resulting mixture was stirred overnight at room temperature. The reaction mixture was diluted with DCM, which was washed sequentially with 1N HCl, water, saturated aqueous NaHCO
3, and brine. The organic layer was separated, dried over Na
2SO4, and concentrated under reduce pressure to give compound 16-04 as colorless oil, which was used without further purification.
Step 2: The compound 16-04 was dissolved in ACN and treated with DMAP (559mg, 4.56mmol) at room temperature, and the resulting mixture was stirred for 10min. A solution of Boc
2O (3.32g, 15.25mmol) in 15mL THF was added to the reaction mixture, and the resulting mixture was stirred overnight at room temperature. The reaction was quenched by the addition of water, and the aqueous phase was extracted by EA for several times. The organic layer was combined, washed with 1N HCl and brine in turn, dried over Na
2SO
4, filtrated and evaporated to give crude product. The crude product was purified by gel silica chromatography (PE: EA=10: 1) to give 2.48g compound 16-05 as colorless oil in a yield of 84.4%for 2 steps.
1HNMR (400 MHz, CDCl
3) δ 3.71 (dd, J=7.6, 6.5Hz, 2H) , 3.53 (t, J=6.5Hz, 2H) , 2.03 (m, 2H) , 1.49 (s, 18H) .
Preparation of N- (3- (3- (2, 3-dihydro-1H-inden-2-yl) -2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-1-yl) propyl) -5- (2-oxohexahydro-1H-thieno [3, 4-d] imidazol-3a-yl) pentanamide (16)
Step 1: The compound 16-06 (16mg, 0.042mmol) was dissolved in 1N HCl (in EtOH) , the reaction mixture was stirred at 50℃ for 2h. The reaction mixture was evaporated to remove the solvent to give 32.9mg 16-07 crude product which was use for the next step without further purification. Mass (m/z) : 286.07 [M+H]
+.
Step 2: The compound 16-08 (14mg) was prepared in a yield of 31.5% (2 steps) as light yellow powder from 16-07 (32.9mg, 0.10mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (21.3mg, 0.11mmol) according to the procedure for compound 1. Mass (m/z) : 445.29 [M+H]
+.
Step 3: The compound 16-08 (14mg, 0.032mmol) was dissolved in DMF, and the solution cooled to 0℃, followed by addition of 60%NaH (1.9mg, 0.047mmol) slowly. The reaction mixture was stirred at 0℃ for 30min followed by addition of compound 16-05 (13.8mg, 0.047mmol) . Then the reaction mixture was heated to 50℃ and stirred overnight. The reaction was quenched by water, extracted by EA for several time. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give 34mg 16-09 crude product which was used for the next step without further purification. Mass (m/z) : 702.64 [M+H]
+.
Step 4: The compound 16-09 (34mg) was dissolved in 1N HCl (in EtOH) , the reaction mixture was stirred at 50℃ for 3h. The reaction mixture was evaporated to remove the solvent to give 32.3mg 16-10 crude product which was use for the next step without further purification. Mass (m/z) : 502.43 [M+H]
+.
Step 5: To a solution of 16-10 (32.3mg, 0.06mmol) in DMF was added TEA (15.2mg, 0.15mmol) . The reaction mixture was stirred at room temperature for 20min, followed by addition of 16-02 (22.6mg, 0.06mmol) . Then the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with water, which extracted by EA for several times. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give crude product. The crude product was purified with pre-HPLC to give 3.8mg compound 16 as white solid in a yield of 16.6% (3 steps) . Mass (m/z) : 728.72 [M+H]
+.
Preparation of 3- (4-benzoylphenyl) -1- (prop-2-yn-1-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (17)
Step 1: The compound 17-02 (100mg) was prepared from 1-01 (200mg, 0.74mmol) and 17-01 (180mg, 0.68mmol) in a yield of 29.96%according to the procedure for compound 3-02. Mass (m/z) : 450.28 [M+H]
+.
Step 2: The compound 17-02 (100mg, 0.22mmol) , 3-bromoprop-1-yne (78mg, 0.66mmol) and K
2CO
3 (91mg, 066mmol) were mixed in the DMF. The reaction mixture was stirred at 50℃ overnight. The reaction mixture was diluted by water, extracted by EA for several times. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give 155mg crude product of 17-03, which was used without further purification. Mass (m/z) : 488.19 [M+H]
+.
Step 3 to 4: The title compound 17 (47.5mg) was prepared as yellow powder in a yield of 39.01% (3 steps) from compound 17-03 (155mg, 0.32mmol) according to the procedure for compound 1. Mass (m/z) : 547.33 [M+H]
+.
Preparation of 1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (18)
Step 1: The compound 1-01 (50mg, 0.19mmol) , Boc
2O (40mg, 0.19mmol) and DMAP (catalyst amount) were dissolved in DCM. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted by DCM, washed by H
2O and brine in turn. The organic phase was dried over Na
2SO
4, filtrated and evaporated to give compound 18-01, which was used without further purification. Mass (m/z) : 370.16 [M+H]
+.
Step 2 to 4: The title compound 18 (18.9mg) was prepared in a yield of 20.8% (4 steps) as yellow powder from 18-01 (86mg, 0.23mmol) according to the procedure for compound 1. Mass (m/z) : 357.29 [M+H]
+.
Preparation of 8- (3-chloro-4- (pyrrolidin-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (19)
Step 1: A solution of 19-01 (890mg, 4.05mmol) , (CH
2OH)
2 (271uL, 4.87mmol) , TsOH H
2O(25mg, 0.11mmol) and molecular sieve in Toluene was reflux for 24h followed by cooled to room temperature. The reaction mixture was diluted with EA, washed with 1N NaOH, H
2O and brine in turn, then dried over Na
2SO
4, filtrated and evaporated to give crude product of 19-02 as light yellow solid, which was used without further purification. Mass (m/z) : 262.96, 264.95 [M+H]
+.
Step 2: The compound 19-02 (1.063g, 2.0mmol) and pyrrolidine (142mg, 2.0mmol) were dissolved in Toluene, followed by addition of Pd
2 (dba)
3 (37mg, 0.04mmol) , BINAP (25mg, 0.04mmol) and t-BuONa (288mg, 3.0mmol) in the solution. The reaction mixture was heated to 70℃ and then stirred overnight. After general post disposal to give crude product which was purified by gel silica column chromatography (PE: EA=20: 1) , and then to give 312.2mg compound 19-03 and 19-04 as a mixture in a yield of 33.2% (2 steps) . Mass (m/z) : 254.23, 256.07 [M+H]
+.
Step 3: The compound 19-03 was dissolved in THF, followed by addition of 1N HCl (1mL) in it. The reaction mixture was stirred at room temperature for 2h. Then the solvent was removed by evaporation to give crude product 19-04 which was used without further purification. Mass (m/z) : 210.09, 212.04 [M+H]
+.
Step 4: The title compound 19 (19.5mg) was prepared as light yellow solid in a yield of 26.9%from 1-05 (50mg, 0.16mmol) and 19-04 (36mg, 0.17mmol) according to the procedure of compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.28 (d, J=2.0Hz, 1H) , 7.17 (m, 5H) , 6.82 (d, J=8.4Hz, 1H) , 4.93 (p, J=9.1Hz, 1H) , 3.65 (s, 2H) , 3.53 (d, J=15.2Hz, 1H) , 3.51 (d, J=15.2Hz, 1H) , 3.40-3.32 (m, 6H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 3.00 (s, 4H) , 2.32 (s, 2H) , 1.94 (m, 4H) , 1.70 (d, J=13.6Hz, 2H) , 1.24 (t, J=7.3Hz, 3H) . Mass (m/z) : 507.36 [M+H]
+.
Preparation of 8- (2-chloro-4- (pyrrolidin-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (20)
The title compound 20 (44.2mg) was prepared as light yellow solid in a yield of 23.3%from compound 20-01 according to the procedure of compound 19.
1H NMR (400 MHz, CDCl
3) δ 7.17 (m, 5H) , 6.52 (d, J=2.4Hz, 1H) , 6.46 (d, J=8.3Hz, 1H) , 4.93 (p, J=9.1Hz, 1H) , 3.83 (br, 2H) , 3.54 (d, J=15.2Hz, 1H) , 3.52 (d, J=15.2Hz, 1H) , 3.36 (m, 2H) , 3.26 (m, 4H) , 3.14 (d, J=15.2Hz, 1H) , 3.12 (d, J=15.2Hz, 1H) , 3.01 (br, 4H) , 2.27 (br, 2H) , 2.00 (m, 4H) , 1.71 (d, J=13.4Hz, 2H) , 1.24 (t, J=7.0Hz, 3H) . Mass (m/z) : 507.34 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (21)
Step 1: The compound 1-03 (2.0g, 5.2mmol) was dissolved in HCl (1N in EtOH) , the reaction mixture was stirred at 50℃ for 2h. The solvent was removed by evaporation to give crude product 21-01 which was used without further purification. Mass (m/z) : 286.13 [M+H]
+.
Step 2: The title compound 21 (1.85g) was prepared in a yield of 80.1% (2 steps) as yellow powder from 21-01 (5.2mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (1.08g, 5.7mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.17 (m, 6H) , 6.86 (s, 1H) , 6.51 (d, J=8.2Hz, 2H) , 4.92 (p, J=9.1Hz, 1H) , 3.63 (s, 2H) , 3.55 (d, J=15.2Hz, 1H) , 3.53 (d, J=15.2Hz, 1H) , 3.28 (m, 4H) , 3.13 (d, J=15.2Hz, 1H) , 3.11 (d, J=15.2Hz, 1H) , 3.05 (m, 2H) , 2.54 (m, 2H) , 2.10 (m, 2H) , 2.00 (m, 4H) , 1.95 (m, 2H) . Mass (m/z) : 445.33 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-propyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (22)
The title compound 22 (45mg) was prepared as light yellow solid in a yield 41.1%from compound 21 (100mg, 0.23mmol) and 1-bromopropane (84mg, 0.68mmol) according to the procedure for compound 1-04.
1HNMR (400 MHz, CDCl
3) δ 7.16 (m, 6H) , 6.52 (d, J=8.6Hz, 2H) , 4.93 (p, J=9.1Hz, 1H) , 3.55 (d, J=15.2Hz, 1H) , 3.53 (d, J=15.2Hz, 1H) , 3.49 (m, 2H) , 3.27 (m, 4H) , 3.17 (m, 2H) , 3.13 (d, J=15.2Hz, 1H) , 3.11 (d, J=15.2Hz, 1H) , 2.03 (m, 2H) , 2.78 (m, 4H) , 1.99 (m, 4H) , 1.65 (m, 4H) , 0.91 (t, J=7.4Hz, 3H) Mass (m/z) : 487.44 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-methyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (23)
The title compound 23 (24.7mg) was prepared as light yellow solid in a yield of 10.4% (3 steps) from 1-03 (200mg, 0.52mmol) and CH
3I (222mg, 1.56mmol) according to the procedure for compound 1.
1HNMR (400 MHz, CDCl
3) δ 7.30 (d, J=8.5Hz, 2H) , 7.17 (m, 4H) , 6.52 (d, J=8.6Hz, 2H) , 4.92 (p, J=9.0Hz, 1H) , 3.88 (s, 2H) , 3.40 (d, J=15.6Hz, 1H) , 3.47 (d, J=15.2Hz, 1H) , 3.27 (m, 4H) , 3.23 (m, 4H) , 3.13 (d, J=15.2Hz, 1H) , 3.11 (d, J=15.2Hz, 1H) , 2.92 (s, 3H) , 2.74 (br, 2H) , 2.00 (m, 4H) , . 1.69 (d, J=14.5Hz, 2H) . Mass (m/z) : 459.34 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2- (3-methyl-3H-diazirin-3-yl) ethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (24)
The compound 21 (30mg, 0.068mmol) was dissolved in DMF, the solution was cooled to 0℃, followed by addition of 60%NaH (10mg, 0.69mmol) slowly. The reaction mixture was stirred at 0℃ for 30min followed by addition of 24-01 (18mg, 0.071mmol) . Then the reaction mixture was warmed to room temperature and stirred overnight. The reaction was quenched by water, extracted by EA for several time. The organic layer was combined, washed with water and brine in turn, filtrated and evaporated to give crude product which was purified with pre-TLC (DCM: MeOH=10: 1) to give 15.1mg 24 as light yellow solid in a yield of 41.9%.
1H NMR (400 MHz, CDCl
3) δ 7.34 (d, J=8.2Hz, 2H) , 7.17 (m, 4H) , 6.53 (d, J=8.6Hz, 2H) , 4.91 (p, J=9.0Hz, 1H) , 3.97 (s, 2H) , 3.49 (d, J=15.2Hz, 1H) , 3.47 (d, J=15.2Hz, 1H) , 3.33 (br, 2H) , 3.27 (m, 4H) , 3.15 (d, J=15.2Hz, 1H) , 3.13 (d, J=15.2Hz, 1H) , 2.00 (m, 4H) , 1.76 (d, J=14.0Hz, 2H) , 1.62 (t, J=7.4Hz, 2H) , 1.30 (br, 2H) , 1.25 (s, 2H) , 1.13 (s, 3H) . Mass (m/z) : 527.49 [M+H]
+.
Preparation of 1- (cyclopropylmethyl) -3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (25)
The title compound 25 (38.6mg) was prepared as light yellow solid in a yield of 67.7%from compound 21 (50mg, 0.11mmol) and 1-bromopropane (46mg, 0.34mmol) according to the procedure for 1-04.
1HNMR (400 MHz, CDCl
3) δ 7.17 (m, 6H) , 6.53 (m, 2H) , 4.96 (m, 1H) , 3.58 (s, J=15.6Hz, 1H) , 3.56 (d, J=15.2Hz, 1H) , 3.50 (s, 2H) , 3.27 (m, 4H) , 3.13 (m, 4H) , 2.77 (m, 4H) , 2.06 (m, 2H) , 1.99 (m, 4H) , 1.639 (d, J=13.0Hz, 2H) , 1.096 (m, 1H) , 0.54 (m, 2H) , 0.33 (m, 2H) . Mass (m/z) : 499.42 [M+H]
+.
Preparation of 1-ethyl-3- (4-methoxybenzyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (26)
The title compound 26 (150 mg) was prepared in a yield of 4.2%from 1-01 (3 g, 11.1mmol) and 1- (chloromethyl) -4-methoxybenzene (2.11g, 1.2eq) according to the procedure for compound 1.
1H NMR (400 MHz, DMSO-d
6) δ 7.15 (d, J = 8.3 Hz, 2H) , 7.07 (d, J = 8.1 Hz, 2H) , 6.88 (d, J = 8.3 Hz, 2H) , 6.47 (d, J = 8.1 Hz, 2H) , 4.44 (s, 2H) , 3.72 (s, 3H) , 3.39 (s, 2H) , 3.24 (q, J = 6.8 Hz, 2H) , 3.18 (d, J = 6.3 Hz, 3H) , 2.67 (d, J = 10.9 Hz, 2H) , 2.62 -2.54 (m, 2H) , 1.93 (dq, J = 9.2, 5.7, 4.3 Hz, 6H) , 1.57 (d, J = 13.0 Hz, 2H) , 1.10 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 477.43 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4-ethynylbenzyl) -1, 3, 8 triazaspiro [4.5] decane-2, 4-dione (27)
The title compound 27 was prepared the same to compound 1 as a pale yellow powder in a yield of 41.8%.
1H NMR (400 MHz, CDCl
3) δ 7.47 (d, J = 7.7 Hz, 2H) , 7.36 (s, 2H) , 7.17 (q, J = 4.9 Hz, 4H) , 4.93 (p, J = 9.1 Hz, 1H) , 3.68 (s, 2H) , 3.53 (dd, J = 15.4, 9.1 Hz, 2H) , 3.35 (q, J = 7.1 Hz, 2H) , 3.13 (dd, J = 15.4, 9.0 Hz, 2H) , 3.08 (s, 1H) , 2.90 (s, 4H) , 2.42-1.94 (br, 2H) , 1.70 (d, J = 13.3 Hz, 2H) , 1.25 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 428.5 [M+ H]
+.
Preparation of 3- (2-chloro-4- (3-hydroxypyrrolidin-1-yl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (28)
The title compound 28 (22.2 mg) was prepared in a yield of 27.5%as white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.17 (d, J = 8.5 Hz, 2H) , 7.07 (d, J = 8.7 Hz, 1H) , 6.59 (dd, J = 2.7, 1.3 Hz, 1H) , 6.55 -6.50 (m, 2H) , 6.43 (ddd, J = 8.8, 2.7, 1.3 Hz, 1H) , 4.50 (hept, J = 2.7 Hz, 1H) , 3.50 (s, 2H) , 3.47 -3.30 (m, 5H) , 3.30 -3.24 (m, 5H) , 3.16 -3.10 (m, 1H) , 2.81 (d, J = 18.8 Hz, 4H) , 2.12 (dtd, J = 13.1, 8.3, 4.8 Hz, 4H) , 1.99 (dd, J = 5.9, 2.8 Hz, 4H) , 1.88 -1.77 (m, 2H) , 1.26 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 552.41 [M+H]
+.
Preparation of 4- ( (3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-2, 4-dioxo-1, 3, 8-triazaspiro [4.5] decan-8-yl) methyl) benzonitrile (29)
The title compound 29 was prepared the same to compound 1 as a yellow powder in a yield of 41.8%
1H NMR (400 MHz, CDCl
3) δ 7.70 -7.59 (m, 2H) , 7.46 (d, J = 7.8 Hz, 2H) , 7.17 (p, J = 4.7 Hz, 4H) , 4.94 (t, J = 9.0 Hz, 1H) , 3.63 (s, 2H) , 3.54 (dd, J = 15.3, 9.1 Hz, 2H) , 3.33 (q, J = 7.0 Hz, 2H) , 3.13 (dd, J = 15.2, 9.0 Hz, 2H) , 2.86 (t, J = 11.7 Hz, 2H) , 2.74 (d, J = 11.8 Hz, 2H) , 2.14 -1.94 (m, 2H) , 1.81 -1.62 (m, 2H) , 1.36 -1.17 (m, 5H) . Mass (m/z) : 429.4 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (3-fluoro-4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (30)
The title compound 30 was prepared as a pale yellow powder in a yield of 18.14%according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.18 (qd, J = 9.5, 5.4 Hz, 4H) , 7.06 -6.87 (m, 2H) , 6.60 (t, J = 8.7 Hz, 1H) , 4.93 (t, J = 9.0 Hz, 1H) , 3.54 (dd, J = 15.2, 9.2 Hz, 3H) , 3.48 (s, 2H) , 3.41 -3.37 (m, 2H) , 3.32 (d, J = 7.1 Hz, 2H) , 3.12 (dd, J = 15.2, 9.0 Hz, 2H) , 2.78 (d, J = 10.8 Hz, 4H) , 2.21 -1.88 (m, 7H) , 1.86 -1.56 (m, 3H) , 1.41 -1.14 (m, 6H) . Mass (m/z) : 491.6 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (2-fluoro-4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (31)
The title compound 31 was prepared as a pale yellow powder in a yield of 46.25%according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.25 -7.11 (m, J = 2.7, 2.3 Hz, 4H) , 6.42 -6.29 (m, 1H) , 6.28 -6.16 (m, 1H) , 5.03 -4.85 (m, 1H) , 3.61 -3.46 (m, 3H) , 3.38 (s, 3H) , 3.33 -3.22 (m, 5H) , 3.21 -3.05 (m, 4H) , 2.11 -1.92 (m, 7H) , 1.73 (d, J = 13.5 Hz, 3H) , 1.35 -1.18 (m, 5H) . Mass (m/z) : 491.5 [M+H]
+.
Preparation of 3- (3-chloro-3′-ethoxy- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (32)
The title compound 32 (22.2 mg) was prepared in a yield of 25.8%as white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.71 (d, J = 2.0 Hz, 1H) , 7.55 (dd, J = 8.2, 2.0 Hz, 1H) , 7.36 (t, J = 7.9 Hz, 2H) , 7.21 -7.16 (m, 2H) , 7.13 (ddd, J = 7.6, 1.7, 0.9 Hz, 1H) , 7.07 (t, J = 2.1 Hz, 1H) , 6.93 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H) , 6.56 -6.50 (m, 2H) , 4.09 (q, J = 6.9 Hz, 2H) , 3.53 (s, 2H) , 3.42 (ddt, J = 19.0, 14.5, 7.2 Hz, 2H) , 3.32 -3.24 (m, 4H) , 2.92 -2.76 (m, 4H) , 2.14 (s, 2H) , 2.03 -1.96 (m, 4H) , 1.88 (ddt, J = 15.4, 13.0, 2.5 Hz, 2H) , 1.45 (t, J = 7.0 Hz, 3H) , 1.30 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 587.27 [M+H]
+.
Preparation of 8- (4- (azetidin-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (33)
The title compound 33 was prepared as a pale yellow powder in a yield of 38.61%according to the procedure for compound 1.
1H NMR (400 MHz, DMSO-d
6) δ 7.48 -7.01 (m, 6H) , 6.35 (d, J = 8.6 Hz, 2H) , 4.80 (t, J = 8.9 Hz, 1H) , 3.77 (q, J = 10.6, 7.2 Hz, 34H) , 3.45-3.36 (m, 3H) , 3.33 -3.20 (m, 3H) , 3.09 (dd, J = 15.8, 9.3 Hz, 2H) , 2.77 -2.54 (m, 4H) , 2.28 (q, J = 7.3 Hz, 2H) , 1.91 (td, J = 13.0, 5.0 Hz, 2H) , 1.64 (d, J = 13.2 Hz, 2H) , 1.21-1.07 (m, 4H) . Mass (m/z) : 459.4 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- ( (6- (pyrrolidin-1-yl) pyridin-3-yl) methyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (34)
The title compound 34 was prepared as a pale yellow powder in a yield of 23.0%according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 8.04 (d, J = 2.3 Hz, 1H) , 7.42 (dd, J = 8.7, 2.5 Hz, 1H) , 7.16 (td, J = 9.6, 9.0, 4.6 Hz, 4H) , 6.35 (t, J = 8.4 Hz, 1H) , 4.93 (p, J = 8.9 Hz, 1H) , 3.54 (dd, J = 15.3, 9.1 Hz, 4H) , 3.33 (dq, J = 14.1, 8.4, 7.0 Hz, 3H) , 3.12 (dd, J = 15.3, 9.0 Hz, 3H) , 2.81 (tt, J = 11.3, 5.1 Hz, 5H) , 2.26 -1.91 (m, 6H) , 1.68 (t, J = 9.3 Hz, 3H) , 1.49 -1.11 (m, 3H) . Mass (m/z) : 474.6 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (3-methoxy-4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (35)
The title compound 35 was prepared as a white powder in a yield of 30.0%according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.22 -7.11 (m, 4H) , 6.81 (dd, J = 6.1, 2.2 Hz, 2H) , 6.71 (d, J = 8.4 Hz, 1H) , 4.94 (td, J = 9.1, 0.7 Hz, 1H) , 3.84 (d, J = 0.7 Hz, 3H) , 3.60 -3.47 (m, 4H) , 3.38 -3.22 (m, 6H) , 3.12 (dd, J = 15.4, 9.1 Hz, 2H) , 2.88 -2.69 (m, 4H) , 2.09 -1.96 (m, 3H) , 1.97 -1.88 (m, 4H) , 1.75 -1.63 (m, 3H) , 1.29-1.21 (m, 4H) . Mass (m/z) : 503.7 [M+H]
+.
Preparation of 3- (4-ethynylphenyl) -1- (2- (3-methyl-3H-diazirin-3-yl) ethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (36)
Step 1: The compound 36-01 (62.7mg) was prepared in a yield of 9.1%from 1-01 (500mg, 1.86mmol) and 1-bromo-4-ethynylbenzene (306mg, 1.69mmol) according to the procedure of 3-02.Mass (m/z) : 370.26 [M+H]
+.
Step 2: The compound 36-02 was prepared from 36-01 (62.4mg, 0.17mmol) according to the procedure for 1-05. Mass (m/z) : 270.22 [M+H]
+.
Step 3: The compound 36-03 (25mg) was prepared in a yield of 34.7% (2 steps) as yellow powder from 36-02 (0.17mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (35mg, 0.19mmol) according to the procedure for compound 1. Mass (m/z) : 429.34 [M+H]
+.
Step 4: The compound 36-03 (25mg, 0.058mmol) , 24-01 (22mg, 0.088mmol) and Cs
2CO
3 (38mg, 0.116mmol) were dissolved in DMF. The reaction mixture was stirred at room temperature overnight. And then the reaction mixture was diluted by water, extracted by EA for several times. The organic phase was combined and washed by water and brine in turn, dried over Na
2SO
4, evaporated to give crude product. Which was purified by pre-TLC (DCM: MeOH=30: 1) to give 15 mg 36 as light powder in a yield of 51.4%.
1HNMR (400 MHz, CDCl
3) δ 7.56 (m, 2H) , 7.39 (m, 2H) , 7.29 (d, J=8.2Hz, 2H) , 6.53 (d, J=8.6Hz, 2H) , 3.88 (s, 2H) , 3.48 (m, 2H) , 3.27 (m, 4H) , 3.23 (m, 2H) , 3.11 (s, 1H) , 2.00 (m, 4H) , 1.85 (d, J=13.7Hz, 2H) , 1.69 (t, J=7.6Hz, 2H) , 1.30 (m, 2H) , 1.25 (m, 2H) , 1.32 (s, 3H) . Mass (m/z) : 511.46 [M+H]
+.
Preparation of 1-butyl-3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (37)
The title compound 37 was prepared as a white powder in a yield of 12.9%from 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, DMSO-d
6) δ 7.21 -7.16 (m, 2H) , 7.16 -7.13 (m, 2H) , 7.07 (d, J = 8.1 Hz, 2H) , 6.47 (d, J = 8.2 Hz, 2H) , 4.80 (t, J = 8.9 Hz, 1H) , 3.38 (s, 2H) , 3.31 -3.28 (m, 2H) , 3.22 -3.06 (m, 8H) , 2.66 (s, 2H) , 2.59 (d, J = 11.5 Hz, 2H) , 1.96 -1.91 (m, 4H) , 1.89 (d, J = 10.9 Hz, 2H) , 1.64 (d, J = 12.9 Hz, 2H) , 1.56 -1.48 (m, 2H) , 1.32 -1.24 (m, 2H) , 0.89 (t, J = 7.3 Hz, 3H) . Mass (m/z) : 501.52 [M+H]
+.
Preparation of 1- (cyclopentylmethyl) -3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (38)
The title compound 38 (8mg) was prepared in a yield of 13.5%as white solid from 13-01 (50mg, 0.11mmol) according to the procedure for the compound 1-04.
1H NMR (400 MHz, DMSO-d
6) δ 7.25 -7.11 (m, 4H) , 7.07 (d, J = 8.5 Hz, 2H) , 6.47 (d, J = 8.6 Hz, 2H) , 4.79 (p, J = 8.9 Hz, 1H) , 3.36 (d, J = 11.5 Hz, 2H) , 3.30 (d, J = 8.5 Hz, 2H) , 3.23 -3.15 (m, 4H) , 3.15 -3.01 (m, 4H) , 2.61 (dd, J = 25.6, 14.1 Hz, 4H) , 2.30 -2.19 (m, 1H) , 1.97 -1.88 (m, 5H) , 1.69 -1.42 (m, 8H) , 1.27 -1.13 (m, 3H) . Mass (m/z) : 527.42 [M+H]
+
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-isopropyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (39)
The title compound 39 (5mg) was prepared in a yield of 9.1%as white solid from 13-01 (50mg, 0.11mmol) according to the procedure for the compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.17-7.11 (m, 6H) , 6.52 (d, J = 8.8 Hz, 2H) , 4.93-4.85 (m, 1H) , 4.82-4.72 (m, 2H) , 3.76-3.72 (m, 1H) , 3.56-3.45 (m, 4H) , 3.31 -3.24 (m, 4H) , 3.13 (dd, J = 15.4, 9.1 Hz, 4H) , 2.02 -1.97 (m, 4H) , 1.70 (d, J = 13.7 Hz, 4H) , 1.42 (d, J = 6.8 Hz, 6H) . Mass (m/z) : 487.37 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (methoxymethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (40)
The title compound 40 (10 mg) was prepared in a yield of 18.2%as white solid from compound 13-01 (50 mg, 0.11mmol) according to the procedure for the compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.23 (s, 2H) , 7.21 -7.15 (m, 4H) , 6.52 (d, J = 8.6 Hz, 2H) , 4.96 (d, J = 9.0 Hz, 1H) , 4.82 (s, 2H) , 3.69 (s, 2H) , 3.52 (dd, J = 15.3, 9.0 Hz, 3H) , 3.35 (s, 3H) , 3.31 -3.25 (m, 4H) , 3.13 (dd, J = 15.4, 9.1 Hz, 3H) , 3.00 (s, 2H) , 2.04 -1.97 (m, 4H) , 1.76 (s, 2H) , 1.31 (d, J = 9.1 Hz, 2H) . Mass (m/z) : 489.24 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2-methoxyethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (41)
The title compound 41 (5 mg) was prepared in a yield of 8.8%as white solid from the compound 13-01 (50 mg, 0.11mmol) according to the procedure for the compound 1-04.
1H NMR (400 MHz, DMSO-d
6) δ 7.21 -7.13 (m, 4H) , 7.09 -7.05 (m, 2H) , 6.49 -6.45 (m, 2H) , 4.80 (p, J = 8.9 Hz, 1H) , 3.45 (t, J = 6.3 Hz, 2H) , 3.37 (d, J = 4.1 Hz, 4H) , 3.33 -3.27 (m, 2H) , 3.25 (s, 3H) , 3.21 -3.16 (m, 4H) , 3.10 (dd, J = 15.8, 9.3 Hz, 2H) , 2.70 -2.53 (m, 4H) , 1.97 -1.88 (m, 6H) , 1.60 (d, J = 13.1 Hz, 2H) . Mass (m/z) : 503.18 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (oxiran-2-ylmethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (42)
The title compound 42 (5mg) was prepared in a yield of 8.9%as white solid from compound 13-01 (50mg, 0.11mmol) according to the procedure for compound 1-04
1H NMR (400 MHz, DMSO-d
6) δ 7.22 -7.13 (m, 4H) , 7.09 -7.04 (m, 2H) , 6.50 -6.44 (m, 2H) , 4.82 (p, J = 8.8 Hz, 1H) , 3.64 (dd, J = 15.4, 3.3 Hz, 1H) , 3.37 (d, J = 4.8 Hz, 2H) , 3.22 -3.07 (m, 8H) , 2.77 (dd, J = 5.1, 4.0 Hz, 1H) , 2.65 (td, J = 5.8, 5.1, 2.9 Hz, 3H) , 2.58 (t, J = 11.8 Hz, 2H) , 2.05 -1.84 (m, 7H) , 1.64 (dd, J = 20.5, 13.2 Hz, 3H) . Mass (m/z) : 501.31 [M+H]
+.
Preparation of 1-benzyl-3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (43)
The title compound 43 (3mg) was prepared in a yield of 5%as white solid from compound 13-01 (50mg, 0.11mmol) according to the procedure for compound 1-04.
1H NMR (400 MHz, DMSO-d
6) δ 7.33 -7.25 (m, 4H) , 7.22 -7.11 (m, 5H) , 6.99 (d, J = 8.5 Hz, 2H) , 6.41 (d, J = 8.5 Hz, 2H) , 4.83 (q, J = 8.8 Hz, 1H) , 4.50 (s, 2H) , 3.39 -3.30 (m, 4H) , 3.18 -3.08 (m, 6H) , 2.52 (d, J = 11.8 Hz, 4H) , 1.91 -1.76 (m, 6H) , 1.54 (d, J = 13.1 Hz, 2H) . Mass (m/z) : 535.41 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- ( (5- (pyrrolidin-1-yl) pyridin-2-yl) methyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (44)
The title compound 44 was prepared in a yield of 7.94%as a pale yellow powder according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.71 (d, J = 2.3 Hz, 1H) , 7.45 (dd, J = 8.7, 2.5 Hz, 1H) , 7.16 (td, J = 9.6, 9.0, 4.6 Hz, 4H) , 6.75 (t, J = 8.4 Hz, 1H) , 4.93 (p, J = 8.9 Hz, 1H) , 4.11 (s, 2H) , 3.54 (dd, J = 15.3, 9.1 Hz, 2H) , 3.33 (dq, J = 14.1, 8.4, 7.0 Hz, 3H) , 3.12 (dd, J = 15.3, 9.0 Hz, 3H) , 2.81 (tt, J = 11.3, 5.1 Hz, 5H) , 2.26 -1.91 (m, 6H) , 1.69 (t, J = 9.3 Hz, 3H) , 1.52 -1.14 (m, 3H) . LC/MS (ES+) m/z found 474.3 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (2-methoxy-4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (45)
The title compound 45 was prepared in a yield of 9.53%as white solid according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.22 -7.11 (m, 4H) , 6.50 (dd, J = 6.1, 2.2 Hz, 2H) , 7.02 (d, J = 8.4 Hz, 1H) , 4.94 (td, J = 9.1, 0.7 Hz, 1H) , 3.70 (d, J = 0.7 Hz, 3H) , 3.68 (s, 2H) , 3.60 -3.47 (m, 2H) , 3.38 -3.22 (m, 6H) , 3.12 (dd, J = 15.4, 9.1 Hz, 2H) , 2.88 -2.69 (m, 4H) , 2.09 -1.96 (m, 3H) , 1.97 -1.88 (m, 4H) , 1.75 -1.63 (m, 3H) , 1.31-1.23 (m, 4H) . Mass (m/z) : 503.5 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (indolin-5-ylmethyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (46)
The title compound 46 was prepared in a yield of 56.32%as a peach powder according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.20 -7.13 (m, 4H) , 7.09 (s, 1H) , 6.99 -6.89 (m, 1H) , 6.58 (d, J = 7.8 Hz, 1H) , 4.93 (t, J = 9.1 Hz, 1H) , 3.55 (q, J = 7.2, 6.1 Hz, 3H) , 3.33 (s, 2H) , 3.12 (dd, J = 15.3, 9.1 Hz, 2H) , 3.02 (t, J = 8.4 Hz, 2H) , 2.80 (s, 3H) , 2.05 (s, 2H) , 1.68 (d, J = 13.3 Hz, 3H) , 1.64 -1.47 (m, 4H) , 1.30 -1.17 (m, 4H) . Mass (m/z) : 445.8 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2- (dimethylamino) ethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (47)
The title compound 47 (7mg) was prepared in a yield of 12.1%as white solid from compound 13-01 (50mg, 0.11mmol) according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.21 -7.16 (m, 2H) , 7.15 -7.07 (m, 4H) , 6.51 -6.44 (m, 2H) , 4.89 -4.82 (m, 1H) , 3.63 (d, J = 13.4 Hz, 2H) , 3.49 -3.42 (m, 2H) , 3.21 (d, J = 6.4 Hz, 4H) , 3.07 (dd, J = 15.5, 9.0 Hz, 2H) , 2.95 (s, 2H) , 2.25 (s, 6H) , 1.94 (dq, J = 6.0, 3.2 Hz, 4H) , 1.65 (d, J = 13.5 Hz, 2H) , 1.38 -1.12 (m, 8H) . Mass (m/z) : 516.76 [M+H]
+.
Preparation of 1-acetyl-3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (48)
A solution of compound 13-01 (30mg 0.067 mmol, 1.0 equivs) and acetic anhydride (2drop, ) in N, N-Dimethylformamide (2 mL) was added DMAP respectively, the resulting solution was stirred at room temperature for overnight, water (3 mL) was added to quench the reaction and the solution was concentrated under reduced pressure and the residue was extracted with dichloromethane (5 mL × 3) , washed with water (5 mL × 2) and brine (5 mL × 2) , dried over MgSO
4, and purified by pre-LC to give the title compound 48 as a white powder (6mg) in a yield of 16.7%.
1H NMR (400 MHz, CDCl
3) δ 7.19 (d, J = 2.3 Hz, 6H) , 6.52 (d, J = 8.2 Hz, 2H) , 5.35 (t, J = 4.9 Hz, 1H) , 5.00 (t, J = 9.1 Hz, 2H) , 3.53 (dd, J = 15.4, 9.0 Hz, 5H) , 3.31 -3.24 (m, 4H) , 3.16 (dd, J = 15.4, 9.1 Hz, 3H) , 3.04 (s, 2H) , 2.56 (s, 3H) , 2.22 (t, J = 7.7 Hz, 1H) , 1.99 (td, J = 7.8, 6.6, 4.6 Hz, 5H) . Mass (m/z) : 487.41 [M+H]
+.
Preparation of (S) -3- (5-ethynyl-2, 3-dihydro-1H-inden-2-yl) -1- (2- (3-methyl-3H-diazirin-3-yl) ethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (49)
Step 1: The mixture of 49-01 (2.37g, 0.014mol) and water was stirred and heated to 58-60℃ to obtain a solution. To the resulting solution was added Br
2 (2.4g, 0.015mol) dropwise while maintaining an internal temperature of 58-60℃. And then the mixture was stirred at an internal temperature 60-62℃ for an additional 1h.
After 1h, 48%HBr (5mL) was added over a period of 5min while maintaining 60-62℃ internal temperature. After stirring for several minutes, the reaction mixture was cooled to room temperature. The solid was collected by filtration, washed with 2-propanol and dried at 58-60℃ to give 2.17g 49-02 as white powder in a yield of 27.02%, which was used directly without further purification. Mass (m/z) : 212.06, 214.07 [M+H]
+.
Step 2: DIEA (2.2g, 17.14mmol) was added dropwise to a stirred solution of 49-03 (2.0g, 4.29mmol) and 49-02 (1.38g, 4.72mmol) in CAN (100mL) containing PyBOP (3.35g, 6.43mmol) at r. t. under N
2. The reaction mixture was stirred at r. t. for 4h, then evaporation to remove the solvent to give crude product. Purification over silica gel column chromatography (PE: EA=5: 1 to 2: 1) to give 2.66g 49-04 as white solid in a yield of 93%. Mass (m/z) : 660.41, 662.51 [M+H]
+.
Step 3: Et
2NH (5.9g, 80.73mmol) was added to the solution of 49-04 (2.66g, 4.04mmol) in DCM at r. t. The reaction mixture was stirred at r. t. for 4h. Evaporated in vacuo to remove the solvent and Et
2NH to give crude 49-05 as light yellow oil, which was used without further purification. Mass (m/z) : 438.26, 440.23 [M+H]
+.
Step 4: Pyridine (4.79g, 60.6mmol) was added dropwise to the solution of BTC (600mg, 2.02mmol) in anhydrous DCM under 0℃. The reaction mixture became clear, and then became slurry. The solution of 49-05 (4.04mmol) in anhydrous DCM was added dropwise to the reaction mixture under 0℃, followed by the reaction mixture became red and clear. After stirred at 0℃ for 2h, the reaction mixture was heated to 40℃ and stirred overnight. The reaction was quenched by sat. NH
4Cl, the organic layer was washed with H
2O and brine in turn, dried over Na
2SO
4. Evaporated in vacuo to remove the solvent to give crude product. Purified over silica gel column chromatography (PE: EA=5: 1 to 1: 1) to give 1.26g 49-06 as light yellow solid in a yield of 67.4% (2 steps) . Mass (m/z) : 464.46, 466.36 [M+H]
+.
Step 5: The compound 49-06 (500mg, 1.08mmol) , ethynyltrimethylsilane (127mg, 1.29mmol) , CuI (20.5mg, 0.108mmol) , Pd (PPh
3)
2Cl
2 (76mg, 0.108mmol) and TEA (164mg, 1.62mmol) were mixed in the DMF. The reaction mixture was stirred at 70℃ overnight. And then the reaction mixture was diluted by water, extracted by EA for several times. The organic phase was combined and washed by water and brine in turn, dried over Na
2SO
4, evaporated to give crude product. Which was purified by silica gel column chromatography (PE: EA=5: 1 to 2: 1) to give 503mg mixture of 49-07 and 49-08 (ratio: 2: 1) as light yellow powder in a yield of about 59%. Mass (m/z) : 482.42 [M+H]
+.
Step 6: The mixture of 49-07 and 49-08 (500mg, ~1.04mmol) was dissolved in MeOH, followed by addition of K
2CO
3 (359mg, 2.6mmol) in it. The reaction mixture was stirred at room temperature for 4h. After 4h, the reaction mixture became clear, and evaporated to remove the solvent. The residue was diluted by DCM, filtrated to remove K
2CO
3, and the filter was evaporated removing DCM to give crude product 49-08, which was used without further purification. Mass (m/z) : 408.21 [M+H]
+.
Step 7: The compound 49-09 was prepared from 49-08 (1.04mmol) according to the procedure for 1-05. Mass (m/z) : 310.11 [M+H]
+.
Step 8: The compound 49-10 (mixture, 211mg) was prepared as a yellow powder from 49-09 (mixture, 1.04mmol) and 4- (pyrrolidin-1-yl) benzaldehyde (215mg, 1.14mmol) according to the procedure for compound 1. Mass (m/z) : 469.57 [M+H]
+.
Step 9: The title compound 49 (27mg) was prepared as a yellow powder from 49-10 (mixture, 200mg, 0.43mmol) and 24-01 (108mg, 0.43mmol) according to the procedure for 24.
1HNMR (400 MHz, CDCl
3) δ 7.30 (m, 2H) , 7.14 (m, 3H) , 6.52 (m, 2H) , 4.92 (p, J=9.0Hz, 1H) , 3.50 (m, 4H) , 3.27 (m, 4H) , 3.21 (m, 2H) , 3.15-3.07 (m, 2H) , 3.01 (s, 1H) , 2.79 (m, 4H) , 1.99 (m, 4H) , 1.95 (br, 2H) , 1.67-1.61 (m, 4H) , 1.07 (s, 3H) . Mass (m/z) : 551.57 [M+H]
+.
Preparation of 8- (4- (aziridin-1-yl) benzyl) -3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (50)
The title compound 50 (7mg) was prepared in a yield of 0.85%as yellow powder according to the procedure for compound 1.
1H NMR (400 MHz, DMSO-d
6) δ 7.44 -7.01 (m, 6H) , 6.36 (d, J = 8.6 Hz, 2H) , 4.83 (t, J = 8.8 Hz, 1H) , 3.77 (q, J = 10.6, 7.1 Hz, 34H) , 3.47-3.36 (m, 3H) , 3.33 -3.21 (m, 3H) , 3.09 (dd, J = 15.9, 9.3 Hz, 2H) , 2.77 -2.54 (m, 4H) , 2.28 (q, J = 7.3 Hz, 2H) , 1.91 (td, J = 13.0, 5.0 Hz, 2H) , 1.56 (s, 4H) . Mass (m/z) : 445.3 [M+H]
+.
Preparation of 2′, 5′-dichloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (51)
The title compound 51 (25.7 mg) was prepared in a yield of 28.7%as light yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.74 -7.70 (m, 2H) , 7.66 (dt, J = 7.9, 1.6 Hz, 1H) , 7.58 (t, J = 8.0 Hz, 1H) , 7.50 (s, 1H) , 7.47 (s, 1H) , 7.17 (d, J = 8.5 Hz, 2H) , 6.53 (d, J = 8.6 Hz, 2H) , 3.52 (s, 2H) , 3.42 (dp, J = 21.9, 7.3 Hz, 2H) , 3.31 -3.23 (m, 4H) , 2.88 (d, J = 11.4 Hz, 2H) , 2.84 -2.70 (m, 2H) , 2.15 (d, J = 13.2 Hz, 2H) , 2.02 -1.97 (m, 4H) , 1.91 -1.82 (m, 2H) , 1.29 (t, J = 7.6 Hz, 3H) . Mass (m/z) : 602.36 [M+H]
+.
Preparation of 1-ethyl-3-phenyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (52)
The title compound 52 was prepared in a yield of 4.05%as yellow powder according to the procedure for compound 3.
1H NMR (400 MHz, CDCl
3) δ 7.52 -7.33 (m, 7H) , 6.59 (d, J = 7.9 Hz, 2H) , 4.13 (s, 2H) , 3.52 (q, J = 6.5 Hz, 6H) , 3.22 (d, J = 12.9 Hz, 2H) , 2.03 (d, J = 5.8 Hz, 4H) , 1.92 (d, J = 13.7 Hz, 2H) , 1.31 (t, J = 7.0 Hz, 4H) , 1.25 (s, 3H) . Mass (m/z) : 433.3 [M+H]
+.
Preparation of 1-ethyl-3- (3-phenylcyclopentyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (53)
The title compound 53 was prepared in a yield of 30.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.30 (q, J = 7.3, 6.7 Hz, 3H) , 7.25 -7.07 (m, 4H) , 6.56 -6.50 (m, 2H) , 4.73-4.63 (m, 1H) , 3.55 (s, 2H) , 3.37 -3.22 (m, 6H) , 3.10-2.98 (m, 1H) , 2.83 (d, J = 15.2 Hz, 4H) , 2.45 -2.15 (m, 4H) , 2.11 -1.96 (m, 8H) , 1.67 -1.61 (m, 2H) , 1.22 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 501.3 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-isopentyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (54)
The title compound 54 (26 mg) was prepared in a yield of 22.6%as white solid from compound 13-01 (50 mg, 0.11mmol) according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.44 -7.35 (m, 2H) , 7.17 (s, 4H) , 6.53 (d, J = 7.8 Hz, 2H) , 4.97 -4.87 (m, 1H) , 3.57 -3.31 (m, 6H) , 3.31 -3.22 (m, 4H) , 3.18 -3.00 (m, 4H) , 2.88 -2.70 (m, 2H) , 2.00 (s, 4H) , 1.80 -1.60 (m, 7H) , 0.94 (d, J = 6.2 Hz, 6H) . Mass (m/z) : 515.57 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (3, 3-dimethylbutyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (55)
The title compound 55 (11.3 mg) was prepared in a yield of 10%as light yellow solid from compound 13-01 (50 mg, 0.11mmol) according to the procedure for compound 1-04
1H NMR (400 MHz, CDCl
3) δ 7.27 (s, 2H) , 7.17 (s, 4H) , 6.53 (d, J = 8.3 Hz, 2H) , 5.07 -4.85 (m, 1H) , 3.46 (d, J = 40.3 Hz, 4H) , 3.28 (s, 5H) , 3.13 (s, 2H) , 2.80 (s, 2H) , 2.00 (s, 5H) , 1.57 (s, 8H) , 0.96 (s, 9H) . Mass (m/z) : 529.65 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2-hydroxyethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (56)
The title compound 56 (5.3mg) was prepared in a yield of 10%as white solid.
1H NMR (400 MHz, CDCl
3) δ 7.25 -7.23 (m, 6H) , 6.52 (d, J = 8.0 Hz, 2H) , 4.95 -4.94 (m, 1H) , 3.79 (d, J = 4.9 Hz, 2H) , 3.63 (s, 2H) , 3.56 -3.45 (m, 4H) , 3.27 (s, 4H) , 3.18 -3.10 (m, 2H) , 3.01 -2.88 (m, 4H) , 2.03 -1.95 (m, 4H) , 1.71 (d, J = 13.7 Hz, 4H) . Mass (m/z) : 489.64 [M+H]
+.
Preparation of 1- (cyclobutylmethyl) -3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (57)
The title compound 57 (25 mg) was prepared in a yield of 43.8%as white solid from compound 13-01 (50 mg, 0.11mmol) according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.24 -7.21 (m, 2H) , 7.18 -7.08 (m, 4H) , 6.50 -6.46 (m, 2H) , 4.97 -4.86 (m, 1H) , 3.56 -3.39 (m, 4H) , 3.32 -3.14 (m, 6H) , 3.14 -3.03 (m, 2H) , 2.85 -2.62 (m, 5H) , 2.05 -1.91 (m, 6H) , 1.86 -1.67 (m, 4H) , 1.63 -1.58 (m, 4H) . Mass (m/z) : 513.59 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2-morpholinoethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (58)
The title compound 58 was prepared in a yield of 4.9%as white solid from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.36 (d, J = 8.1 Hz, 2H) , 7.19 -7.13 (m, 4H) , 6.56 -6.49 (m, 2H) , 4.95-4.83 (m, 1H) , 4.02 (s, 2H) , 3.74 -3.61 (m, 3H) , 3.47 (t, J = 12.6 Hz, 5H) , 3.40 -3.31 (m, 2H) , 3.26 (s, 4H) , 3.13 (t, J = 13.0 Hz, 4H) , 2.58 (s, 6H) , 1.99 (s, 4H) , 1.88 -1.73 (m, 4H) . Mass (m/z) : 558.71 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- (2- (piperidin-1-yl) ethyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (59)
The title compound 59 was prepared in a yield of 12.8%as white solid from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.26 -7.24 (m, 2H) , 7.16 (d, J = 7.0 Hz, 4H) , 6.52 (d, J = 8.0 Hz, 2H) , 4.92 -4.90 (m, 1H) , 3.50 (d, J = 23.1 Hz, 4H) , 3.41 -3.32 (m, 2H) , 3.30 -3.24 (m, 4H) , 3.11 (dd, J = 15.4, 9.3 Hz, 2H) , 2.75 (d, J = 18.4 Hz, 4H) , 2.47 (d, J = 31.9 Hz, 6H) , 2.03 -1.90 (m, 6H) , 1.66 -1.49 (m, 6H) , 1.45 -1.34 (m, 2H) . Mass (m/z) : 556.66 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1- ( (2-methyloxiran-2-yl) methyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (60)
The title compound 60 was prepared in a yield of 6.04%as white solid from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.41 -7.31 (m, 2H) , 7.21 -7.13 (m, 4H) , 6.56 -6.50 (m, 2H) , 4.95 -4.85 (m, 1H) , 3.65 -3.39 (m, 8H) , 3.31 -3.23 (m, 4H) , 3.14 (dd, J = 15.4, 9.3 Hz, 4H) , 2.95 (d, J = 2.3 Hz, 2H) , 2.88 (d, J = 2.3 Hz, 1H) , 2.61 (s, 1H) , 2.05 -1.95 (m, 4H) , 1.83 -1.70 (m, 2H) , 1.36 (s, 3H) . Mass (m/z) : 515.68 [M+H]
+.
Preparation of 1-allyl-3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (61)
The title compound 61 was prepared in a yield of 5.2%as yellow solid from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.42 -7.34 (m, 2H) , 7.21 -7.15 (m, 4H) , 6.53 (d, J = 7.8 Hz, 2H) , 5.85 (s, 1H) , 5.45 (d, J = 17.3 Hz, 1H) , 5.18 (d, J = 10.0 Hz, 1H) , 5.00 -4.87 (m, 1H) , 4.28 (s, 2H) , 4.07 (s, 2H) , 3.67 (s, 2H) , 3.47 (d, J = 11.0 Hz, 4H) , 3.32 -3.20 (m, 4H) , 3.14 (d, J = 22.1 Hz, 4H) , 2.05 -1.94 (m, 4H) , 1.76 (d, J = 14.4 Hz, 2H) . Mass (m/z) : 485.53 [M+H]
+.
Preparation of 1-ethyl-3- (1-phenylpyrrolidin-3-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (62)
The title compound 62 was prepared in a yield of 42.3%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.28 -7.14 (m, 4H) , 6.70 (t, J = 7.3 Hz, 1H) , 6.54 (dd, J = 16.2, 8.2 Hz, 4H) , 4.80 (p, J = 8.4 Hz, 1H) , 3.72 -3.51 (m, 5H) , 3.44 -3.18 (m, 7H) , 2.85 (td, J = 27.1, 23.4, 15.1 Hz, 4H) , 2.72 -2.62 (m, 1H) , 2.23 (dtd, J = 11.8, 7.7, 3.6 Hz, 1H) , 2.09 (d, J = 33.5 Hz, 2H) , 2.03 -1.94 (m, 4H) , 1.66 (dt, J = 13.4, 2.5 Hz, 2H) , 1.22 (t, J = 7.0 Hz, 3H) . 502.61 [M+H]
+.
Preparation of 1-ethyl-3- (3-methoxyphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (63)
The title compound 63 was prepared in a yield of 4.56%as a yellow powder according to the procedure for compound 3.
1H NMR (400 MHz, CDCl
3) δ 7.32 (d, J = 22.9 Hz, 3H) , 6.94 (dd, J = 23.5, 10.9 Hz, 3H) , 6.54 (d, J = 8.0 Hz, 2H) , 3.81 (s, 4H) , 3.54 -3.37 (m, 2H) , 3.28 (s, 4H) , 3.22 -3.09 (m, 3H) , 2.66 (s, 2H) , 2.01 (s, 4H) , 1.85 (d, J = 14.3 Hz, 2H) , 1.28 (dd, J = 13.9, 6.8 Hz, 5H) . Mass (m/z) : 463.9 [M+H]
+.
Preparation of 3- (3-bromophenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (64)
The title compound 64 was prepared in a yield of 23.40%as a white powder according to the procedure for compound 3.
1H NMR (400 MHz, CDCl
3) δ 7.86 -7.08 (m, 6H) , 6.80 -6.31 (m, 2H) , 3.97 (d, J = 18.2 Hz, 2H) , 3.51 (s, 3H) , 3.42 -3.09 (m, 8H) , 2.90 (s, 2H) , 2.04 (d, J = 18.0 Hz, 3H) , 1.89 (s, 2H) , 1.47 -1.09 (m, 3H) . Mass (m/z) : 511.4 [M+H]
+.
Preparation of 3- ( [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (65)
The title compound 65 was prepared in a yield of 11.96%as a yellow powder according to the procedure for compound 3.
1H NMR (400 MHz, CDCl
3) δ 7.70 -7.63 (m, 2H) , 7.62 -7.56 (m, 2H) , 7.52 -7.41 (m, 5H) , 7.41 -7.33 (m, 1H) , 7.28 (d, J = 8.3 Hz, 1H) , 6.57 -6.51 (m, 2H) , 3.80 (s, 2H) , 3.48 (q, J = 7.1 Hz, 2H) , 3.36 -3.22 (m, 4H) , 3.22 -3.06 (m, 3H) , 2.64 (s, 2H) , 2.10 -1.94 (m, 4H) , 1.87 (d, J = 13.9 Hz, 2H) , 1.36 -1.22 (m, 4H) . Mass (m/z) : 509.7 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1- (thiophen-3-ylmethyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (66)
The title compound 66 was prepared in a yield of 10.85%as a white powder according to the procedure for compound 1.
1H NMR (400 MHz, CDCl
3) δ 7.59 (s, 1H) , 7.35 (d, J = 8.1 Hz, 2H) , 7.28 -7.21 (m, 3H) , 7.20 -7.14 (m, 3H) , 6.54 (d, J = 8.2 Hz, 2H) , 4.96 (t, J = 8.9 Hz, 1H) , 4.61 (s, 2H) , 3.99 (s, 2H) , 3.58 -3.45 (m, 3H) , 3.43 -3.22 (m, 4H) , 3.16 (dd, J = 15.4, 9.0 Hz, 5H) , 2.00 (q, J = 3.4 Hz, 5H) , 1.61 (d, J = 14.2 Hz, 3H) . Mass (m/z) : 541.4 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-1-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (67)
The title compound 67 was prepared in a yield of 9.5%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.31 (s, 2H) , 7.25 (s, 2H) , 7.20 -7.12 (m, 1H) , 7.03 (d, J = 7.4 Hz, 1H) , 6.51 (d, J = 8.0 Hz, 2H) , 5.62 (t, J = 8.1 Hz, 1H) , 3.99 (d, J = 54.4 Hz, 2H) , 3.41 (s, 4H) , 3.26 (q, J = 4.6 Hz, 4H) , 3.00 -2.88 (m, 2H) , 2.50 -2.33 (m, 2H) , 2.09 -1.90 (m, 4H) , 1.80 -1.48 (m, 6H) , 1.25 (t, J = 6.9 Hz, 3H) . Mass (m/z) : 473.61 [M+H]
+.
Preparation of 1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -3- (1, 2, 3, 4-tetrahydro naphthalen-2-yl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (68)
The title compound 68 (2.4mg) was prepared in a yield of 8.73%as a yellow powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.33 (s, 1H) , 7.25 (dd, J = 3.7, 1.8 Hz, 1H) , 7.15 -7.00 (m, 4H) , 6.60 -6.48 (m, 2H) , 3.59 -3.21 (m, 10H) , 3.06 -2.72 (m, 6H) , 2.55 (d, J = 14.2 Hz, 1H) , 2.11 -1.84 (m, 6H) , 1.81 -1.58 (m, 4H) , 1.27 -1.21 (m, 3H) . Mass (m/z) : 487.52 [M+H]
+.
Preparation of 1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -3- (1, 2, 3, 4-tetrahydronaphthalen-1-yl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (69)
The title compound 69 (30 mg) was prepared in a yield of 40.0%as a light yellow solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.27 -7.25 (m, 2H) , 7.16 -7.08 (m, 3H) , 6.85 (d, J = 7.5 Hz, 1H) , 6.52 (dd, J = 8.4, 1.8 Hz, 2H) , 5.31 -5.24 (m, 1H) , 3.50 -3.29 (m, 4H) , 3.29 -3.23 (m, 4H) , 3.00 -2.87 (m, 2H) , 2.78 (d, J = 16.8 Hz, 2H) , 2.32 (d, J = 12.3 Hz, 1H) , 2.13 -1.92 (m, 7H) , 1.87 -1.58 (m, 6H) , 1.28 -1.21 (m, 3H) . Mass (m/z) : 487.41 [M+H]
+.
3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1- (2- ( (tetrahydro-2H-pyran-2-yl) oxy) ethyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (70)
The title compound 70 was prepared from 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.39 (d, J = 8.2 Hz, 2H) , 7.18 (s, 4H) , 6.54 (d, J = 8.0 Hz, 2H) , 4.98 -4.87 (m, 2H) , 4.63 (s, 1H) , 4.14 (s, 2H) , 3.89 (d, J = 50.5 Hz, 4H) , 3.65 -3.41 (m, 10H) , 3.28 (s, 4H) , 3.13 (dd, J = 15.5, 8.9 Hz, 4H) , 2.01 (s, 4H) , 1.85 -1.69 (m, 4H) , 1.55 -1.45 (m, 2H) . Mass (m/z) : 573.66 [M+H]
+.
Preparation of 3- (3, 4-dimethoxyphenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (71)
The title compound 71 was prepared in a yield of 45.85%as a white powder according to the procedure for compound 3.
1H NMR (400 MHz, CDCl
3) δ 7.32 (d, J = 8.2 Hz, 2H) , 6.92 (d, J = 1.7 Hz, 2H) , 6.87 (t, J = 1.3 Hz, 1H) , 6.57 -6.51 (m, 2H) , 3.94 -3.90 (m, 2H) , 3.89 (dd, J = 4.9, 1.2 Hz, 6H) , 3.48 (q, J = 7.1 Hz, 2H) , 3.35 -3.19 (m, 8H) , 2.85 (s, 2H) , 2.03 -1.98 (m, 4H) , 1.91 -1.81 (m, 2H) , 1.32 -1.27 (m, 3H) . Mass (m/z) : 493.7 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1- (2- (pyrrolidin-1-yl) ethyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (72)
The title compound 72 was prepared as white solid in a yield of 4.76%from 13-01 and 1- (2-bromoethyl) pyrrolidine according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.48 (d, J = 8.0 Hz, 2H) , 7.21 -7.17 (m, 4H) , 6.83 (s, 2H) , 4.06 (t, J = 6.4 Hz, 4H) , 3.88 (s, 2H) , 3.55 -3.34 (m, 13H) , 3.14 (dd, J = 15.4, 8.8 Hz, 2H) , 2.89 (s, 3H) , 2.23 (dd, J = 17.2, 9.5 Hz, 3H) , 2.09 (s, 5H) , 2.01 (s, 3H) . Mass (m/z) : 542.6 [M+H]
+.
Preparation of 1- (2-cyclohexylethyl) -3- (2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (73)
The title compound 73 was prepared as white solid in a yield of 55.29%from 13-01 and (2-bromoethyl) cyclopentane according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.37 (d, J = 8.2 Hz, 2H) , 7.21 -7.13 (m, 4H) , 6.56 -6.48 (m, 2H) , 4.91 (t, J = 9.0 Hz, 1H) , 4.07 (s, 1H) , 3.55 -3.39 (m, 4H) , 3.39 -3.32 (m, 2H) , 3.32 -3.22 (m, 4H) , 3.13 (dd, J = 15.3, 9.1 Hz, 2H) , 3.31 (s, 1H) , 2.03 -1.96 (m, 4H) , 1.74 (d, J = 13.9 Hz, 5H) , 1.67 (dd, J = 12.8, 3.3 Hz, 3H) , 1.60 (d, J = 11.4 Hz, 1H) , 1.56 -1.48 (m, 2H) , 1.38 -1.05 (m, 4H) , 0.94 (qd, J = 11.8, 6.6 Hz, 2H) . Mass (m/z) : 555.6 [M+H]
+.
Preparation of 1-ethyl-3- (4-fluoro-2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (74)
The title compound 74 (20mg) was prepared in a yield of 28.0%as a light yellow solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.37 (s, 2H) , 7.20 -7.08 (m, 1H) , 6.97 (d, J = 7.4 Hz, 1H) , 6.91 -6.79 (m, 1H) , 6.61 -6.36 (m, 2H) , 4.96 (t, J = 9.1 Hz, 1H) , 4.25 (s, 2H) , 3.86 -3.13 (m, 10H) , 3.12 -2.73 (m, 3H) , 2.00 (s, 3H) , 1.78 (d, J = 14.5 Hz, 2H) , 1.60 (s, 4H) , 1.26 (s, 3H) . Mass (m/z) : 491.33 [M+H]
+.
Preparation of 1-ethyl-3- (1-phenylpiperidin-3-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (75)
The title compound 75 was prepared in a yield of 13.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.36 (s, 2H) , 7.26 -7.19 (m, 2H) , 7.08 (d, J = 8.2 Hz, 1H) , 6.73 (s, 2H) , 6.53 (d, J = 8.1 Hz, 2H) , 5.00 -4.80 (m, 1H) , 4.13 (s, 1H) , 3.77 (d, J = 4.7 Hz, 3H) , 3.45 (d, J = 19.6 Hz, 5H) , 3.27 (s, 4H) , 3.09 (dt, J = 18.4, 9.8 Hz, 3H) , 2.00 (s, 4H) , 1.75 (d, J = 14.0 Hz, 2H) , 1.60 (s, 6H) , 1.30 -1.17 (m, 3H) . Mass (m/z) : 516.65 [M+H]
+.
Preparation of 1-ethyl-3- (5-methoxy-2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (76)
The title compound 76 (3.1 mg) was prepared in a yield of 9.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.36 (d, J = 8.0 Hz, 1H) , 7.21 (d, J = 8.1 Hz, 1H) , 7.03 -6.75 (m, 3H) , 6.52 (d, J = 8.0 Hz, 2H) , 4.18 (s, 3H) , 3.67 -3.19 (m, 10H) , 2.90 (d, J = 29.4 Hz, 1H) , 2.70 (t, J = 12.2 Hz, 1H) , 2.36 -2.18 (m, 1H) , 1.98 (dt, J = 6.7, 3.3 Hz, 3H) , 1.72 (dd, J = 47.7, 33.0 Hz, 6H) , 1.23 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 503.43 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-neopentyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (77)
The title compound 77 was prepared in a yield of 4.0%as yellow powder (3mg) from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.22-7.11 (m 6H) , 6.56 -6.50 (m, 2H) , 4.99-4.89 (m, 1H) , 3.52 (dd, J = 14.8, 9.5 Hz, 4H) , 3.35 -3.20 (m, 6H) , 3.18 -3.03 (m, 6H) , 2.10 -1.88 (m, 6H) , 1.34 -1.29 (m, 2H) , 0.99 (s, 9H) . Mass (m/z) : 515.50 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-2-yl) -1-isobutyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (78)
The title compound 78 was prepared in a yield of 6.04%as white powder from compound 13-01 according to the procedure for compound 1-04.
1H NMR (400 MHz, CDCl
3) δ 7.46 -7.35 (m, 2H) , 7.24 -7.13 (m, 4H) , 6.61 -6.49 (m, 2H) , 5.03 -4.84 (m, 1H) , 4.39 (s, 2H) , 3.90 -3.70 (m, 2H) , 3.66 -3.42 (m, 4H) , 3.36 -3.20 (m, 5H) , 3.14 (dd, J = 15.4, 9.1 Hz, 2H) , 3.10 -2.98 (m, 2H) , 2.18 (dd, J = 13.9, 7.1 Hz, 1H) , 2.09 -1.95 (m, 4H) , 1.79 (d, J = 14.4 Hz, 2H) , 1.26 (s, 1H) , 0.94 (t, J = 6.4 Hz, 6H) . Mass (m/z) : 501.4 [M+H]
+.
Preparation of 2- (3- (2, 3-dihydro-1H-inden-2-yl) -2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-1-yl) acetonitrile (79)
The title compound 79 was prepared in a yield of 6.07%as brown solid from compound 13-01 according to the procedure for compound 13.
1H NMR (400 MHz, CDCl
3) δ 7.31 (d, J = 8.2 Hz, 2H) , 7.20 (s, 4H) , 6.54 (d, J = 8.2 Hz, 2H) , 4.94 (p, J = 9.0 Hz, 1H) , 4.44 (s, 2H) , 4.10 (s, 2H) , 3.58 -3.38 (m, 7H) , 3.34 -3.22 (m, 5H) , 3.16 (dt, J = 17.5, 8.8 Hz, 5H) , 1.91 (d, J = 14.3 Hz, 3H) . Mass (m/z) : 484.5 [M+H]
+.
Preparation of 3- (3- (tert-butyl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (80)
The title compound 80 (3.1 mg) was prepared in a yield of 19.50%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl3) δ 7.45 -7.30 (m, 5H) , 7.22 -7.12 (m, 1H) , 6.60 -6.50 (m, 2H) , 3.94 (s, 2H) , 3.49 (q, J = 7.2 Hz, 2H) , 3.43 -3.19 (m, 8H) , 3.00 -2.78 (br, 2H) , 2.01 (p, J = 3.3 Hz, 4H) , 1.89 (d, J = 13.9 Hz, 2H) , 1.39 -1.27 (m, 12H) . Mass (m/z) : 489.4 [M+H]
+.
Preparation of 1-ethyl-3- (3-methoxy-4-methylphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (81)
The title compound 81 was prepared in a yield of 25.31%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.36 (d, J = 8.3 Hz, 2H) , 7.18 (dd, J = 7.9, 1.0 Hz, 1H) , 6.83 (dd, J = 7.9, 2.0 Hz, 1H) , 6.79 (d, J = 2.0 Hz, 1H) , 6.57 -6.51 (m, 2H) , 4.00 (s, 2H) , 3.82 (s, 3H) , 3.53 -3.47 (m, 2H) , 3.40 (d, J = 23.5 Hz, 4H) , 3.31 -3.23 (m, 4H) , 3.04 (s, 2H) , 2.21 (s, 3H) , 2.03 -1.98 (m, 4H) , 1.89 (d, J = 14.1 Hz, 2H) , 1.30 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 477.7 [M+H]
+.
Preparation of 1-ethyl-3- (5-methoxy-2-methylphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (82)
The title compound 82 was prepared in a yield of 27.97%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.34 (d, J = 8.2 Hz, 2H) , 7.19 (dd, J = 8.5, 0.8 Hz, 1H) , 6.89 (dd, J = 8.5, 2.7 Hz, 1H) , 6.65 (d, J = 2.6 Hz, 1H) , 6.57 -6.49 (m, 2H) , 4.05 -3.93 (m, 2H) , 3.77 (s, 3H) , 3.50 (q, J = 6.7, 6.2 Hz, 2H) , 3.44 -3.31 (m, 4H) , 3.30 -3.23 (m, 4H) , 2.95 (br, 2H) , 2.06 (s, 3H) , 2.03 -1.97 (m, 4H) , 1.96 -1.78 (m, 2H) , 1.30 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 477.6 [M+H]
+.
Preparation of 5- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -2-fluorobenzonitrile (83)
The title compound 83 (176 mg) was prepared in a yield of 47.5%as a light yellow solid from compound 135-02 (218mg, 0.63mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.34 -8.21 (m, 2H) , 7.82 -7.68 (m, 2H) , 7.34 (dd, J = 9.4, 7.7 Hz, 1H) , 7.18 (d, J = 7.6Hz, 2H) , 6.57 -6.45 (m, 2H) , 3.52-3.36 (m, 4H) , 3.29 -3.26 (m, 4H) , 2.88 (s, 2H) , 2.83 -2.65 (m, 2H) , 2.13 (s, 2H) , 2.01-1.98 (m, 4H) , 1.93 -1.77 (m, 2H) , 1.30 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 587.41 [M+H]
+.
Preparation of 1-ethyl-3- (2-phenylcyclopropyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (84)
The title compound 84 (8mg) was prepared in a yield of 13.7%as a light yellow solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.33 -7.26 (m, 2H) , 7.26 -7.25 (m, 3H) , 7.19 (d, J = 12.7 Hz, 2H) , 6.52 (d, J = 8.1 Hz, 2H) , 3.55-3.44 (m, 2H) , 3.37-3.15 (m, 6H) , 2.85 -2.62 (m, 4H) , 2.51-2.45 (m, 1H) , 2.07-1.87 (m, 5H) , 1.69 -1.57 (m, 5H) , 1.43 (q, J = 6.8, 6.0 Hz, 1H) , 1.21 (t, J = 6.9 Hz, 3H) . Mass (m/z) : 473.51 [M+H]
+.
Preparation of 1-ethyl-3- (4-phenylcyclohexyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (85)
The title compound 85 was prepared in a yield of 8.1%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.46-7.27 (m, 5H) , 7.22-7.11 (m, 2H) , 6.57 -6.46 (m, 2H) , 4.41-4.26 (m, 2H) , 4.05-3.92 (m, 1H) , 3.81 -3.63 (m, 2H) , 3.60 -3.33 (m, 4H) , 3.30 -3.21 (m, 3H) , 3.05 -2.92 (m, 2H) , 2.41 -2.12 (m, 4H) , 2.07 -1.91 (m, 4H) , 1.86 -1.53 (m, 8H) , 1.28-1.16 (m, 3H) . Mass (m/z) : 515.86 [M+H]
+.
Preparation of 1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -3- (4- (pyrrolidin-1-yl) phenyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (86)
The title compound 86 was prepared in a yield of 30.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.36 (d, J = 8.3 Hz, 2H) , 7.09 (d, J = 8.5 Hz, 2H) , 6.66 -6.43 (m, 4H) , 4.36 (s, 1H) , 3.84 -3.71 (m, 2H) , 3.69 -3.47 (m, 4H) , 3.32 -3.22 (m, 5H) , 3.14 -3.00 (m, 2H) , 2.64 (s, 1H) , 2.06 -1.85 (m, 8H) , 1.29-1.23 (m, 4H) . Mass (m/z) : 502.39 [M+H]
+.
Preparation of 1-ethyl-3- (4-ethynylphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (87)
The title compound 87 was prepared in a yield of 31.11%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.59 -7.54 (m, 2H) , 7.42 -7.37 (m, 4H) , 6.55 (d, J = 8.7 Hz, 2H) , 4.15 (d, J = 4.8 Hz, 2H) , 3.54 (t, J = 7.2 Hz, 6H) , 3.33 -3.25 (m, 4H) , 3.25-3.14 (m, 2H) , 3.12 (s, 1H) , 2.06 -1.96 (m, 4H) , 1.91 (d, J = 14.4 Hz, 2H) , 1.34 -1.27 (m, 3H) . Mass (m/z) : 457.9 [M+H]
+.
Preparation of 1-ethyl-3- ( (1S, 3S) -3-phenoxycyclopentyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (88)
The title compound 88 was prepared in a yield of 7.41%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.40 (d, J = 8.1 Hz, 3H) , 7.05 -6.78 (m, 4H) , 6.55 (d, J = 8.3 Hz, 2H) , 4.96 (s, 1H) , 4.77 (dd, J = 17.0, 7.3 Hz, 1H) , 4.16 (d, J = 9.9 Hz, 2H) , 3.46 (d, J = 24.4 Hz, 6H) , 3.29 (s, 3H) , 3.15 -2.92 (m, 2H) , 2.57 -2.27 (m, 3H) , 2.23 -2.09 (m, 3H) , 2.02 (s, 5H) , 1.74 (d, J = 14.5 Hz, 2H) , 1.38 -1.20 (m, 3H) . Mass (m/z) : 517.5 [M+H]
+.
Preparation of 3- (2, 3-dihydro-1H-inden-5-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (89)
The title compound 89 was prepared in a yield of 2.1%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.45 -7.29 (m, 3H) , 7.20-7.14 (m, 1H) , 7.06 (d, J = 8.2 Hz, 1H) , 6.60 -6.49 (m, 2H) , 4.20-4.01 (m, 2H) , 3.57-3.42 (m, 4H) , 3.35 -3.22 (m, 4H) , 3.15-3.05 (m, 2H) , 3.00-2.82 (m, 4H) , 2.18 -1.85 (m, 8H) , 1.35 -1.22 (m, 5H) . Mass (m/z) : 473.43 [M+H]
+.
Preparation of 1-ethyl-3- (naphthalen-1-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (90)
The title compound 90 was prepared in a yield of 5.8%as a white powder according to the procedure for compound 97 (the last 3 steps) . Mass (m/z) : 483.45 [M+H]
+.
Preparation of 3- ( [1, 1′-biphenyl] -3-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (91)
The title compound 91 was prepared in a yield of 16.22%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.57 (dtd, J = 9.4, 3.0, 1.5 Hz, 4H) , 7.51 (t, J = 8.1 Hz, 1H) , 7.46 -7.39 (m, 2H) , 7.39 -7.32 (m, 4H) , 6.57 -6.49 (m, 2H) , 4.12 (s, 2H) , 3.52 (dt, J = 17.6, 8.4 Hz, 6H) , 3.32 -3.18 (m, 4H) , 3.11 (s, 2H) , 2.02 -1.96 (m, 4H) , 1.96 -1.87 (m, 2H) , 1.31 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 509.4 [M+H]
+.
Preparation of 1-ethyl-3- (3-phenoxyphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (92)
The title compound 92 was prepared in a yield of 5.40%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.43 -7.38 (m, 2H) , 7.38 -7.33 (m, 2H) , 7.32 -7.29 (m, 2H) , 7.17 -7.12 (m, 1H) , 7.08 -7.01 (m, 4H) , 6.58 (d, J = 8.3 Hz, 2H) , 4.20 (d, J = 4.7 Hz, 2H) , 3.54 (d, J = 7.2 Hz, 6H) , 3.34 -3.24 (m, 4H) , 3.24 -3.11 (m, 2H) , 2.07 -1.96 (m, 4H) , 1.92 (d, J = 14.2 Hz, 2H) , 1.31 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 525.8 [M+H]
+.
Preparation of 1-ethyl-3- (3-morpholinophenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (93)
The title compound 93 was prepared in a yield of 20.32%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.42 -7.37 (m, 2H) , 7.37 -7.30 (m, 1H) , 6.94 -6.82 (m, 3H) , 6.55 (d, J = 8.7 Hz, 2H) , 4.14 (s, 2H) , 3.88 -3.81 (m, 4H) , 3.60 -3.45 (m, 6H) , 3.33 -3.24 (m, 5H) , 3.24 -3.11 (m, 6H) , 2.06 -1.96 (m, 5H) , 1.91 (d, J = 14.2 Hz, 2H) , 1.31 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 518.6 [M+H]
+.
Preparation of 1-ethyl-3- (4-methoxy-2, 3-dihydro-1H-inden-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (94)
The title compound 94 was prepared in a yield of 3.3%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.32 -7.29 (m, 1H) , 7.22 -7.19 (m, 1H) , 7.14 (t, J = 7.4 Hz, 1H) , 6.80 (d, J = 7.5 Hz, 1H) , 6.68 (d, J = 8.1 Hz, 1H) , 6.52 (d, J = 8.4 Hz, 2H) , 4.94 (q, J = 8.9 Hz, 1H) , 3.80 (d, J = 4.0 Hz, 2H) , 3.68 (s, 1H) , 3.48 (dd, J = 15.4, 8.7 Hz, 1H) , 3.40 -3.24 (m, 5H) , 3.17 (dt, J = 15.7, 10.6 Hz, 2H) , 3.00 (s, 3H) , 2.00 (p, J = 3.2 Hz, 4H) , 1.64 (d, J = 44.9 Hz, 8H) , 1.22 (t, J = 6.8 Hz, 3H) . Mass (m/z) : 503.29 [M+H]
+.
Preparation of 1-ethyl-3- (3-isopropoxyphenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (95)
The title compound 95 was prepared in a yield of 19%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.44 -7.30 (m, 3H) , 6.94 -6.83 (m, 3H) , 6.57 -6.49 (m, 2H) , 4.53 (q, J = 6.3 Hz, 1H) , 4.22 (s, 2H) , 3.65 -3.47 (m, 6H) , 3.32 -3.22 (m, 4H) , 3.17 (d, J = 14.2 Hz, 2H) , 2.05 -1.96 (m, 4H) , 1.90 (d, J = 14.3 Hz, 2H) , 1.38 -1.25 (m, 9H) . Mass (m/z) : 491.51 [M+H]
+.
Preparation of 4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) benzonitrile (96)
The title compound 96 was prepared in a yield of 21.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.74 -7.63 (m, 4H) , 7.19 -7.14 (m, 2H) , 6.54 -6.48 (m, 2H) , 3.62 -3.50 (m, 2H) , 3.40 (p, J = 7.0, 6.1 Hz, 2H) , 3.30 -3.22 (m, 4H) , 2.84 (d, J = 38.3 Hz, 4H) , 2.27 -2.05 (m, 2H) , 2.02-1.98 (m, 4H) , 1.78 (d, J = 13.3 Hz, 2H) , 1.29 -1.24 (m, 3H) . Mass (m/z) : 458.06 [M+H]
+.
Preparation of 1-ethyl-3- (4- (pyridin-2-yl) phenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (97)
Step 1: To a stirred solution of 4-amino-1- (tert-butoxycarbonyl) piperidine-4-carboxylic acid 97-01 (25 g, 0.1 mol) in THF (1.5 L) was added aqueous 10%Na
2CO
3 (32.54 g, 310 mL) solution, then a solution of FmocCl (6.47 g, 0.1 mol) in THF was added dropwise at 0℃. then the mixture was stirred at rt overnight. Concentrated most of the THF, then 1N H
2SO
4 was added to aqueous layer until pH=2~3, then extracted with EA for several times. Organic layer was combined, washed with H
2O, brine, dried over Na
2SO
4. The filtrate was concentrated, and purified by flash column chromatography (PE/EA = 5/1-2/1) to give 40 g of 97-02 as white solid. Mass (m/z) : 489.27, [M+Na]
+; 367.28 , [M-Boc]
+.
Step 2: Preparation of 1N HCl in MeOH: 36 mL of AcCl was added slowly to anhydrous MeOH (500 mL) in ice bath at 0℃, which was stirred for another 1hrs. A solution of 97-02 (54.5 g, 0.12 mol) in MeOH (200 mL) was added to the above 1 N HCl solution in MeOH, the reaction mixture was heated to 60℃ for 24 hrs. Concentrated the solvent and the residue was used directly for the next step. Mass (m/z) : 381.46, [M+H]
+
Step 3: 97-03 (41.7 g, 0.1 mol) , 4- (pyrrolidin-1-yl) benzaldehyde (19.1 g, 0.11 mol) was dissolved in DCE (500 mL) , NaBH (AcO)
3 (63 g, 0.3 mol) and catalytic Ti (Oi-Pr)
4 (2 mL) was added subsequently to the above system, the reaction mixture was stirred at room temperature overnight. Saturated Na
2CO
3 aqueous solution and CH
2Cl
2 was added and the organic layer was separated, the water layer was extracted with CH
2Cl
2 for three times, combine the organic layer, dried, and filtered, the filtrate was concentrated, the residue was purified by flash column chromatography (CH
2Cl
2/MeOH = 70/1) , to afford 30 g of 97-04 as pale yellow solid. Mass (m/z) : 540.54, [M+H]
+.
Step 4: To a stirred solution of 97-04 (30 g, 0.056 mol) in CH
2Cl
2 (300 mL) was added Et
2NH (120 mL, 1.16 mol) , the reaction mixture was stirred at rt for 4hrs. Concentrated the solvent and the residue was purified by flash column chromatography (PE/EA = 10/1 ~ EA~ CH
2Cl
2/MeOH = 10/1) to afford 14.8 g of 97-05 as yellow syrup. Mass (m/z) : 318.33, [M+H]
+.
Step 5: The 4- (pyridin-2-yl) aniline 97-06 (59mg, 0.35mmol) in THF was added BTC (37mg, 0.12mmol) and Et
3N (64 mg, 0.63mmol) at rt under nitrogen protection. 10 min later, 28-05 (100 mg, 0.32mmol) and another Et
3N (64mg, 0.63mmol) was added. The mixture was stirred at rt for 2 h. The reaction mixture was diluted by H
2O, extracted with EA for 3 times. The organic layers were combined, washed by brine, dried over Na
2SO
4, filtrated and evaporated to give 160 mg 97-07 which was used without further purification.
Step 6: 160 mg 97-07 in DMF was added tBuOK (178mg, 1.58mmol) , The mixture was stirred at 50℃ for 2 h. The resulting solution was diluted by H
2O, extracted with EA for 3 times. The organic layers were combined, washed by brine, dried over Na
2SO
4, filtrated and evaporated to give 150 mg 97-08 which was used without further purification.
Step 7: The title compound 97 (7mg, 4.4%for 3 steps) was prepared as white solid from compound 97-08 (150mg, crude product) and CH
3CH
2I (75mg, 0.47mmol) according to the procedure for 1-04.
1H NMR (400 MHz, CDCl
3) δ 8.74-8.65 (m, 1H) , 8.12-8.03 (m, 2H) , 7.80-7.69 (m, 2H) , 7.59-7.48 (m, 2H) , 7.34-7.27 (m, 1H) , 7.26-7.22 (m, 2H) , 6.58-6.47 (d, J=8Hz, 2H) , 3.46 (s, 4H) , 3.32-3.21 (m, 4H) , 2.96-2.74 (br, 2H) , 2.07-1.94 (m, 4H) , 1.92-1.78 (m , 2H) , 1.66 (s, 1H) , 1.36-1.26 (t, J=6Hz, 3H) . Mass (m/z) : 510.28, [M+H]
+.
Preparation of 1-ethyl-3- (4- (pyridin-4-yl) phenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (98)
The title compound 98 (18mg) was prepared in a yield of 11.2%for three steps as white solid from 97-05 (100mg, 0.32mmol) and 4- (pyridin-4-yl) aniline (59mg, 0.35mmol) according to the procedure for compound 97.
1HNMR (400 MHz, CDCl
3) δ 8.75-8.62 (m, 2H) , 7.78-7.64 (m, 2H) , 7.53-7.62 (m, 2H) , 7.43-7.53 (m, 2H) , 7.33-7.15 (m, 2H) , 6.59-6.45 (m, 2H) , 3.86-3.67 (br, 2H) , 3.47 (s, 2H) , 3.35-3.20 (m, 4H) , 3.17-3.05 (m, 2H) , 2.08-1.93 (m , 4H) , 1.92-1.79 (m, 2H) , 1.61 (s, 2H) , 1.33-1.25 (m, 3H) . Mass (m/z) : 510.82, [M+H]
+.
Preparation of 1-ethyl-3- (3-phenylcyclobutyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (99)
The title compound 99 (18mg) was prepared in a yield of 11.7%for three steps as white solid from 97-05 (100mg, 0.32mmol) and 3-phenylcyclobutan-1-amine (59mg, 0.35mmol) according to the procedure for 97. Mass (m/z) : 487.62, [M+H]
+.
Preparation of 3- (4- (1H-pyrrol-1-yl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (100)
The title compound 100 was prepared in a yield of 30.0%as a yellow powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.56 -7.43 (m, 4H) , 7.20 (s, 2H) , 7.12 -7.06 (m, 2H) , 6.59 -6.50 (m, 2H) , 6.40 -6.33 (m, 2H) , 3.54 (s, 2H) , 3.42 (d, J = 6.8 Hz, 2H) , 3.28 (q, J = 6.3, 5.1 Hz, 4H) , 2.86 (s, 4H) , 2.11 (s, 2H) , 2.00 (q, J = 3.4 Hz, 4H) , 1.81 (d, J = 13.3 Hz, 2H) , 1.29 (t, 3H) . Mass (m/z) : 498.54 [M+H]
+.
Preparation of 1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -3- (4- (thiazol-2-yl) phenyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (101)
The title compound 101 was prepared in a yield of3.0%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 8.04 (dd, J = 8.8, 2.1 Hz, 2H) , 7.88 (d, J = 3.2 Hz, 1H) , 7.57 (d, J = 8.7 Hz, 2H) , 7.35 (d, J = 3.2 Hz, 1H) , 7.18 (d, J = 8.1 Hz, 2H) , 6.53 (d, J = 8.3 Hz, 2H) , 3.61 -3.38 (m, 4H) , 3.28 (t, J = 4.9 Hz, 4H) , 2.85 (s, 4H) , 2.21 -1.94 (m, 6H) , 1.81 (d, J = 13.2 Hz, 2H) , 1.29 (t, 3H) . Mass (m/z) : 516.76 [M+H]
+.
Preparation of 1-ethyl-3- (3′-methoxy- [1, 1′-biphenyl] -4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (102)
The title compound 102 (16mg) was prepared in a yield of 17.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.65 (dd, J = 8.6, 1.9 Hz, 2H) , 7.55 -7.46 (m, 2H) , 7.36 (t, J = 8.0 Hz, 1H) , 7.25 -7.16 (m, 3H) , 7.15 -7.10 (m, 1H) , 6.91 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H) , 6.54 (dd, J = 9.0, 2.2 Hz, 2H) , 3.87 (s, 3H) , 3.61 (s, 2H) , 3.43 (t, J = 7.1 Hz, 2H) , 3.35 -3.24 (m, 4H) , 2.94 (s, 4H) , 2.23 (s, 2H) , 2.03 -1.99 (m, 4H) , 1.85 (s, 2H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 539.52 [M+H]
+.
Preparation of 1-ethyl-3- (2′-methoxy- [1, 1′-biphenyl] -4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (103)
The title compound 103 (2.2 mg) was prepared in a yield of 2.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.70 -7.29 (m, 7H) , 7.10 -6.94 (m, 3H) , 6.64 -6.49 (m, 2H) , 3.84 -3.76 (m, 3H) , 3.73 -3.39 (m, 4H) , 3.38 -3.22 (m, 4H) , 3.18 -2.72 (m, 4H) , 2.40 -1.93 (m, 6H) , 1.84 (s, 2H) , 1.30 (t, 3H) . Mass (m/z) : 539.48 [M+H]
+.
Preparation of 3- (3-chloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (104)
The title compound 104 (2.0 mg) was prepared in a yield of 2.9%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.71 (d, J = 2.0 Hz, 1H) , 7.56 (dt, J = 8.1, 1.1 Hz, 3H) , 7.52 -7.34 (m, 4H) , 7.23 -7.16 (m, 2H) , 6.61 -6.50 (m, 2H) , 3.52 (s, 2H) , 3.49 -3.36 (m, 2H) , 3.33 -3.25 (m, 4H) , 2.99 -2.73 (m, 4H) , 2.12 (t, J = 10.9 Hz, 2H) , 2.00 (q, J = 6.5, 4.7 Hz, 4H) , 1.88 (t, J = 15.2 Hz, 2H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 543.51 [M+H]
+.
Preparation of 3- (4- (cyclopent-1-en-1-yl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (105)
The title compound 105 (2.0 mg) was prepared in a yield of 2.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.49 (d, J = 8.0 Hz, 2H) , 7.41 -7.28 (m, 4H) , 6.54 (d, J = 8.1 Hz, 2H) , 6.21 (s, 1H) , 4.09 (s, 2H) , 3.61 -3.36 (m, 6H) , 3.27 (t, J = 5.8 Hz, 4H) , 3.01 (s, 2H) , 2.62 (d, J = 63.4 Hz, 4H) , 2.02 (dt, J = 12.0, 6.1 Hz, 6H) , 1.89 (d, J = 14.1 Hz, 2H) , 1.37 -1.26 (m, 3H) . Mass (m/z) : 499.72 [M+H]
+.
Preparation of 3- (benzo [b] thiophen-2-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (106)
The title compound 106 (11mg) was prepared in a yield of 7.1%for three steps as white solid from 97-05 (100mg, 0.32mmol) and benzo [b] thiophen-2-amine hydrochloride (64mg, 0.34mmol) according to the procedure for 97.
1HNMR (400 MHz, CDCl3) δ 7.90 (s, 1H) , 7.81-7.71 (m, 2H) , 7.38-7.29 (m, 2H) , 7.23-7.17 (m, 2H) , 6.56-6.50 (d, J=8Hz, 2H) , 3.59 (s, 2H) , 3.40-3.47 (m, 2H) , 3.24-3.31 (m, 4H) , 2.93 (s, 2H) , 2.30-2.10 (br, 2H) , 2.02-1.96 (m , 4H) , 1.83-1.77 (m, 2H) , 1.32-1.27 (m, 3H) . Mass (m/z) : 489.28, [M+H] +.
Preparation of 3- (benzo [b] thiophen-3-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (107)
The title compound 107 (19mg) was prepared in a yield of 12.3%for three steps as white solid from 97-05 (100mg, 0.32mmol) and benzo [b] thiophen-3-amine hydrochloride (64mg, 0.34mmol) according to the procedure for 97.
1HNMR (400 MHz, CDCl
3) δ 7.79-7.86 (m, 1H) , 7.52-7.47 (m, 1H) , 7.44-7.33 (m, 8H) , 7.31-7.26 (d, J=4Hz, 2H) , 6.54-6.48 (d, J=8Hz, 2H) , 3.92 (s, 2H) , 3.56-3.44 (m, 2H) , 3.34-3.16 (m, 8H) , 2.89-2.73 (m, 2H) , 2.01-1.93 (m, 2H) , 1.84-1.93 (d, J=12Hz, 4H) , 1.35-1.28 (t, J=8Hz, 3H) . Mass (m/z) : 489.10, [M+H]
+.
Preparation of 3- (3, 5-dichloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (108)
The title compound 108 (18mg) was prepared in a yield of 12.3%for three steps as white solid from (50mg, 0.16mmol) and 3, 5-dichloro- [1, 1′-biphenyl] -4-amine (41mg, 0.17mmol) according to the procedure for 97.
1HNMR (400 MHz, CDCl
3) δ 7.62 (s, 1H) , 7.54-7.49 (m, 1H) , 7.49-7.39 (m, 3H) , 7.29 (s, 1H) , 7.27 (s, 1H) , 6.56-6.49 (d, J=8Hz , 2H) , 3.85 (s, 2H) , 3.55-3.44 (q, J=6.67Hz, 2H) , 3.31-3.23 (m, 4H) , 3.21 (s, 2H) , 2.83-2.63 (br, 2H) , 2.02-1.97 (m, 4H) , 1.95 (s, 1H) , 1.92 (s, 1H) , 1.35-1.28 (t, J=6Hz, 3H) . Mass (m/z) : 577.58, [M+H]
+.
Preparation of 1-ethyl-3- (3-phenylcyclohexyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (109)
The title compound 109 (2.9 mg) was prepared in a yield of 3.6%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1HNMR (400 MHz, CDCl
3) δ 7.43-7.33 (m, 1H) , 7.31-7.27 (m, 1H) , 7.22-7.15 (m, 3H) , 6.56-6.51 (m , 2H) , 4.23-4.18 (s, 1H) , 4.10-4.00 (m, 2H) , 3.62-3.45 (m, 2H) , 3.45-3.35 (m, 2H) , 3.30-3.21 (t, J=6.4Hz, 4H) , 3.05-2.94 (m, 2H) , 2.66-2.55 (m, 1H) , 2.20-2.11 (m, 2H) , 1.98-2.02 (m, 4H) , 1.89-1.79 (m, 2H) , 1.78-1.63 (m, 4H) , 1.52-1.43 (t, J=10Hz, 2H) , 1.27-1.23 (m, 3H) . Mass (m/z) : 515.60 [M+H]
+.
Preparation of 3- (5, 6-difluoro-2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (110)
The title compound 110 (15 mg) was prepared in a yield of 3.6%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.28 (d, J = 8.6 Hz, 2H) , 6.96 (t, J = 8.8 Hz, 2H) , 6.52 (d, J = 8.6 Hz, 2H) , 4.99-4.86 (m, 1H) , 3.82 (s, 2H) , 3.45 -3.33 (m, 4H) , 3.29 -3.22 (m, 4H) , 3.20-3.13 (m, 4H) , 3.13-3.04 (m, 2H) , 2.65 (s, 2H) , 2.02 -1.97 (m, 4H) , 1.75 -1.63 (m, 2H) , 1.23 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 509.59 [M+H]
+.
Preparation of 1-ethyl-3- (4- (pyridin-3-yl) phenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (111)
The title compound 111 (13 mg) was prepared in a yield of 16.2%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1HNMR (400 MHz, CDCl
3) δ 8.84 (s, 1H) , 8.62 (s, 1H) , 7.92-7.84 (d, J=8Hz, 1H) , 7.69-7.62 (d, J=8.4Hz, 1H) , 7.54-7.48 (d, J=8.4Hz, 1H) , 7.43-7.36 (m, 1H) , 7.36-7.29 (d, J=8Hz, 2H) , 6.56-6.50 (d, J=8Hz, 2H) , 4.08 (s, 1H) , 3.56-3.42 (m, 6H) , 3.27 (s, 1H) , 3.12-2.98 (m, 2H) , 2.04-1.96 (m, 4H) , 3.56-3.42 (m, 6H) , 1.95 (s, 1H) , 1.91 (s, 1H) , 1.34-1.27 (t, J=7.2Hz, 3H) . Mass (m/z) : 510.85 [M+H]
+.
Preparation of 3- ( [1, 1′-biphenyl] -2-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (112)
The title compound 112 (22 mg) was prepared in a yield of 27.5%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.55 -7.38 (m, 3H) , 7.34 -7.20 (m, 8H) , 6.54-6.48 (m, 2H) , 3.70 (s, 2H) , 3.41 -3.22 (m, 6H) , 3.11 -2.97 (m, 2H) , 2.92 -2.83 (m, 1H) , 2.70 (t, J = 12.4 Hz, 1H) , 2.48 (s, 1H) , 2.27 (s, 1H) , 2.02-1.96 (m, 4H) , 1.75 (d, J = 13.7 Hz, 2H) , 1.14 (t, J = 6.9 Hz, 3H) . Mass (m/z) : 509.66 [M+H]
+.
Preparation of 3- (2′-chloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (113)
The title compound 113 (28 mg) was prepared in a yield of 32.7%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.57 -7.41 (m, 5H) , 7.34 -7.20 (m, 5H) , 6.53 (d, J = 8.1 Hz, 2H) , 3.78 (s, 2H) , 3.53-3.39 (m, 2H) , 3.27 (s, 4H) , 3.13 (s, 2H) , 2.94 (s, 1H) , 2.87 (s, 1H) , 2.60 (s, 2H) , 2.05 -1.91 (m, 4H) , 1.85 (d, J = 13.6 Hz, 2H) , 1.28 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 543.51 [M+H]
+.
Preparation of 1-ethyl-3- (1-phenylazetidin-3-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (114)
The title compound 114 was prepared in a yield of 5.04%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.53 -7.45 (m, 2H) , 7.34 (dd, J = 8.6, 1.8 Hz, 2H) , 7.25 -7.18 (m, 2H) , 6.53 (d, J = 8.7 Hz, 2H) , 6.24 -6.18 (m, 1H) , 3.59 (s, 1H) , 3.41 (d, J = 7.7 Hz, 2H) , 3.36 -3.25 (m, 4H) , 2.91 (s, 4H) , 2.78 -2.67 (m, 2H) , 2.55 (d, J = 8.0 Hz, 2H) , 2.01 (qd, J = 7.7, 6.6, 2.3 Hz, 7H) , 1.81 (d, J = 13.4 Hz, 3H) , 1.30 -1.25 (m, 3H) . Mass (m/z) : 488.60 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (115)
The title compound 115 (1.8mg) was prepared in a yield of 1.9%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.88 -7.84 (m, 1H) , 7.80 (d, J = 7.8 Hz, 1H) , 7.69 -7.52 (m, 6H) , 7.19 (d, J = 8.1 Hz, 2H) , 6.53 (d, J = 8.3 Hz, 2H) , 3.63 -3.50 (m, 2H) , 3.42 (q, J = 7.1 Hz, 2H) , 3.29 (d, J = 6.2 Hz, 4H) , 2.90 (s, 4H) , 2.18 (s, 2H) , 2.05 -1.97 (m, 4H) , 1.82 (d, J = 13.3 Hz, 2H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 534.62 [M+H]
+.
Preparation of 1-ethyl-3- (2′-fluoro- [1, 1′-biphenyl] -4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (116)
The title compound 116 (9mg) was prepared in a yield of 13.8%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.68 -7.60 (m, 2H) , 7.55 -7.49 (m, 2H) , 7.44 (qd, J = 5.7, 3.0 Hz, 1H) , 7.32 (ddt, J = 9.7, 4.9, 2.4 Hz, 1H) , 7.25 -7.13 (m, 4H) , 6.58 -6.49 (m, 2H) , 3.55 (s, 2H) , 3.42 (q, J = 7.2 Hz, 2H) , 3.35 -3.26 (m, 4H) , 3.04 -2.72 (m, 4H) , 2.15 (s, 2H) , 2.00 (dq, J = 6.7, 4.1, 3.2 Hz, 4H) , 1.82 (d, J = 13.4 Hz, 2H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 527.24 [M+H]
+.
Preparation of 3- (3-chloro-2′-methoxy- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (117)
The title compound 117 (18mg) was prepared in a yield of 19.9%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.61 (s, 1H) , 7.49-7.38 (m, 1H) , 7.34 -7.18 (m, 3H) , 7.15-7.05 (m, 2H) , 7.02 -6.86 (m, 2H) , 6.53 -6.41 (m, 2H) , 3.73 (s, 3H) , 3.58 -3.44 (m, 2H) , 3.43 -3.30 (m, 2H) , 3.28 -3.10 (m, 4H) , 2.83 (s, 4H) , 2.13 (s, 2H) , 2.01 -1.88 (m, 4H) , 1.86-1.72 (m, 2H) , 1.27-1.21 (m, 3H) . Mass (m/z) : 573.62 [M+H]
+.
Preparation of 3- (3- (2-chlorophenyl) cyclopentyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (118)
The title compound 118 (16mg) was prepared in a yield of 19.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.43 -7.30 (m, 4H) , 7.26 -7.18 (m, 1H) , 7.17 -7.10 (m, 1H) , 6.54 (d, J = 8.1 Hz, 2H) , 4.69 -4.55 (m, 1H) , 4.05 -3.90 (m, 2H) , 3.55 -3.20 (m, 12H) , 2.51-2.38 (m, 1H) , 2.32-2.14 (m, 2H) , 2.13 -1.92 (m, 6H) , 1.80 -1.66 (m, 4H) , 1.26 -1.22 (m, 3H) . Mass (m/z) : 535.48 [M+H]
+.
Preparation of 3- (3-chloro-2′-fluoro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (119)
The title compound 119 (19mg) was prepared in a yield of 21.5%for three steps as white solid from 3-chloro-2′-fluoro- [1, 1′-biphenyl] -4-amine (50mg, 0.16mmol) and 97-05 (38mg, 0.17mmol) according to the procedure for compound 97.
1H NMR (400 MHz, CDCl
3) δ 7.70 (s, 1H) , 7.55 (d, J = 8.2 Hz, 1H) , 7.46-7.29 (m, 4H) , 7.25-7.12 (m, 3H) , 6.53 (d, J = 8.0 Hz, 2H) , 4.07-3.93 (m, 2H) , 3.62-3.46 (m, 2H) , 3.37 (s, 4H) , 3.27 (s, 4H) , 3.08-2.91 (m, 2H) , 2.06 -1.90 (m, 6H) , 1.31 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 561.48, [M+H]
+.
Preparation of 1-ethyl-3- (5-phenylthiophen-2-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (120)
The title compound 120 was prepared in a yield of 18.5%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.62 -7.55 (m, 2H) , 7.48 (d, J = 4.1 Hz, 1H) , 7.44-7.33 (m, 2H) , 7.32 -7.26 (m, 3H) , 7.21-7.15 (m, 1H) , 6.60-6.52 (m, 2H) , 4.14 (s, 2H) , 3.53 (s, 6H) , 3.35-3.24 (m, 4H) , 3.22-3.07 (m, 2H) , 2.10-1.96 (m, 4H) , 1.94-1.84 (m, 2H) , 1.35-1.27 (m, 3H) . Mass (m/z) : 515.78 [M+H]
+.
Preparation of 1-ethyl-3- (1-phenylpiperidin-4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (121)
The title compound 121 was prepared in a yield of 47%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.26 -7.22 (m, 2H) , 7.21 -7.15 (m, 2H) , 6.98 -6.91 (m, 2H) , 6.83 (t, J = 7.3 Hz, 1H) , 6.53 (td, J = 6.1, 2.6 Hz, 2H) , 4.04 (ddt, J = 12.2, 8.2, 3.7 Hz, 1H) , 3.84 -3.73 (m, 2H) , 3.52 (s, 2H) , 3.37 -3.23 (m, 6H) , 2.88 -2.69 (m, 6H) , 2.58 (qd, J = 12.4, 4.1 Hz, 2H) , 2.00 (td, J = 6.6, 5.5, 3.1 Hz, 6H) , 1.75 -1.60 (m, 4H) , 1.21 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 516.43 [M+H]
+.
Preparation of 1-ethyl-3- (4′-methyl- [1, 1′-biphenyl] -4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (122)
The title compound 122 (2.4mg) was prepared in a yield of 3.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.71 -7.62 (m, 2H) , 7.53 -7.38 (m, 6H) , 7.25 (d, J = 6.1 Hz, 2H) , 6.61 -6.51 (m, 2H) , 4.11 (s, 2H) , 3.67 -3.45 (m, 6H) , 3.35 -3.22 (m, 6H) , 2.40 (s, 3H) , 2.05 -1.92 (m, 6H) , 1.32 (t, J = 6.2 Hz, 3H) . Mass (m/z) : 523.64 [M+H]
+.
Preparation of 3- (3-chloro-2′-methyl- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (123)
The title compound 123 (6 mg) was prepared in a yield of 8.1%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.48 (d, J = 1.8 Hz, 1H) , 7.37 -7.28 (m, 5H) , 7.23 -7.17 (m, 3H) , 6.58 -6.51 (m, 2H) , 3.59 (s, 2H) , 3.47 -3.38 (m, 2H) , 3.34 -3.26 (m, 4H) , 2.93 (s, 4H) , 2.28 (s, 3H) , 2.23 (s, 2H) , 2.00 (q, J = 4.0, 3.5 Hz, 4H) , 1.91 (d, J = 14.6 Hz, 2H) , 1.31 (d, J = 7.1 Hz, 3H) . Mass (m/z) : 557.81 [M+H]
+.
Preparation of 3- (2′, 3-dichloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (124)
The title compound 124 (5.6 mg) was prepared in a yield of 7.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.68 -7.32 (m, 7H) , 7.20 (s, 2H) , 6.53 (d, J = 8.4 Hz, 2H) , 3.59 (s, 2H) , 3.51 -3.36 (m, 2H) , 3.34 -3.21 (m, 4H) , 2.93 (s, 4H) , 2.24 (s, 2H) , 2.05 -1.96 (m, 4H) , 1.94 -1.85 (m, 2H) , 1.37 -1.26 (m, 3H) . Mass (m/z) : 577.40 [M+H]
+.
Preparation of 1-ethyl-3- (4- (pyrimidin-2-yl) phenyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (125)
The title compound 125 (1.0 mg) was prepared in a yield of 1.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 8.82 (d, J = 4.9 Hz, 2H) , 8.58 -8.52 (m, 2H) , 7.58 (d, J = 8.6 Hz, 2H) , 7.24 -7.17 (m, 3H) , 6.54 (d, J = 8.6 Hz, 2H) , 3.80 (s, 2H) , 3.55 -3.43 (m, 2H) , 3.29 (d, J = 6.1 Hz, 4H) , 3.22 -2.80 (m, 4H) 2.21 -1.72 (m, 8H) , 1.30 (t, 3H) . Mass (m/z) : 511.39 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (126)
The title compound 126 (16mg) was prepared in a yield of 17.9%for three steps as white solid from 4′-amino-3′-chloro- [1, 1′-biphenyl] -3-carbonitrile (50mg, 0.16mmol) and 97-05 (43mg, 0.19mmol) according to the procedure for compound 97.
1H NMR (400 MHz, CDCl
3) δ 7.88-7.81 (m, 1H) , 7.81-7.74 (m, 1H) , 7.73 -7.65 (m, 2H) , 7.63 -7.50 (m, 2H) , 7.43 (d, J = 8.1 Hz, 1H) , 7.18 (d, J = 8.6 Hz, 2H) , 6.53 (d, J = 8.6 Hz, 2H) , 3.55 (s, 2H) , 3.50-3.36 (m, 2H) , 3.34-3.20 (m, 4H) , 2.97-2.76 (m, 4H) , 2.29 -2.12 (m, 2H) , 2.10 -1.95 (m, 4H) , 1.88 (t, J = 13.4 Hz, 2H) , 1.30 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 568.58, [M+H]
+.
Preparation of 1-ethyl-3- (3- (4-methoxyphenyl) cyclopentyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (127)
The title compound 127 (17 mg) was prepared in a yield of 20.3%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.35 -7.25 (m, 2H) , 7.25 -7.20 (m, 1H) , 7.19 -7.13 (m, 1H) , 6.88-6.81 (m, 2H) , 6.59 -6.49 (m, 2H) , 4.71-4.61 (m, 1H) , 4.61-4.51 (m, 1H) , 3.78 (s, 5H) , 3.60-3.45 (m, 1H) , 3.35 (q, J = 7.2 Hz, 2H) , 3.31 -3.23 (m, 4H) , 3.12 (s, 4H) , 3.04 -2.96 (m, 1H) , 2.65-2.40 (m, 2H) , 2.36 -2.12 (m, 2H) , 2.11 -1.96 (m, 6H) , 1.74 -1.64 (m, 2H) , 1.26 -1.23 (m, 3H) . Mass (m/z) : 531.70 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -4-carbonitrile (128)
The title compound 128 (2.5 mg) was prepared in a yield of 3.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.75 -7.65 (m, 6H) , 7.57 -7.52 (m, 2H) , 7.34 (d, J = 8.0 Hz, 2H) , 6.59 -6.52 (m, 2H) , 4.06 (s, 2H) , 3.53 (d, J = 8.3 Hz, 2H) , 3.47 -3.37 (m, 4H) , 3.33 -3.26 (m, 4H) , 2.07 -1.87 (m, 8H) , 1.34 -1.30 (m, 3H) . Mass (m/z) : 535.05 [M+H]
+.
Preparation of 1-ethyl-3- (4′-methoxy- [1, 1′-biphenyl] -4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (129)
The title compound 129 (16mg) was prepared in a yield of 30.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.67 -7.59 (m, 2H) , 7.52 (td, J = 6.4, 5.8, 2.4 Hz, 2H) , 7.47 -7.34 (m, 4H) , 6.98 (dd, J = 8.9, 2.2 Hz, 2H) , 6.53 (d, J = 8.0 Hz, 2H) , 4.23 -4.10 (m, 2H) , 3.84 (d, J = 1.9 Hz, 3H) , 3.53 (d, J = 13.2 Hz, 6H) , 3.34 -3.22 (m, 4H) , 3.09 (s, 2H) , 2.09 -1.98 (m, 4H) , 1.96 -1.88 (m, 2H) , 1.32 (d, J = 7.2 Hz, 3H) . Mass (m/z) : 539.55 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-carbonitrile (130)
The title compound 130 (10 mg) was prepared in a yield of 11.9%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.83 -7.75 (m, 1H) , 7.71 -7.62 (m, 3H) , 7.61-7.54 (m, 2H) , 7.54 -7.42 (m, 2H) , 7.39-7.29 (m, 2H) , 6.54 (d, J = 7.7 Hz, 2H) , 3.94 (s, 2H) , 3.60-3.43 (m, 2H) , 3.41 -3.16 (m, 8H) , 3.06-2.72 (m, 2H) , 2.03 -1.97 (m, 6H) , 1.89 (d, J = 13.8 Hz, 2H) , 1.31 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 534.26 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3′-fluoro- [1, 1′-biphenyl] -3-carbonitrile (131)
The title compound 131 (10 mg) was prepared in a yield of 11.5%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.89 -7.79 (m, 1H) , 7.79-7.73 (m, 1H) , 7.72-7.64 (m, 1H) , 7.64-7.52 (m, 1H) , 7.51 -7.35 (m, 3H) , 7.35 -7.27 (m, 2H) , 6.62 -6.48 (m, 2H) , 3.86 (s, 2H) , 3.59 -3.41 (m, 2H) , 3.38 -3.05 (m, 6H) , 2.99 -2.61 (m, 2H) , 2.10 -1.96 (m, 6H) , 1.94-1.84 (m, 2H) , 1.38 -1.27 (m, 3H) . Mass (m/z) : 552.62 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3′, 5′-difluoro- [1, 1′-biphenyl] -3-carbonitrile (132)
The title compound 132 (19 mg) was prepared in a yield of 21.2%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.86 -7.80 (m, 1H) , 7.80 -7.73 (m, 1H) , 7.74-7.70 (m, 1H) , 7.64-7.57 (m, 1H) , 7.34 (d, J = 7.7 Hz, 2H) , 7.25 -7.20 (m, 2H) , 6.54 (d, J = 8.6 Hz, 2H) , 4.07-3.87 (m, 2H) , 3.63-3.49 (m, 2H) , 3.45-3.31 (m, 2H) , 3.31-3.23 (m, 6H) , 3.14 -2.78 (m, 2H) , 2.03-1.98 (m, 4H) , 1.94 (d, J = 13.9 Hz, 2H) , 1.32 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 570.52 [M+H]
+.
Preparation of 3- (2, 3-dichloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (133)
The title compound 133 (2 mg) was prepared in a yield of 3.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.60 -7.21 (m, 9H) , 6.69 -6.45 (m, 2H) , 4.03 (s, 2H) , 3.69 -3.39 (m, 4H) , 3.37 -3.22 (m, 4H) , 3.37 -3.22 (m, 4H) , 2.24 -1.86 (m, 6H) , 1.49 -1.32 (m, 3H) . Mass (m/z) : 595.23 [M+H]
+.
Preparation of 3- (3-chloro-3′-cyclopropyl- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (134)
The title compound 134 (3.8 mg) was prepared in a yield of 4.5%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.70 (d, J = 2.0 Hz, 1H) , 7.55 (dd, J = 8.2, 2.0 Hz, 1H) , 7.47 -7.28 (m, 5H) , 7.25 (d, J = 1.9 Hz, 1H) , 7.09 (dt, J = 6.9, 1.9 Hz, 1H) , 6.59 -6.49 (m, 2H) , 3.60-3.40 (m, 4H) , 3.34-3.14 (m, 6H) , 2.15 -1.80 (m, 7H) , 1.33 (t, J = 7.1 Hz, 3H) , 1.30 -1.18 (m, 4H) , 1.07 -0.98 (m, 2H) , 0.78 -0.68 (m, 2H) . Mass (m/z) : 583.20 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carboxamide (135)
Step1: To a solution of compound 97-05 (1g) in super dry dichloromethane (10 mL) , compound 135-01 (150 mg, 1.1 equivs) and Titanium (IV) isopropoxide (one drops) was added at room temperature. The mixture was stirred for further 30 minutes at the same temperature. Sodium triacetoxyborohydride (1g, 1.5 equivs) was added at 0℃ with ice-water bath. The resulting mixture was stirred for 2 hours. The reaction was quenched with sat. NH
4Cl (aq) (20 mL) and the water phase was extracted with dichloromethane (20 mL × 3) , washed with water (20 mL × 2) and brine (10 mL × 2) , dried over Na
2SO
4, the solvent was evaporated and the resulting solid was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1: 2) to give compound 135-02 (600mg, 56%) .
Step2: The tittle compound 135 (48.2mg) was prepared in a yield of 50%as white solid from 135-02 (60mg, 0.17mmol) and compound 135-03 (40.5mg, 0.19mmol) according to the procedure for compound 97-08.
1H NMR (400 MHz, CDCl
3) δ 8.14 -8.04 (m, 1H) , 7.80 (d, J = 7.8 Hz, 1H) , 7.73 -7.59 (m, 3H) , 7.52 -7.37 (m, 3H) , 7.29 (d, J = 8.4 Hz, 2H) , 6.94 (s, 1H) , 6.47 (d, J = 8.0 Hz, 2H) , 6.32 (s, 1H) , 3.92 (s, 2H) , 3.45 -3.39 (m, 2H) , 3.39 -3.18 (m, 8H) , 2.90 (s, 2H) , 1.95 (qd, J = 6.5, 4.2, 2.9 Hz, 4H) , 1.84 (d, J = 13.8 Hz, 2H) , 1.23 (t, J = 6.9 Hz, 3H) . Mass (m/z) : 552.59 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3′-methyl- [1, 1′-biphenyl] -3-carbonitrile (136)
The title compound 136 (24 mg) was prepared in a yield of 27.8%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.83-7.78 (m, 1H) , 7.78-7.72 (m, 1H) , 7.65-7.58 (m, 1H) , 7.56-7.48 (m, 1H) , 7.48 -7.40 (m, 2H) , 7.30-7.19 (m, 3H) , 6.55-6.47 (m, 2H) , 3.83 (s, 2H) , 3.54-3.38 (m, 2H) , 3.32 -3.09 (m, 8H) , 2.89-2.57 (m, 2H) , 2.26-2.17 (m, 3H) , 2.01-1.94 (m, 4H) , 1.93 -1.76 (m, 2H) , 1.31-1.25 (m, 3H) . Mass (m/z) : 548.74 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3′-methoxy- [1, 1′-biphenyl] -3-carbonitrile (137)
The title compound 137 (23 mg) was prepared in a yield of 25.9%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.88 -7.81 (m, 1H) , 7.78 (d, J = 7.4 Hz, 1H) , 7.70 -7.63 (m, 1H) , 7.59-7.52 (m, 1H) , 7.33 -7.27 (m, 2H) , 7.22 -7.16 (m, 1H) , 7.10 (s, 1H) , 6.52 (d, J = 8.0 Hz, 2H) , 3.87 (s, 3H) , 3.85 -3.78 (m, 2H) , 3.57-3.37 (m, 2H) , 3.23-3.34 (m, 4H) , 3.22-3.11 (m, 4H) , 2.85-2.50 (m, 2H) , 2.03 -1.96 (m, 4H) , 1.89 (t, J = 11.6 Hz, 2H) , 1.29 (t, J = 6.5 Hz, 3H) . Mass (m/z) : 564.62 [M+H]
+.
Preparation of 3- (3-chloro-2′- (trifluoromethyl) - [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (138)
The title compound 138 (21 mg) was prepared in a yield of 21.8%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.74 (d, J = 7.3 Hz, 1H) , 7.56 (t, J = 7.1 Hz, 1H) , 7.50 (d, J = 7.9 Hz, 1H) , 7.47 (s, 1H) , 7.34 -7.26 (m, 5H) , 6.51 (d, J = 8.3 Hz, 2H) , 3.93 (s, 2H) , 3.56 -3.42 (m, 2H) , 3.39 -3.19 (m, 8H) , 3.06 -2.78 (m, 2H) , 2.00 -1.95 (m, 4H) , 1.95-1.88 (m, 2H) , 1.30 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 611.57 [M+H]
+.
Preparation of 3- (3-chloro-2′-ethoxy- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (139)
The title compound 139 (24mg) was prepared in a yield of 28.2%for three steps as white solid from 3-chloro-2′-ethoxy- [1, 1′-biphenyl] -4-amine (50mg, 0.14mmol) and 97-05 (39mg, 0.16mmol) according to the procedure for compound 97.
1H NMR (400 MHz, CDCl
3) δ 7.75-7.71 (m, 1H) , 7.55 (dd, J = 8.1, 1.9 Hz, 1H) , 7.36 -7.28 (m, 3H) , 7.27-7.21 (m, 2H) , 7.05 -6.94 (m, 2H) , 6.52 (d, J = 8.6 Hz, 2H) , 4.04 (q, J = 7.0 Hz, 2H) , 3.74 (s, 2H) , 3.55 -3.38 (m, J = 7.1 Hz, 2H) , 3.34 -3.21 (m, 4H) , 3.17-3.00 (m, 4H) , 2.67-2.41 (m, 2H) , 2.03-1.96 (m, 4H) , 1.96 -1.84 (m, 2H) , 1.37 (t, J = 7.0 Hz, 3H) , 1.34-1.26 (m, 3H) . Mass (m/z) : 587.59, [M+H]
+.
Preparation of 3- (3-chloro-2′-isopropoxy- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (140)
The title compound 140 (15 mg) was prepared in a yield of 15.8%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.76-7.70 (m, 1H) , 7.58-7.52 (m, 1H) , 7.38 -7.27 (m, 5H) , 7.04 -6.95 (m, 2H) , 6.53 (d, J = 8.7 Hz, 2H) , 4.61-4.46 (m, 1H) , 3.93 (s, 2H) , 3.60 -3.41 (m, 2H) , 3.40 -3.18 (m, 8H) , 3.05-2.72 (m, 2H) , 2.03 -1.89 (m, 6H) , 1.31 (t, J = 7.1 Hz, 2H) , 1.29-1.24 (m, 6H) . Mass (m/z) : 601.64 [M+H]
+.
Preparation of methyl 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -4-carboxylate (141)
The title compound 141 (43 mg) was prepared in a yield of 49.4%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.12-7.99 (m, 2H) , 7.67 (s, 1H) , 7.60-7.47 (m, 3H) , 7.40-7.27 (m, 1H) , 7.26-7.15 (m, 2H) , 6.53 -6.40 (m, 2H) , 3.86 (s, 3H) , 3.78 (s, 2H) , 3.50 -3.33 (m, 2H) , 3.28 -3.04 (m, 8H) , 2.83-2.58 (m, 2H) , 2.00 -1.79 (m, 6H) , 1.31-1.20 (m, 3H) . Mass (m/z) : 601.60 [M+H]
+.
Preparation of 3- (3-chloro-3′- (methylsulfonyl) - [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (142)
The title compound 142 (15 mg) was prepared in a yield of 15.3%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 8.14-8.10 (m, 1H) , 8.01-7.93 (m, 1H) , 7.86-7.80 (m, 1H) , 7.78-7.73 (m, 1H) , 7.67 (t, J = 7.8 Hz, 1H) , 7.62-7.56 (m, 1H) , 7.42 (d, J = 8.1 Hz, 1H) , 7.30-7.27 (m, 2H) , 6.52 (d, J = 8.8 Hz, 2H) , 3.80 (s, 2H) , 3.56-3.40 (m, 2H) , 3.33 -3.22 (m, 4H) , 3.21-3.01 (m, 7H) , 2.80-2.47 (m, 2H) , 2.03 -1.95 (m, 4H) , 1.96-1.87 (m, 2H) , 1.30 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 621.55 [M+H]
+.
Preparation of 3- (2, 5-dichloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (143)
The title compound 143 (38mg) was prepared in a yield of 36.2%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.49 (d, J = 0.3 Hz, 1H) , 7.46 -7.41 (m, 4H) , 7.41 -7.38 (m, 3H) , 7.37 (d, J = 1.6 Hz, 1H) , 6.53 (d, J = 8.6 Hz, 2H) , 4.10 (s, 2H) , 3.59 -3.43 (m, 6H) , 3.36 -3.10 (m, 6H) , 2.01 -1.92 (m, 6H) , 1.32 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 577.58 [M+H]
+.
Preparation of 4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2′-methoxy- [1, 1′-biphenyl] -3-carbonitrile (144)
The title compound 144 (5 mg) was prepared in a yield of 6.8%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.85 -7.80 (m, 1H) , 7.76 -7.70 (m, 1H) , 7.66 -7.60 (m, 1H) , 7.52 (tt, J = 8.3, 7.7, 2.5 Hz, 1H) , 7.41 (d, J = 8.0 Hz, 2H) , 7.35 (d, J = 8.1 Hz, 1H) , 7.13 -7.07 (m, 1H) , 7.04 (d, J = 1.9 Hz, 1H) , 6.60 -6.53 (m, 2H) , 4.15 (s, 2H) , 3.84 (d, J = 1.4 Hz, 3H) , 3.56 (d, J = 16.4 Hz, 6H) , 3.26 (d, J = 20.0 Hz, 6H) , 2.09 -1.91 (m, 6H) , 1.33 (t, 3H) . Mass (m/z) : 564.51 [M+H]
+.
Preparation of 3- (5-chloro-6- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-3-yl) benzonitrile (145)
The title compound 145 (8 mg) was prepared in a yield of 8.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.69 (d, J = 2.1 Hz, 1H) , 8.01 (t, J = 1.9 Hz, 1H) , 7.87 -7.81 (m, 1H) , 7.76 (ddt, J = 16.8, 7.8, 1.3 Hz, 2H) , 7.62 (t, J = 7.8 Hz, 1H) , 7.21 -7.13 (m, 2H) , 6.57 -6.48 (m, 2H) , 3.51 (s, 2H) , 3.49 -3.34 (m, 2H) , 3.30 -3.23 (m, 4H) , 2.83 (d, J = 30.9 Hz, 4H) , 2.24 -2.07 (m, 2H) , 1.97 (td, J = 6.6, 5.7, 3.1 Hz, 4H) , 1.94 -1.83 (m, 2H) , 1.29 (d, J = 7.0 Hz, 3H) . Mass (m/z) : 569.51 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) benzonitrile (146)
The title compound 146 (6 mg) was prepared in a yield of 6.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.37 -8.30 (m, 1H) , 8.27 -8.22 (m, 1H) , 7.78 (d, J = 3.1 Hz, 2H) , 7.77 -7.72 (m, 1H) , 7.61 (t, J = 7.8 Hz, 1H) , 7.23 -7.16 (m, 2H) , 6.59 -6.49 (m, 2H) , 3.67 -3.56 (m, 2H) , 3.45 (dq, J = 13.9, 7.1 Hz, 2H) , 3.28 (dd, J = 7.9, 5.2 Hz, 4H) , 2.90 (d, J = 41.6 Hz, 4H) , 2.22 (s, 2H) , 2.05 -1.98 (m, 4H) , 1.97 -1.84 (m, 2H) , 1.31 (d, J = 6.9 Hz, 3H) . Mass (m/z) : 569.69 [M+H]
+.
Preparation of 1-ethyl-3- (3- (2-methoxyphenyl) cyclopentyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (147)
The title compound 147 was prepared in a yield of 34.7%as a yellow powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.26 -7.09 (m, 4H) , 7.00 -6.80 (m, 2H) , 6.62 -6.48 (m, 2H) , 4.78 -4.50 (m, 1H) , 3.82 (s, 3H) , 3.62-3.45 (m 2H) , 3.36-3.20 (m, 6H) , 2.92-2.68 (m, 4H) , 2.46-2.34 (m, 1H) , 2.31 -2.12 (m, 3H) , 2.10 -1.94 (m, 9H) , 1.70-1.58 (m, 2H) , 1.23-1.89 (m, 3H) . Mass (m/z) : 531.63 [M+H]
+.
Preparation of 1-ethyl-3- (3- (3-methoxyphenyl) cyclopentyl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (148)
The title compound 148 was prepared in a yield of 26.04%as a white powder according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.19 (td, J = 8.4, 2.8 Hz, 3H) , 7.00 -6.72 (m, 3H) , 6.59 -6.50 (m, 2H) , 4.76 -4.53 (m, 1H) , 3.82 (dq, J = 7.6, 3.7, 3.2 Hz, 3H) , 3.52 (s, 2H) , 3.29 (qd, J = 6.9, 2.2 Hz, 6H) , 2.79 (d, J = 17.0 Hz, 4H) , 2.42 -1.92 (m, 13H) , 1.64 (dt, J = 13.0, 3.1 Hz, 2H) , 1.22 (td, J = 7.1, 1.7 Hz, 3H) . Mass (m/z) : 531.59 [M+H]
+.
Preparation of 3- (3-chloro-3′-ethynyl- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (149)
The title compound 149 (11.2mg) was prepared in a yield of 15.0%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.70 (dd, J = 8.1, 1.9 Hz, 2H) , 7.53 (tdd, J = 7.8, 4.4, 1.8 Hz, 3H) , 7.48 -7.36 (m, 2H) , 7.25 -7.16 (m, 2H) , 6.61 -6.50 (m, 2H) , 3.58 (s, 2H) , 3.43 (tt, J = 14.2, 7.3 Hz, 2H) , 3.29 (d, J = 7.0 Hz, 4H) , 3.13 (s, 1H) , 2.92 (s, 4H) , 2.20 (s, 2H) , 2.00 (td, J = 6.4, 5.8, 3.3 Hz, 4H) , 1.89 (t, J = 14.4 Hz, 2H) , 1.34 -1.27 (m, 3H) . Mass (m/z) : 567.43 [M+H]
+.
Preparation of 3- (2-chloro-4- (1-methyl-6-oxo-1, 6-dihydropyridin-2-yl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (150)
The title compound 150 (1.7 mg) was prepared in a yield of 1.8%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.52 (d, J = 1.9 Hz, 1H) , 7.47 -7.42 (m, 1H) , 7.40 -7.32 (m, 2H) , 7.21 -7.15 (m, 2H) , 6.63 (dd, J = 9.2, 1.5 Hz, 1H) , 6.53 (dd, J = 8.9, 2.2 Hz, 2H) , 6.10 (dt, J = 6.8, 1.4 Hz, 1H) , 3.53 (s, 2H) , 3.48 -3.41 (m, 2H) , 3.39 (d, J = 3.4 Hz, 3H) , 3.33 -3.24 (m, 4H) , 2.85 (d, J = 37.0 Hz, 4H) , 2.17 (s, 2H) , 2.04 -1.97 (m, 4H) , 1.87 (t, J = 12.7 Hz, 2H) , 1.29 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 574.52 [M+H]
+.
Preparation of 3- (3′-acetyl-3-chloro- [1, 1′-biphenyl] -4-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (151)
The title compound 151 (15 mg) was prepared in a yield of 17.7%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.18 -8.11 (m, 1H) , 8.03 -7.94 (m, 1H) , 7.81 -7.71 (m, 2H) , 7.63 -7.53 (m, 2H) , 7.39 (d, J = 8.0 Hz, 1H) , 7.33 -7.26 (m, 2H) , 6.52 (d, J = 8.1 Hz, 2H) , 3.84 (s, 2H) , 3.58-3.40 (m, 2H) , 3.36 -3.07 (m, 8H) , 2.73-2.62 (m, 5H) , 2.09 -1.87 (m, 6H) , 1.31 (t, J = 6.7 Hz, 3H) . Mass (m/z) : 585.54 [M+H]
+.
Preparation of N- (3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-yl) acetamide (152)
The title compound 152 (18 mg) was prepared in a yield of 20.7%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.13 (d, J = 8.0 Hz, 1H) , 7.54 (s, 1H) , 7.45-7.36 (m, 3H) , 7.31-7.27 (m, 1H) , 7.22 (s, 1H) , 7.06 (s, 1H) , 6.53 (d, J = 8.5 Hz, 1H) , 3.81 (s, 2H) , 3.58-3.40 (m, 2H) , 3.35-3.23 (m, 4H) , 3.18 (s, 4H) , 2.81 -2.51 (m, 2H) , 2.07 (s, 3H) , 2.06 -1.96 (m, 4H) , 1.96 -1.86 (m, 2H) , 1.31 (t, J = 6.1 Hz, 3H) . Mass (m/z) : 600.27 [M+H]
+.
Preparation of 5- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) nicotinonitrile (153)
The title compound 153 (18 mg) was prepared in a yield of 43.7%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.99 (d, J = 2.3 Hz, 1H) , 8.91 (d, J = 2.0 Hz, 1H) , 8.14-8.08 (m, 1H) , 7.71 (d, J = 2.0 Hz, 1H) , 7.59-7.54 (m, 1H) , 7.50-7.44 (m, 1H) , 7.37-7.28 (m, 2H) , 6.53 (d, J = 8.7 Hz, 2H) , 3.90 (s, 2H) , 3.60-3.41 (m, 2H) , 3.37 -3.14 (m, 8H) , 2.98 -2.67 (m, 2H) , 2.03-1.97 (m, 4H) , 1.94 (d, J = 13.2 Hz, 2H) , 1.31 (t, J = 6.9 Hz, 3H) . Mass (m/z) : 569.55 [M+H]
+.
Preparation of 3- (4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) piperidin-1-yl) benzonitrile (154)
The title compound 154 (7 mg) was prepared in a yield of 8.9%as a white powder from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.37 (d, J = 8.1 Hz, 2H) , 7.32 -7.24 (m, 1H) , 7.14 -7.03 (m, 3H) , 6.52 (d, J = 7.8 Hz, 2H) , 4.10 (s, 2H) , 4.05 -3.98 (m, 1H) , 3.77 (d, J = 12.6 Hz, 2H) , 3.53-3.36 (m, 6H) , 3.33-3.19 (m, 4H) , 3.15 -2.98 (m, 2H) , 2.82 (t, J = 12.6 Hz, 2H) , 2.58 -2.35 (m, 2H) , 2.03 -1.94 (m, 4H) , 1.71 (d, J = 13.1 Hz, 4H) , 1.23 (t, J = 3.0 Hz, 3H) . Mass (m/z) : 541.64 [M+H]
+.
Preparation of 3- (1- (2-chlorophenyl) pyrrolidin-3-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (155)
The title compound 155 (7 mg) was prepared in a yield of 9.0%as a white powder from compound 155-02 according to the procedure for compound 155.
1H NMR (400 MHz, CDCl
3) δ 7.34-7.27 (m, 1H) , 7.23-7.09 (m, 3H) , 7.05-6.93 (m, 1H) , 6.90-6.80 (m, 1H) , 6.61-6.45 (m, 2H) , 4.89-4.70 (m, 1H) , 3.77-3.60 (m, 2H) , 3.59-3.47 (m, 2H) , 3.47-3.36 (m, 1H) , 3.27 (s, 6H) , 2.96-2.66 (m, 4H) , 2.53-2.39 (m, 1H) , 2.31-2.22 (m, 1H) , 2.02-1.92 (m, 6H) , 1.71-1.61 (m, 2H) , 1.22-1.17 (m, 3H) . Mass (m/z) : 536.49 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2-methoxy- [1, 1′-biphenyl] -3-carbonitrile (156)
The title compound 156 (13.4 mg) was prepared in a yield of 15.0%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.75 -7.67 (m, 1H) , 7.67 -7.59 (m, 1H) , 7.55 (dtd, J = 9.6, 5.5, 4.9, 2.6 Hz, 2H) , 7.40 (dd, J = 8.0, 4.1 Hz, 1H) , 7.27 (d, J = 3.4 Hz, 1H) , 7.18 (dq, J = 8.5, 4.0 Hz, 2H) , 6.53 (dq, J = 8.8, 4.5, 4.0 Hz, 2H) , 3.75 (h, J = 4.3, 3.5 Hz, 3H) , 3.58 (s, 2H) , 3.44 (ddq, J = 14.1, 7.3, 4.1 Hz, 2H) , 3.28 (tt, J = 7.3, 3.7 Hz, 4H) , 3.05 -2.75 (m, 4H) , 2.21 (s, 2H) , 2.00 (tt, J = 7.0, 3.8 Hz, 4H) , 1.91 (d, J = 14.8 Hz, 2H) , 1.30 (t, 3H) . Mass (m/z) : 598.50 [M+H]
+.
Preparation of 3′-chloro-6-ethoxy-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (157)
The title compound 157 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.69-7.66 (m, 1H) , 7.63 (dd, J = 8.6, 2.2 Hz, 1H) , 7.57-7.54 (m, 1H) , 7.49 (dd, J = 8.2, 1.9 Hz, 1H) , 7.40-7.30 (m, 3H) , 7.03-6.99 (m, 1H) , 6.58-6.50 (m, 2H) , 4.18-4.07 (m, 2H) , 4.00 (s, 2H) , 3.61-3.46 (m, 2H) , 3.37 (s, 4H) , 3.32-3.17 (m, 4H) , 2.97 (d, J = 17.6 Hz, 2H) , 2.06-1.91 (m, 6H) , 1.39 (t, J = 7.0 Hz, 3H) , 1.32 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 612.55 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -5-methoxy- [1, 1′-biphenyl] -3-carbonitrile (158)
The title compound 158 (25.4 mg) was prepared in a yield of 29.3%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.67 -7.64 (m, 1H) , 7.50 (dd, J = 8.2, 2.0 Hz, 1H) , 7.39 -7.35 (m, 2H) , 7.35 -7.30 (m, 2H) , 7.24 -7.23 (m, 1H) , 7.14 (dd, J = 2.5, 1.3 Hz, 1H) , 6.53 -6.49 (m, 2H) , 4.01 (d, J = 27.3 Hz, 2H) , 3.86 (s, 3H) , 3.59 -3.42 (m, 4H) , 3.35 (s, 2H) , 3.27 -3.21 (m, 4H) , 3.00 (d, J = 51.4 Hz, 2H) , 1.97 (td, J = 7.5, 7.1, 3.8 Hz, 6H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 598.54 [M+H]
+.
Preparation of 3- (2-chloro-3-methoxyphenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (159)
The title compound 159 (17 mg) was prepared in a yield of 72%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.35 -7.28 (m, 1H) , 7.20 (d, J = 8.2 Hz, 2H) , 7.01 (dd, J = 8.4, 1.3 Hz, 1H) , 6.92 (dt, J = 7.8, 1.0 Hz, 1H) , 6.55 -6.49 (m, 2H) , 3.91 (s, 3H) , 3.61 (s, 2H) , 3.42 (ddt, J = 18.3, 14.5, 7.3 Hz, 2H) , 3.32 -3.22 (m, 4H) , 3.06 -2.82 (m, 4H) , 2.33 (d, J = 18.2 Hz, 2H) , 1.99 (dd, J = 10.0, 3.3 Hz, 4H) , 1.88 (ddt, J = 22.5, 13.2, 2.6 Hz, 2H) , 1.29 (d, J = 7.1 Hz, 3H) . Mass (m/z) : 497.42 [M+H]
+.
Preparation of 3- (2-chloro-6- (2-ethoxyphenyl) pyridin-3-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (160)
The title compound 160 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.08-8.01 (m, 1H) , 7.90 (dd, J = 7.7, 1.9 Hz, 1H) , 7.70-7.62 (m, 1H) , 7.42-7.33 (m, 1H) , 7.23-7.14 (m, 2H) , 7.11-7.04 (m, 1H) , 7.01-6.95 (m, 1H) , 6.60-6.49 (m, 2H) , 4.16-4.06 (m, 2H) , 3.54 (s, 2H) , 3.50-3.35 (m, 2H) , 3.34 -3.23 (m, 4H) , 2.98-2.74 (m, 4H) , 2.24-2.10 (m, 2H) , 2.04-1.96 (m, 4H) , 1.96-1.80 (m, 2H) , 1.41 (t, J = 7.0 Hz, 3H) , 1.30 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 588.49 [M+H]
+.
Preparation of N- (3′-chloro-3-cyano-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-yl) acetamide (161)
The title compound 161 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135. Mass (m/z) : 625.62 [M+H]
+.
Preparation of N-acetyl-N- (3′-chloro-3-cyano-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-yl) acetamide (162)
The title compound 162 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.84 (dd, J = 7.1, 2.2 Hz, 1H) , 7.69-7.60 (m, 2H) , 7.46-7.35 (m, 2H) , 7.26-7.22 (m, 1H) , 7.21-7.14 (m, 2H) , 6.58-6.50 (m, 2H) , 3.55 (s, 2H) , 3.48-3.34 (m, 2H) , 3.33-3.22 (m, 4H) , 2.99-2.75 (m, 4H) , 2.29-2.11 (m, 8H) , 2.05-1.94 (m, 4H) , 1.92-1.80 (m, 2H) , 1.34-1.25 (m, 3H) . Mass (m/z) : 667.53 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -4-ethoxybenzonitrile (163)
The title compound 163 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.24 (d, J = 2.2 Hz, 1H) , 8.01 (d, J = 8.1 Hz, 1H) , 7.70 (d, J = 8.1 Hz, 1H) , 7.66 (dd, J = 8.6, 2.2 Hz, 1H) , 7.18 (d, J = 8.3 Hz, 2H) , 7.03 (d, J = 8.7 Hz, 1H) , 6.55-6.49 (m, 2H) , 3.55 (s, 2H) , 3.51-3.34 (m, 2H) , 3.31-3.22 (m, 4H) , 2.97-2.72 (m, 4H) , 2.26-2.10 (m, 2H) , 2.02-1.96 (m, 4H) , 1.93-1.78 (m, 2H) , 1.46 (t, J = 7.0 Hz, 3H) , 1.30 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 613.45 [M+H]
+.
Preparation of N- (3′-chloro-5-cyano-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-yl) acetamide (164)
The title compound 164 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.55 (d, J = 8.7 Hz, 1H) , 7.68 (dd, J = 8.7, 2.0 Hz, 1H) , 7.54 (d, J = 1.9 Hz, 1H) , 7.52-7.46 (m, 2H) , 7.40-7.35 (m, 1H) , 7.19 (d, J = 7.9 Hz, 2H) , 6.58-6.50 (m, 2H) , 3.58 (s, 2H) , 3.50-3.37 (m, 2H) , 3.35-3.23 (m, 4H) , 3.02-2.74 (m, 4H) , 2.32-2.22 (m, 2H) , 2.12 (s, 3H) , 2.04-1.96 (m, 4H) , 1.89 (t, J = 11.8 Hz, 2H) , 1.36-1.28 (m, 3H) . Mass (m/z) : 625.44 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -6-methoxy- [1, 1′-biphenyl] -3-carbonitrile (165)
The title compound 165 was prepared in a yield of 40.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.74-7.62 (m, 2H) , 7.60-7.54 (m, 1H) , 7.51-7.41 (m, 1H) , 7.40-7.34 (m, 1H) , 7.18 (d, J = 8.1 Hz, 2H) , 7.08-6.99 (m, 1H) , 6.59-6.50 (m, 2H) , 3.87 (s, 3H) , 3.55 (s, 2H) , 3.50-3.35 (m, 2H) , 3.34-3.21 (m, 4H) , 2.99-2.77 (m, 5H) , 2.34-2.23 (m, 2H) , 2.06-1.95 (m, 4H) , 1.88 (t, J = 14.2 Hz, 2H) , 1.40-1.29 (m, 3H) . Mass (m/z) : 598.47 [M+H]
+.
Preparation of 5′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2′-methoxy- [1, 1′-biphenyl] -3-carbonitrile (166)
The title compound 166 (13 mg) was prepared in a yield of 15.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.81 -7.80 (m, 1H) , 7.74 -7.63 (m, 2H) , 7.53 (t, J = 7.6 Hz, 1H) , 7.41 (m, 1H) , 7.19 (d, J = 7.6 Hz, 2H) , 6.92 (s, 1H) , 6.53 (d, J = 8.4 Hz, 2H) , 3.83 (s, 3H) , 3.58 (s, 2H) , 3.50 -3.41 (m, 2H) , 3.30 -3.26 (m, 4H) , 3.01 -2.81 (m, 4H) , 2.33 -2.24 (m, 2H) , 2.02 -1.99 (m, 4H) , 1.94 -1.85 (m, 2H) , 1.31 (d, J = 6.8 Hz, 3H) . Mass (m/z) : 598.43 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -5-fluoro- [1, 1′-biphenyl] -3-carbonitrile (167)
The title compound 167 (28 mg) was prepared in a yield of 33.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.76 -7.62 (m, 2H) , 7.54 -7.38 (m, 4H) , 7.19 (m, J = 8.0 Hz, 2H) , 6.53 (d, J = 8.0 Hz, 2H) , 3.55 (s, 2H) , 3.29 -3.27 (m, 2H) , 3.29 -3.27 (m, 4H) , 3.01 -2.74 (m, 4H) , 2.23 -2.17 (m, 2H) , 2.01 (m, 4H) , 1.88 (t, J = 12.4 Hz, 2H) , 1.32 -1.30 (m, 3H) . Mass (m/z) : 586.37 [M+H]
+.
Preparation of 2- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) isonicotinonitrile (168)
The title compound 168 (11.3 mg) was prepared in a yield of 13.7%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.87 (dd, J = 5.0, 1.1 Hz, 1H) , 8.21 (dd, J = 2.1, 0.9 Hz, 1H) , 8.02 -7.92 (m, 2H) , 7.54 -7.44 (m, 2H) , 7.19 (d, J = 8.2 Hz, 2H) , 6.58 -6.50 (m, 2H) , 3.54 (s, 2H) , 3.49 -3.38 (m, 2H) , 3.28 (td, J = 6.1, 3.1 Hz, 4H) , 2.98 -2.80 (m, 4H) , 2.35 -2.27 (m, 2H) , 2.00 (dq, J = 6.3, 3.3 Hz, 4H) , 1.94 -1.83 (m, 2H) , 1.33 -1.29 (m, 3H) . Mass (m/z) : 569.62 [M+H]
+.
Preparation of 4- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) picolinonitrile (169)
The title compound 169 (15.8 mg) was prepared in a yield of 19.2%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.76 (dd, J = 5.2, 0.8 Hz, 1H) , 7.84 (dd, J = 1.8, 0.8 Hz, 1H) , 7.73 (d, J = 2.0 Hz, 1H) , 7.65 (dd, J = 5.2, 1.8 Hz, 1H) , 7.58 (dd, J = 8.2, 2.1 Hz, 1H) , 7.49 -7.45 (d, 1H) 7.19 (d, J = 8.3 Hz, 1H) , 6.55 -6.49 (m, 2H) , 3.58 (s, 2H) , 3.43 (ddt, J = 18.7, 14.6, 7.3 Hz, 2H) , 3.30 -3.23 (m, 4H) , 3.02 -2.82 (m, 4H) , 2.32 -2.27 (m, 2H) , 2.01 -1.96 (m, 4H) , 1.88 (ddt, J = 10.8, 8.4, 2.4 Hz, 2H) , 1.28 (t, 3H) . Mass (m/z) : 569.41 [M+H]
+.
Preparation of 3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -5′-methyl- [1, 1′-biphenyl] -3-carbonitrile (170)
The title compound 170 (8.6 mg) was prepared in a yield of 10.21%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.82 (d, J = 1.8 Hz, 1H) , 7.76 (dt, J = 7.8, 1.5 Hz, 1H) , 7.67 (dt, J = 7.8, 1.4 Hz, 1H) , 7.56 (t, J = 7.8 Hz, 1H) , 7.52 (d, J = 2.0 Hz, 1H) , 7.38 (d, J = 2.0 Hz, 1H) , 7.22 (d, J = 8.1 Hz, 2H) , 6.54 (d, J = 8.6 Hz, 2H) , 3.61 (s, 2H) , 3.46 (q, J = 7.1 Hz, 2H) , 3.32 -3.25 (m, 4H) , 3.05 -2.83 (m, 4H) , 2.29 (d, J = 11.7 Hz, 5H) , 2.04 -1.98 (m, 4H) , 1.97 -1.82 (m, 2H) , 1.31 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 582.59 [M+H]
+.
Preparation of 4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3, 3′-dicarbonitrile (171)
The title compound 171 (8.2 mg) was prepared in a yield of 10.4%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.92 (d, J = 2.0 Hz, 1H) , 7.88 -7.82 (m, 2H) , 7.81 -7.76 (m, 1H) , 7.73 (dd, J = 7.7, 1.4 Hz, 1H) , 7.61 (ddd, J = 17.2, 8.1, 1.0 Hz, 2H) , 7.18 (d, J = 8.2 Hz, 2H) , 6.53 (d, J = 8.3 Hz, 2H) , 3.53 (s, 2H) , 3.44 (q, J = 7.0 Hz, 2H) , 3.32 -3.25 (m, 4H) , 2.94 -2.78 (m, 4H) , 2.34 -2.25 (m, 2H) , 2.03 -1.97 (m, 4H) , 1.93 (d, J = 13.8 Hz, 2H) , 1.33 -1.29 (m, 3H) . Mass (m/z) : 559.39 [M+H]
+.
Preparation of 3′-chloro-2-ethoxy-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (172)
The title compound 172 (55 mg) was prepared in a yield of 88.5%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.73 (d, J = 1.9 Hz, 1H) , 7.64 -7.51 (m, 3H) , 7.38 (d, J = 8.2 Hz, 1H) , 7.30 (d, J = 8.1 Hz, 2H) , 7.28 -7.23 (m, 1H) , 6.53 (d, J = 8.4 Hz, 2H) , 3.98 -3.82 (m, 4H) , 3.50 (tt, J = 11.3, 4.9 Hz, 2H) , 3.27 (d, J = 7.1 Hz, 6H) , 3.02 -2.76 (m, 2H) , 2.31 -2.18 (m, 2H) , 2.04 -1.92 (m, 6H) , 1.31 (t, J = 7.1 Hz, 3H) , 1.26 -1.22 (m, 3H) . Mass (m/z) : 612.51 [M+H]
+.
Preparation of N- (3′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -2-yl) cyclopropanecarboxamide (173)
The title compound 173 (22 mg) was prepared in a yield of 14.3%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.22 (s, 1H) , 7.58 -7.57 (m, 1H) , 7.47 -7.35 (m, 3H) , 7.29 (s, 1H) , 7.25 -7.13 (m, 4H) , 6.61 -6.49 (m, 2H) , 3.55 (s, 2H) , 3.49 -3.37 (m, 2H) , 3.35 -3.23 (m, 4H) , 2.90 (m, 2H) , 2.82 (d, J = 11.6 Hz, 2H) , 2.19 -2.17 (m, 2H) , 2.07 -1.96 (m, 4H) , 1.95 -1.83 (m, 2H) , 1.34 -1.28 (m, 4H) , 1.08 -1.03 (m, 2H) , 0.84 -0.78 (m, 2H) . Mass (m/z) : 626.52 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) piperidine-3-carbonitrile (174)
The title compound 174 (4 mg) was prepared in a yield of 4.8%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.23 -7.13 (m, 3H) , 6.99 (d, J = 2.8 Hz, 1H) , 6.85 (dd, J = 8.8, 2.8 Hz, 1H) , 6.52 (d, J = 8.4 Hz, 2H) , 3.59 -3.57 (m, 3H) , 3.52 -3.23 (m, 9H) , 3.20 -3.07 (m, 2H) , 3.10 -2.85 (m, 4H) , 2.35 -2.17 (m, 2H) , 2.11 -1.96 (m, 6H) , 1.95 -1.79 (m, 4H) , 1.77 -1.66 (m, 2H) . Mass (m/z) : 626.52 [M+H]
+.
Preparation of 6- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) picolinonitrile (175)
The title compound 175 (3.3mg) was prepared in a yield of 4.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.22 (d, J = 2.0 Hz, 1H) , 8.02 (dd, J = 8.3, 2.0 Hz, 1H) , 7.97 -7.92 (m, 2H) , 7.69 (dd, J = 6.1, 2.4 Hz, 1H) , 7.45 (d, J = 8.2 Hz, 1H) , 7.23 -7.17 (m, 2H) , 6.53 (d, J = 8.5 Hz, 2H) , 3.70 -3.53 (m, 2H) , 3.44 (dt, J = 16.4, 7.3 Hz, 2H) , 3.31 -3.23 (m, 4H) , 2.94 (s, 4H) , 2.42 -2.10 (m, 2H) , 2.03 -1.97 (m, 4H) , 1.89 (t, J = 12.8 Hz, 2H) , 1.29 (t, 3H) . Mass (m/z) : 569.44 [M+H]
+.
Preparation of 3- (2-chloro-4- (1H-pyrrol-1-yl) phenyl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (176)
The title compound 176 (2.0 mg) was prepared in a yield of 2.6%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.53 (d, J = 2.1 Hz, 1H) , 7.37 -7.33 (m, 2H) , 7.20 -7.14 (m, 2H) , 7.07 -7.03 (m, 2H) , 6.51 (d, J = 8.4 Hz, 2H) , 6.37 -6.33 (m, 2H) , 3.49 (d, J = 21.2 Hz, 2H) , 3.39 (dq, J = 14.6, 7.3 Hz, 2H) , 3.30 -3.23 (m, 4H) , 2.85 (s, 4H) , 2.22 -2.05 (m, 2H) , 2.00 -1.95 (m, 4H) , 1.85 (t, J = 13.0 Hz, 2H) , 1.29 -1.26 (m, 3H) . Mass (m/z) : 532.42 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) -1H-pyrrole-3-carbonitrile (177)
The title compound 177 (23.2 mg) was prepared in a yield of 28.7%as a yellow solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.52 (d, J = 2.4 Hz, 1H) , 7.49 (dd, J = 2.3, 1.6 Hz, 1H) , 7.41 (d, J = 8.5 Hz, 1H) , 7.35 (dd, J = 8.5, 2.4 Hz, 1H) , 7.21 (d, J = 8.1 Hz, 2H) , 7.01 (dd, J = 3.1, 2.3 Hz, 1H) , 6.60 (dd, J = 3.1, 1.6 Hz, 1H) , 6.54 -6.49 (m, 2H) , 3.64 (s, 2H) , 3.53 -3.39 (m, 2H) , 3.29 -3.23 (m, 4H) , 3.12 -2.85 (m, 4H) , 2.39 (s, 2H) , 2.03 -1.94 (m, 4H) , 1.88 (d, J = 13.4 Hz, 2H) , 1.28 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 557.41 [M+H]
+.
Preparation of 2- (4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) piperidin-1-yl) benzonitrile (178)
The title compound 178 (5.7 mg) was prepared in a yield of 6.7%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.55 (dd, J = 7.7, 1.6 Hz, 1H) , 7.46 (ddd, J = 8.9, 7.7, 1.7 Hz, 1H) , 7.29 -7.26 (m, 2H) , 7.03 -6.96 (m, 2H) , 6.57 -6.50 (m, 2H) , 4.04 (tt, J = 12.1, 4.1 Hz, 1H) , 3.95 -3.63 (m, 4H) , 3.56 -2.99 (m, 10H) , 2.98 -2.82 (m, 3H) , 2.66 (tt, J = 12.3, 7.0 Hz, 3H) , 2.02 -1.96 (m, 4H) , 1.76 -1.61 (m, 4H) , 1.21 (t, 3H) . Mass (m/z) : 541.46 [M+H]
+.
Preparation of 1-ethyl-3- (1- (2-methoxyphenyl) piperidin-4-yl) -8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione (179)
The title compound 179 (11.5 mg) was prepared in a yield of 11.5%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.22 (d, J = 8.0 Hz, 2H) , 6.99 -6.88 (m, 3H) , 6.84 (dd, J = 7.9, 1.4 Hz, 1H) , 6.56 -6.47 (m, 2H) , 4.07 -3.92 (m, 1H) , 3.84 (s, 3H) , 3.75 -3.62 (m, 2H) , 3.60 -3.53 (m, 2H) , 3.38 -3.21 (m, 6H) , 3.02 -2.89 (m, 2H) , 2.71 -2.60 (m, 4H) , 2.02 -1.96 (m, 4H) , 1.82 -1.51 (m, 8H) , 1.21 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 546.54 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) -1H-pyrrole-2-carbonitrile (180)
The title compound 180 (37 mg) was prepared in a yield of 45.9%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.25 (s, 1H) , 8.08 -8.03 (m, 2H) , 7.82 (s, 1H) , 7.55 (m, 3H) , 6.96 (d, J = 8.0 Hz, 2H) , 6.87 (s, 1H) , 3.93 (s, 2H) , 3.83 (dd, J = 7.6, 14.8 Hz, 2H) , 3.68 -3.65 (m, 4H) , 3.34 (d, J = 11.6 Hz, 2H) , 3.25 -3.17 (m, 2H) , 2.66 -2.54 (m, 2H) , 2.44 -2.29 (m, 6H) , 1.72 -1.68 (m, 3H) . Mass (m/z) : 557.31 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -4-ethoxy-5-fluorobenzonitrile (181)
The title compound 181 (12 mg) was prepared in a yield of 13.1%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.06 -7.97 (m, 2H) , 7.75 (dd, J = 8.0 Hz, 1H) , 7.45 (dd, J = 2.0, 10.8 Hz, 1H) , 7.19 (d, J = 8.0 Hz, 2H) , 6.61 -6.50 (m, 2H) , 4.34 -4.20 (m, 2H) , 3.74 -3.34 (m, 4H) , 3.36 -3.21 (m, 4H) , 2.94 -2.83 (m, 4H) , 2.35 -2.15 (m, 2H) , 2.00 (m, 4H) , 1.96 -1.82 (m, 2H) , 1.35 -1.25 (m, 6H) . Mass (m/z) : 631.31 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3-fluoropyridin-2-yl) -4-ethoxybenzonitrile (182)
The title compound 182 (26 mg) was prepared in a yield of 13.1%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.77 (d, J = 2.0 Hz, 1H) , 7.71 (dd, J = 8.4, 2.0 Hz, 1H) , 7.56 (d, J = 8.4 Hz, 1H) , 7.18 (d, J = 8.4 Hz, 2H) , 7.03 (d, J = 8.8 Hz, 1H) , 6.53 (d, J = 8.8 Hz, 2H) , 4.15 (q, J = 7.2 Hz, 2H) , 3.54 (s, 2H) , 3.49 -3.36 (m, 2H) , 3.32 -3.23 (m, 4H) , 2.91 (d, J = 11.6 Hz, 2H) , 2.78 (q, J = 12.8 Hz, 2H) , 2.22 -2.13 (m, 2H) , 2.03 -1.95 (m, 4H) , 1.93 -1.83 (m, 2H) , 1.37 (t, J = 7.2 Hz, 3H) , 1.30 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 631.31 [M+H]
+.
Preparation of 5′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -4-fluoro-2′-methoxy- [1, 1′-biphenyl] -3-carbonitrile (183)
The title compound 183 (6 mg) was prepared in a yield of 6.7%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.75 (dd, J = 6.0, 2.3 Hz, 1H) , 7.70 -7.65 (m, 1H) , 7.36 (s, 1H) , 7.25 (s, 1H) , 7.17 (d, J = 8.1 Hz, 2H) , 6.89 (s, 1H) , 6.51 (d, J = 8.5 Hz, 2H) , 3.81 (s, 3H) , 3.55 (s, 2H) , 3.48 -3.37 (m, 2H) , 3.32 -3.23 (m, 4H) , 2.89 (s, 4H) , 2.16 (s, 2H) , 2.02 -1.95 (m, 4H) , 1.87 (t, J = 11.1 Hz, 2H) , 1.28 (t, 3H) . Mass (m/z) : 616.33 [M+H]
+.
Preparation of 4- (5-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2-methoxyphenyl) picolinonitrile (184)
The title compound 184 (40.9 mg) was prepared in a yield of 22.2%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.72 (d, J = 5.1 Hz, 1H) , 7.84 (s, 1H) , 7.60 (d, J = 5.2 Hz, 1H) , 7.43 (s, 1H) , 7.21 (d, J = 8.0 Hz, 2H) , 6.95 (s, 1H) , 6.51 (d, J = 8.0 Hz, 2H) , 3.84 (s, 3H) , 3.64 (s, 2H) , 3.45 (dt, J = 11.3, 6.3 Hz, 2H) , 3.26 (d, J = 6.3 Hz, 4H) , 2.97 (d, J = 29.6 Hz, 4H) , 2.46 -2.21 (m, 2H) , 2.02 -1.85 (m, 6H) , 1.29 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 599.51 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) piperidine-4-carbonitrile (185)
The title compound 185 (23 mg) was prepared in a yield of 27.6%as a white solid from compound 135-02 according to the procedure for compound 135. Mass (m/z) : 575.42 [M+H]
+.
Preparation of 5′-chloro-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -5-fluoro-2′-methoxy- [1, 1′-biphenyl] -3-carbonitrile (186)
The title compound 186 (3 mg) was prepared in a yield of 3.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.58 (d, J = 1.4 Hz, 1H) , 7.44 (ddd, J = 9.4, 2.6, 1.5 Hz, 1H) , 7.39 (s, 1H) , 7.33 (ddd, J = 7.8, 2.6, 1.4 Hz, 1H) , 7.16 (d, J = 8.1 Hz, 2H) , 6.91 (s, 1H) , 6.54 -6.48 (m, 2H) , 3.82 (s, 3H) , 3.59 -3.50 (m, 2H) , 3.42 (tt, J = 14.3, 7.3 Hz, 2H) , 3.30 -3.23 (m, 4H) , 2.90- (m, 4H) , 2.24-2.08 (m, 2H) , 2.02 -1.96 (m, 4H) , 1.92 -1.82 (m, 2H) , 1.28 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 616.26 [M+H]
+.
Preparation of 5- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3-methoxypyridin-2-yl) -2-fluorobenzonitrile (187)
The title compound 187 (10.2 mg) was prepared in a yield of 11.4%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.37 -8.32 (m, 1H) , 8.29 (dddd, J = 8.8, 5.2, 2.3, 0.8 Hz, 1H) , 7.33 (d, J = 0.8 Hz, 1H) , 7.29 (d, J = 8.8 Hz, 1H) , 7.18 (d, J = 8.2 Hz, 2H) , 6.53 (d, J = 8.3 Hz, 2H) , 3.94 (s, 3H) , 3.56 -3.36 (m, 4H) , 3.31 -3.24 (m, 4H) , 2.96 -2.73 (m, 4H) , 2.24 -2.11 (m, 2H) , 2.01 -1.99 (m, 4H) , 1.94 -1.83 (m, 2H) , 1.30 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 617.23 [M+H]
+.
Preparation of 3′-chloro-6-ethoxy-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -5-fluoro- [1, 1′-biphenyl] -3-carbonitrile (188)
The title compound 188 (19 mg) was prepared in a yield of 20.8%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.72 -7.65 (m, 1H) , 7.52 -7.48 (m, 1H) , 7.47 -7.36 (m, 2H) , 7.18 (d, J = 8.8 Hz, 2H) , 6.59 -6.50 (m, 2H) , 4.13 (qd, J = 7.2, 2.0 Hz, 2H) , 3.66 -3.35 (m, 4H) , 3.32 -3.23 (m, 4H) , 2.98 -2.77 (m, 4H) , 2.19 (m, 2H) , 2.08 -1.95 (m, 4H) , 1.95 -1.82 (m, 2H) , 1.28 -1.20 (m, 6H) . Mass (m/z) : 630.23 [M+H]
+.
Preparation of 3′-chloro-6-ethoxy-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -4-fluoro- [1, 1′-biphenyl] -3-carbonitrile (189)
The title compound 189 (46 mg) was prepared in a yield of 32.8%as a white solid from compound 135-02 (77mg, 0.14mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.61 (s, 1H) , 7.50 (d, J = 7.2 Hz, 1H) , 7.47 -7.39 (m, 1H) , 7.35 (dd, J = 8.4, 2.8 Hz, 1H) , 7.18 (d, J = 8.0 Hz, 2H) , 6.80 -6.75 (m, 1H) , 6.52 (d, J = 8.0 Hz, 2H) , 4.10 (q, J = 6.8 Hz, 2H) , 3.53 (s, 2H) , 3.48 -3.36 (m, 2H) , 3.32 -3.26 (m, 4H) , 2.94 -2.74 (m, 4H) , 2.16 (m, 2H) , 2.06 -1.94 (m, 4H) , 1.87 (t, J = 14.0 Hz, 2H) , 1.41 (t, J = 6.8 Hz, 3H) , 1.29 (t, J = 6.8 Hz, 3H) . Mass (m/z) : 630.41 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3-methoxypyridin-2-yl) benzonitrile (190)
The title compound 190 (30 mg) was prepared in a yield of 34.5%as a white solid according to the procedure for compound 97.
1H NMR (400 MHz, CDCl
3) δ 8.86 (dd, J = 4.9, 0.9 Hz, 1H) , 8.22 -8.19 (m, 1H) , 8.11 (d, J = 0.8 Hz, 1H) , 7.48 -7.44 (m, 1H) , 7.23 -7.14 (m, 2H) , 6.97 (s, 1H) , 6.53 (d, J = 8.4 Hz, 2H) , 3.93 (d, J = 0.8 Hz, 3H) , 3.48 (d, J = 0.8 Hz, 4H) , 3.27 (td, J = 5.4, 4.2, 2.0 Hz, 4H) , 2.92 (td, J = 18.0, 15.7, 9.0 Hz, 4H) , 2.23 -2.07 (m, 2H) , 2.03 -1.98 (m, 4H) , 1.89 (t, J = 12.1 Hz, 2H) , 1.31 (t, 3H) . Mass (m/z) : 599.40 [M+H]
+.
Preparation of 2- (5-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2-methoxyphenyl) isonicotinonitrile (191)
The title compound 191 (4 mg) was prepared in a yield of 3.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.86 (dd, J = 4.9, 1.0 Hz, 1H) , 8.20 (dd, J = 1.5, 1.0 Hz, 1H) , 8.12 (s, 1H) , 7.73 -7.51 (m, 1H) , 7.46 (dd, J = 5.0, 1.5 Hz, 1H) , 7.22 -7.13 (m, 1H) , 6.96 (s, 1H) , 6.53 (d, J = 8.6 Hz, 2H) , 3.93 (s, 3H) , 3.46 (dt, J = 10.6, 6.0 Hz, 4H) , 3.31 -3.25 (m, 4H) , 3.15 -2.76 (m, 4H) , 2.17 (s, 2H) , 2.02 -1.97 (m, 4H) , 1.94 -1.87 (m, 2H) , 1.31 (t, 3H) . Mass (m/z) : 599.26 [M+H]
+.
Preparation of 3- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -3-methoxypyridin-2-yl) -5-fluorobenzonitrile (192)
The title compound 192 (32.5mg) was prepared in a yield of 36.0%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.18 (q, J = 1.3 Hz, 1H) , 8.03 (ddt, J = 9.9, 2.6, 1.3 Hz, 1H) , 7.40 -7.35 (m, 2H) , 7.20 -7.14 (m, 2H) , 6.54 -6.49 (m, 2H) , 3.95 (d, J = 1.1 Hz, 3H) , 3.52 (s, 2H) , 3.41 (dddd, J = 25.3, 14.5, 7.3, 1.1 Hz, 2H) , 3.31 -3.23 (m, 4H) , 2.95 -2.84 (m, 2H) , 2.83 -2.71 (m, 2H) , 2.15 (td, J = 14.0, 13.2, 7.2 Hz, 2H) , 1.99 -1.97 (m, 4H) , 1.94 -1.83 (m, 2H) , 1.32 -1.27 (m, 3H) . Mass (m/z) : 617.30 [M+H]
+.
Preparation of 3- (4-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -4-ethoxybenzonitrile (193)
The title compound 193 (46 mg) was prepared in a yield of 33.8%as a white solid from compound 135-02 (130mg, 0.38 mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.58 (s, 1H) , 8.30 -8.22 (m, 1H) , 8.15 (s, 1H) , 7.69 -7.65 (m, 1H) , 7.18 (d, J = 8.0 Hz, 2H) , 7.04 (d, J = 8.4 Hz, 1H) , 6.57 -6.47 (m, 2H) , 4.29 -4.13 (m, 2H) , 3.62 -3.35 (m, 4H) , 3.33 -3.26 (m, 4H) , 2.94 -2.79 (m, 4H) , 2.16 (m, 2H) , 2.01 -1.98 (m, 4H) , 1.89 (t, J = 14.4 Hz, 2H) , 1.49 (t, J = 6.8 Hz, 3H) , 1.31 (t, J = 6.8 Hz, 3H) . Mass (m/z) : 630.27 [M+H]
+.
Preparation of 5- (6-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -4-ethoxy-2-fluorobenzonitrile (194)
The title compound 194 (113 mg) was prepared in a yield of 42.1%as a white solid from compound 135-02 (147mg, 0.43mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.24 (d, J = 8.0 Hz, 1H) , 7.96 (d, J = 8.0 Hz, 1H) , 7.70 (dd, J = 8.0, 0.8 Hz, 1H) , 7.22-7.19 (m, 2H) , 6.81 (d, J = 10.8 Hz, 1H) , 6.53 (d, J = 8.4 Hz, 2H) , 4.18 (q, J = 6.8 Hz, 2H) , 3.60 -3.36 (m, 4H) , 3.30 -3.26 (m, 4H) , 2.95 -2.80 (m, 2H) , 2.14 (m, 2H) , 2.05 -1.96 (m, 4H) , 1.93 -1.83 (m, 2H) , 1.49 (t, J = 7.2 Hz, 3H) , 1.30 (t, J = 7.2 Hz, 3H) . Mass (m/z) : 631.49 [M+H]
+.
Preparation of 5′-chloro-6-ethoxy-2′-ethynyl-4′- (1- (2- (3-methyl-3H-diazirin-3-yl) ethyl) -2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) - [1, 1′-biphenyl] -3-carbonitrile (195)
The title compound 195 was prepared according to the procedure for compound 97 (the last 3 steps) . Mass (m/z) : 690.40 [M+H]
+.
Preparation of 4- (4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) piperidin-1-yl) benzonitrile (196)
The title compound 196 (1.2mg) was prepared in a yield of 2.0%as a white solid according to the procedure for compound 97 (the last 3 steps) .
1H NMR (400 MHz, CDCl
3) δ 7.47 (dd, J = 9.0, 1.3 Hz, 2H) , 7.16 (d, J = 8.0 Hz, 2H) , 6.84 (dd, J = 9.1, 1.2 Hz, 2H) , 6.55 -6.48 (m, 2H) , 4.12 (tt, J = 12.3, 4.2 Hz, 1H) , 3.94 (d, J = 13.2 Hz, 2H) , 3.49 (s, 2H) , 3.35 -3.22 (m, 6H) , 2.99 -2.88 (m, 2H) , 2.75 (d, J = 34.3 Hz, 4H) , 2.48 (qd, J = 12.4, 4.1 Hz, 2H) , 1.99 (tt, J = 4.0, 2.0 Hz, 6H) , 1.78 -1.57 (m, 4H) , 1.19 (t, 3H) . Mass (m/z) : 541.43 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) -1H-imidazole-4-carbonitrile (197)
The title compound 197 (47.3mg) was prepared in a yield of 80.8%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.84 (d, J = 14.9 Hz, 2H) , 7.60 -7.55 (m, 1H) , 7.47 (dd, J = 8.5, 1.1 Hz, 1H) , 7.39 (dt, J = 8.5, 1.7 Hz, 1H) , 7.17 (d, J = 8.0 Hz, 2H) , 6.51 (d, J = 8.2 Hz, 2H) , 3.54 (s, 2H) , 3.42 (tt, J = 14.2, 7.3 Hz, 2H) , 3.24 (d, J = 6.4 Hz, 4H) , 3.01 -2.70 (m, 4H) , 2.17 (d, J = 19.9 Hz, 2H) , 2.04 -1.93 (m, 4H) , 1.86 (d, J = 13.3 Hz, 2H) , 1.28 (t, J = 7.0 Hz, 3H) . Mass (m/z) : 558.39 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) -1H-pyrazole-4-carbonitrile (198)
The title compound 198 (24 mg) was prepared in a yield of 29.7%as a white solid from compound 135-02 according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.36 (s, 1H) , 7.97 (s, 1H) , 7.87 (d, J = 2.4 Hz, 1H) , 7.63 (dd, J = 8.6, 2.5 Hz, 1H) , 7.40 (d, J = 8.6 Hz, 1H) , 7.19 (d, J = 8.1 Hz, 2H) , 6.52 (d, J = 8.2 Hz, 2H) , 3.57 (s, 2H) , 3.50 -3.35 (m, 2H) , 3.30 -3.22 (m, 4H) , 2.94 (d, J = 10.9 Hz, 2H) , 2.84 (q, J = 11.3 Hz, 2H) , 2.27 (d, J = 14.2 Hz, 2H) , 2.03 -1.93 (m, 4H) , 1.92 -1.82 (m, 2H) , 1.29 (t, J = 7.1 Hz, 3H) . Mass (m/z) : 558.42 [M+H]
+.
Preparation of 1- (3-chloro-4- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) phenyl) pyrrolidine-3-carbonitrile (199)
The title compound 199 was prepared in a yield of 36.9%as a yellow solid from compound 135-02 according to the procedure for compound 135. Mass (m/z) : 561.67 [M+H]
+
Preparation of 5′-chloro-6-ethoxy-4′- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) -2′-fluoro- [1, 1′-biphenyl] -3-carbonitrile (200)
The title compound 200 (254 mg) was prepared in a yield of 52.0%as a white solid from compound 135-02 (147mg, 0.43mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 7.69-7.65 (m, 1H) , 7.584-7.47 (m, 2H) , 7.18 -7.14 (m, 3H) , 7.03 -7.00 (m, 1H) , 6.54 -6.51 (m, 2H) , 4.15 -4.06 (m, 2H) , 3.53 (s, 2H) , 3.48 -3.35 (m, 2H) , 3.29 -3.25 (m, 4H) , 2.94 -2.75 (m, 4H) , 2.16 (m, 2H) , 2.10 -1.97 (m, 4H) , 1.86 (t, J = 12.6 Hz, 2H) , 1.38 -1.24 (m, 6H) . Mass (m/z) : 630.41 [M+H]
+
Preparation of 5- (4-chloro-5- (1-ethyl-2, 4-dioxo-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decan-3-yl) pyridin-2-yl) -4-ethoxy-2-fluorobenzonitrile (201)
The title compound 201 (187 mg) was prepared in a yield of 48.3%as light yellow solid from compound 135-02 (212mg, 0.61mmol) according to the procedure for compound 135.
1H NMR (400 MHz, CDCl
3) δ 8.56 (s, 1H) , 8.26 (dd, J = 7.6, 2.0 Hz, 1H) , 8.09 (d, J = 2.0 Hz, 1H) , 7.23 -7.11 (m, 2H) , 6.81 (d, J = 10.8 Hz, 1H) , 6.60 -6.44 (m, 2H) , 4.26 -4.11 (m, 2H) , 3.61 (s, 2H) , 3.45 (s, 2H) , 3.27 (d, J = 6.1 Hz, 4H) , 3.10 -2.74 (m, 4H) , 2.34-2.10 (m, 2H) , 2.04 -1.80 (m, 6H) , 1.56 -1.43 (m, 3H) , 1.37 -1.26 (m, 3H) . Mass (m/z) : 631.49 [M+H]
+.
Example: A small molecule protects mitochondrial integrity by inhibiting mTOR activity:
Abstract. Apoptosis activation by cytochrome c release from mitochondria to cytosol is a normal cellular response to mitochondrial damage. Using cellular apoptosis assay, we have found small molecule apoptosis inhibitors that protect cells from mitochondrial damage. Previously, we reported the discovery of a small molecule, Compound A, which blocks dopaminergic neuron death in a rat model of Parkinson’s disease through targeting succinate dehydrogenase subunit B (SDHB) of complex II to protect the integrity of the mitochondrial respiratory chain. Here, we report a novel small molecule, Compound R6, which saves cells from apoptosis via mTOR-mediated induction of autophagy. Additionally, we show that Compound R6 protects mitochondrial integrity and respiration after induction of the intrinsic apoptosis pathway. Encouragingly, and supporting the potential further application of Compound R6 as a tool for basic and medicinal research, a pharmacokinetics (PK) profiling study showed that Compound R6 is metabolically stable and can pass the blood brain barrier. Moreover, Compound R6 accumulates in the brain of test animals via intravenous (IV) and intraperitoneal (IP) administration. Finally, we found that Compound R6 confers significant neuro-protective effects on a rat cerebral ischemia/reperfusion model, demonstrating its potential as a promising drug candidate for neurodegenerative diseases.
Introduction. Mitochondria in mammalian cells play many functional roles in maintaining the well being of the organism, acting as the major bio-energy source, as well as a signaling compartment that can trigger apoptosis and inflammation (1, 2) . Upon damage to mitochondria, intermembrane proteins are released into the cytosol. One such protein, cytochrome c, is able to initiate an apoptotic caspase-9/3 activation cascade, causing apoptotic cell death (3, 4) . The release of cytochrome c during apoptosis is controlled by the Bcl-2 family of proteins that come in three known flavors: the mitochondrial outer membrane gate-keepers Bax and Bak; the anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1 hetero-dimerize with Bax or Bak, and prevent them from forming oligomers on the mitochondria and altering mitochondrial outer membrane permeability; and the so-called BH-3-only proteins like Bim or tBid, which free Bax/Bak from Bcl-2/Bcl-xL/Mcl-1 by competitively binding to them (5, 6) .
Our laboratory has been using the Bim protein driven by a doxycycline (Dox) -inducible promoter to specifically induce mitochondrial damage in U2OS cells (7) . Upon addition of Dox to the culture medium, Bim is induced and the cells undergo apoptosis in a Bax/Bak-dependent manner. Using this system, we have identified the mitochondrial inner membrane protein OpaI, a dynamin-related GTPase for which loss of function mutations cause optical nerve atrophy, as well as the mitochondrial inner membrane protease OmaI, which cleaves OpaI upon Bax/Bak oligomerization, are important mediators of apoptosis that cause the mitochondrial cristae dilation to facilitate the release of cytochrome c from mitochondria.
In addition to OpaI and OmaI, we also identified a small molecule compound, 1- (3, 4-dimethoxybenzyl) -5- (2- (methylsulfonyl) -6- (trifluoromethyl) pyrimidin-4-yl) pyridin-2 (1H) -one, named Compound A, that protects U2OS cells from Bim-induced apoptosis by covalently interacting with the a subunit of the mitochondrial electron transfer chain Complex II: component succinate dehydrogenase B (SDHB) (8) .
In this example we report the identification of a novel compound that specifically blocks Bim-induced apoptosis. Unlike Compound A, this compound is not a covalent modifier; it blocks apoptosis through mTOR-mediated induction of autophagy. Moreover, this compound shows significant neuro-protective effects in a rat cerebral ischemia/reperfusion model, and together with its ability to pass the blood brain barrier and accumulate in the brain via both IV and IP administration, provides a promising treatment for neurodegenerative diseases.
A small molecule blocks Bim-induced intrinsic apoptosis
The U2OS_Bim cell line that we previously established responds to the addition of doxycycline (Dox) by undergoing apoptosis within a few hours (7) . The addition of Dox induces the expression of Bim (henceforth Bim is referred to as BimEL, unless otherwise stated) , which subsequently activates the intrinsic apoptosis pathway in this cell line. A chemical library of ~50,000 compounds was screened for hits that could inhibit Dox-induced apoptosis in these U2OS_Bim cells. One of the hits, 3- (2, 3-dihydro-1H-inden-2-yl) -1-ethyl-8- (4- (pyrrolidin-1-yl) benzyl) -1, 3, 8-triazaspiro [4.5] decane-2, 4-dione, hereafter named Compound R6, had a half-maximal inhibitory concentration (IC50) around 207.6nM. Compound R6, when present in the culture medium alongside Dox, blocked the release of cytochrome c from mitochondria and the subsequent activation of caspase-9, which is the well-characterized initiator caspase of the intrinsic apoptosis pathway.
Unlike our previously reported apoptosis inhibitor Compound A (8) , Compound R6 prevented the Bax protein from oligomerizing on the mitochondrial outer membrane, as analyzed by blue native gel electrophoresis. This result clearly indicates that Compound R6 functions upstream of any mitochondrial damage. Similar to Compound A, this compound protected the normal function of the mitochondria respiratory chain as measured by oxygen consumption.
Another similarity with compound A is that the presence of Compound R6 also enabled Dox-treated cells to continue to proliferate. This capacity of Compound R6 to preserve cell proliferation contrasts with the well-known pan-caspase inhibitor z-VAD-FMK (zVAD) , which acts downstream of mitochondrial damage and cannot prevent cells from eventual death even the apoptotic morphological changes were abolished. Compound R6′s preservation of long-term cell viability was further confirmed in colony-formation assays. U2OS_Bim cells readily formed cell colonies on the culture dish after one week of culture with continuous co-treatment of Compound R6 and Dox, whereas hardly any colonies formed in cells with co-treatment of DMSO or zVAD and Dox. All of these results indicate that Compound R6 functions upstream of mitochondrial damage after Bim-induction.
Compound R6 prevents apoptosis by inhibiting mTOR and activating autophagy
The unique ability of Compound R6 to prevent apoptosis upstream of Bax/Bak activation promoted us to investigate additional signaling pathways which may influence activation of the intrinsic apoptosis pathway. Interestingly, we noticed that Compound R6 was able to block phosphorylation of the threonine 389 residue of the ribosomal protein S6 kinase (S6K) , a classical substrate of mTOR kinase (9-11) . Moreover, this inhibition of mTOR does not seem to result from alteration of its upstream signaling events: we found no evidence for such inhibition of the activity of its upstream kinase Akt. Nevertheless, a direct functional contribution of mTOR inhibition to block apoptosis was confirmed when we knocked down mTOR with two independent siRNA oligos, which showed that restricting mTOR activity promoted cell viability upon Dox treatment. Importantly, these experiments also showed treatment of mTOR knockdown cells with Compound R6 does not further increase these protective effects. Moreover, the addition the well-known mTOR inhibitor Rapamycin provided a similar level of protection as did mTOR knockdown and/or treatment with Compound R6 (12, 13) .
To expand the scope of our search for how mTOR inhibition of Compound R6 could lead to blocking of the intrinsic apoptosis pathway, we investigated if Compound R6 affects the activity of autophagy, an activity known to be activated by mTOR inhibition (14) . We monitored the cellular levels of the classic autophagy activity marker LC3-II in Compound R6-treated cells, and found that Compound R6 treatment induced accumulation of LC3-II. Also, the protective effects of Compound R6 were significantly diminished upon co-treatment with the autophagy inhibitor 3-MA or chloroquine (CQ) (15) , a finding that confirms compound R6 blocks apoptosis through induction of autophagy by inhibiting mTOR.
Compound R6 also inhibits intrinsic apoptosis specifically induced by serum withdrawal plus a Bcl-2/Bcl-xL dual inhibitor
To explore if autophagy induction by Compound R6 has general protection effects against intrinsic apoptosis, we used another intrinsic apoptosis induction system to test Compound R6. We initially confirmed that ABT263, a small molecule Bcl-2/Bcl-xL dual inhibitor, can induce intrinsic apoptosis in serum withdrawal conditions in U2OS cells. As expected, Compound R6 prevented apoptosis upstream of mitochondrial damage (16-18) . Specifically, we observed that Compound R6 protected mitochondrial integrity upstream of Bax/Bak oligomerization, and it did not block cell proliferation-cells continued to grow when we added serum back to the medium after treatment. Moreover, when we applied similar treatments to other cell lines including HeLa cells and mouse embryonic fibroblasts (MEF) , we again found that Compound R6 blocked apoptosis, clearly indicating that the protective effect of Compound R6 is general in mammalian cells.
Next we confirmed that Compound R6 also protected cells from apoptosis through autophagy induction by mTOR inhibition in this condition: Compound R6 could decrease the phosphorylation of S6K and increase the accumulation of LC3-II, and we observed that autophagy inhibitor 3-MA or CQ could diminish this protective effect from Compound R6. Moreover, there are 4 compounds which share structural similarity with Compound R6 that also showed apoptosis inhibition ability during the initial compound screen:
We again tested these four analogs and found that they could also inhibit mTOR and up-regulate LC3-II accumulation; and co-treatment with 3-MA diminish the protective effect of each of them. The consistency of these compounds’ behavior on autophagy induction and apoptosis inhibition confirms Compound R6’s capacity to block apoptosis through mTOR inhibition-mediated autophagy induction.
Compound R6 has protective effect against neuronal injury in a rat model of transient focal cerebral ischemia/reperfusion injury
To explore the potential of Compound R6 as a drug lead, we profiled its IP/IV pharmacokinetics (PK) , which revealed that its IP T1/2 was 6.36 hours and its bioavailability (F%) was near 100%, results clearly underscoring Compound R6′s apparent metabolic stability. Strikingly, these analyses also found that Compound R6 can pass the blood brain barrier. Moreover, we observed that Compound R6 accumulated in the brain upon both IV and IP administration, indicating that Compound R6 provides a promising drug lead for multiple brain diseases with mitochondrial-damage-related etiologies.
One such disease is cerebral ischemia followed by reperfusion, which is caused by the loss of available oxygen resulting from temporary blockage of blood flow to certain parts of the brain. The exceptional pharmacological properties of Compound R6 allowed us to test its effect in a rat ischemic/reperfusion model wherein ischemia is caused by occlusion of the rat’s left-side middle cerebral artery (MCA) using a nylon suture; the subsequent reperfusion results from removal of the suture 1 hour later (19-21) . This ischemia/reperfusion injury caused severe damage to the left side of the rats’ brain, as shown by the infarct area in the control group. Treatment of Compound R6 by IP administration at 12.5 or 25 mg/kg doses before the surgery significantly, and dose-dependently, decreased brain infarct volumes. When the brain tissues were harvested from the vehicle or Compound R6-treated animals with ischemia/reperfusion injury and subjected to western blotting analysis using anti-LC3 antibody, we noticed the increase of LC3-II levels in the Compound R6-treated animals, indicating that autophagy was indeed induced by the compound.
Transient focal cerebral ischemia/reperfusion injury: We modified the procedure described in ref. 20. Briefly, male Sprague Dawley rats (weight 230-250 g) were given Compound R6 by IP injection and then anesthetized with 2%isoflurane. The left common, external, and internal carotid arteries (CCA, ECA, and ICA) were exposed. A 4-0 monofilament nylon suture with a silicon-coated tip was introduced through an incision of the ECA into the ICA to occlude the origin of the middle cerebral artery for 1 hr. Animals were sacrificed 24 hr later. Brains were removed and sliced into sections of 2 mm thickness. Infarct size was examined via staining with 1.5 %2, 3, 5-triphenyltetrazolium chloride (TTC) at 37℃ for 10min.
A compound blocks the mitochondrial pathway of apoptosis by inhibiting mTOR
Our study demonstrated that Compound R6 inhibits the mitochondrial pathway of apoptosis. In addition to our results for the U2O2_Bim cell line that we used for the initial screening, we also confirmed that Compound R6 can block apoptosis induced by serum withdrawal plus the addition of the Bcl-2/Bcl-xL inhibitor ABT263 in a variety of mammalian cell lines. We determined that Compound R6′s protective effects are exerted upstream of mitochondria damage, since Bax oligomerization was prevented in the presence of R6.
Compound R6 as a drug for neurodegenerative diseases
Compound R6 possesses unusual and potentially highly attractive pharmacological properties. In addition to its good pharmacodynamics properties, it passes the blood brain barrier readily and accumulates in the brain tissue after both IV and IP administration. Compound R6 showed significant protective effects by decreasing the brain infarct volume in a rat cerebral ischemia/reperfusion injury model. Mitochondrial damage is known to increase during the normal aging process and is also a common feature of many neurodegenerative diseases. R6, and its analogs provide therapeutic benefits for such diseases and for aging-related effects.
REFERENCES
1. Balaban RS, et al. (2005) Mitochondria, oxidants, and aging. cell 120 (4) : 483-495.
2. Wang X (2001) The expanding role of mitochondria in apoptosis. Genes & development 15 (22) : 2922-2933.
3. Li P, et al. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (4) : 479-489.
4. Liu X, Kim CN, Yang J, Jemmerson R, & Wang X (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1) : 147-157.
5. Czabotar PE, et al. (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology 15 (1) : 49.
6. Annis MG, et al. (2005) Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. The EMBO journal 24 (12) : 2096-2103.
7. Jiang X, Jiang H, Shen Z, & Wang X (2014) Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis. PNAS 111 (41) : 14782-14787.
8. Jiang X, et al. (2016) A small molecule that protects the integrity of the electron transfer chain blocks the mitochondrial apoptotic pathway. Molecular cell 63 (2) : 229-239.
9. Pullen N & Thomas G (1997) The modular phosphorylation and activation of p70s6k. FEBS letters 410 (1) : 78-82.
10. Laplante M (2012) mTOR signaling in growth control and disease. Cell 149 (2) : 274-293.
11. Ramanathan A & Schreiber SL (2009) Direct control of mitochondrial function by mTOR. Proceedings of the National Academy of Sciences 106 (52) : 22229-22232.
12. Brown EJ, et al. (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature369 (6483) : 756.
13. Sabatini DM, et al. (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78 (1) : 35-43.
14. Jung CH, Ro S-H, Cao J, Otto NM, & Kim D-H (2010) mTOR regulation of autophagy. FEBS letters 584 (7) : 1287-1295.
15. Tanida I, Ueno T, & Kominami E (2008) LC3 and Autophagy. Autophagosome and Phagosome, (Springer) , pp 77-88.
16. Ley R, et al. (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation.... JBC 278 (21) : 18811-18816.
17. Tse C, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer research 68 (9) : 3421-3428.
18. Vartak SV, et al. (2017) Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction. Biochemical pharmacology 131: 16-28.
19. Lin MT & Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (7113) : 787.
20. Li L, et al. (2017) Discovery of highly potent 2-sulfonyl-pyrimidinyl derivatives for apoptosis inhibition and ischemia treatment. ACS medicinal chemistry letters 8 (4) : 407-412.
21. Putcha GV, et al. (2001) Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 29 (3) : 615-628.
Claims (10)
- A compound of formula I, or a salt, hydrate or stereosomer thereof:wherein:R1 is substituted or unsubstituted, 0-3 heteroatom C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl; or substituted or unsubstituted, 0-3 heteroatom C5-C14 aryl;R2 is substituted or unsubstituted phenyl; andR3 is H, substituted or unsubstituted, 0-3 heteroatom hydrocarbyl.
- The compound of claim 1 wherein:R1 is substituted or unsubstituted: phenyl, biphenyl or 2, 3-dihydro-indenyl.
- The compound of claim 1 wherein:R2 is 4- (pyrrolidin-1-yl) phenyl.
- The compound of claim 1 wherein:R3 is substituted or unsubstituted ethyl.
- The compound of claim 1 wherein:R1 is substituted or unsubstituted: phenyl, biphenyl or 2, 3-dihydro-indenyl;R2 is 4- (pyrrolidin-1-yl) phenyl; andR3 is substituted or unsubstituted ethyl.
- The compound of claim 1 having a structure of Table 1.
- A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, 2, 3, 4, 5 or 6 and one or more pharmaceutically acceptable excipients, in predetermined, unit dosage form.
- Use of a compound of claim 1, 2, 3, 4, 5 or 6 herein in the manufacture of a medicament to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof.
- A compound of claim 1, 2, 3, 4, 5 or 6 to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, in a person in need thereof, or in the manufacture of a medicament thereof in a person in need thereof.
- A method of using a compound of claim 1, 2, 3, 4, 5 or 6 to inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, and optionally detecting a resultant improvement in the person’s health or condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2019/112228 | 2019-10-21 | ||
CN2019112228 | 2019-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021078132A1 true WO2021078132A1 (en) | 2021-04-29 |
Family
ID=75619635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/122341 WO2021078132A1 (en) | 2019-10-21 | 2020-10-21 | Inhibitors of mtor-mediated induction of autophagy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021078132A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024092043A1 (en) * | 2022-10-26 | 2024-05-02 | Protego Biopharma, Inc. | Spirocycle containing pyridine compounds |
WO2024092037A1 (en) * | 2022-10-26 | 2024-05-02 | Protego Biopharma, Inc. | Spirocycle containing pyridone compounds |
WO2024107434A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
WO2024105007A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050039A2 (en) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
CN102459278A (en) * | 2009-06-16 | 2012-05-16 | 默沙东公司 | Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones |
-
2020
- 2020-10-21 WO PCT/CN2020/122341 patent/WO2021078132A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050039A2 (en) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
CN102459278A (en) * | 2009-06-16 | 2012-05-16 | 默沙东公司 | Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024092043A1 (en) * | 2022-10-26 | 2024-05-02 | Protego Biopharma, Inc. | Spirocycle containing pyridine compounds |
WO2024092037A1 (en) * | 2022-10-26 | 2024-05-02 | Protego Biopharma, Inc. | Spirocycle containing pyridone compounds |
WO2024107434A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
WO2024105007A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021078132A1 (en) | Inhibitors of mtor-mediated induction of autophagy | |
JP6423372B2 (en) | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | |
TWI352084B (en) | Gsk-3 inhibitors | |
US11851428B2 (en) | Activator of TREK (TWIK RElated K+channels) channels | |
CN112312904A (en) | Spiro compounds | |
WO2014066726A2 (en) | Compounds for modulating il-17 | |
CN108699055A (en) | Heterocyclic compound as anticancer drug | |
BR112014030284B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND OR PHARMACEUTICAL COMPOSITION | |
TW200936140A (en) | Substituted arylamide oxazepinopyrimidone derivatives | |
WO2019014303A1 (en) | Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure | |
AU2019384283B2 (en) | RIP1 inhibitors | |
US11591319B2 (en) | Small molecule inducers of autophagy | |
WO2017083756A1 (en) | Heterocyclic compounds for the treatment of disease | |
WO2015110077A1 (en) | Crystal form α of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same | |
US20230391765A1 (en) | Heterobifunctional compounds as degraders of enl | |
WO2017207340A1 (en) | Novel substituted benzimidazole, methods for the production thereof, pharmaceutical preparations containing same, and use thereof to produce medicaments | |
WO2020001392A1 (en) | Cathepsin c inhibitors | |
CA3196153A1 (en) | Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals | |
AU2021296681A1 (en) | Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same | |
WO2016127455A1 (en) | Pyrimidine derivative, cytotoxic agent, pharmaceutical composition and use thereof | |
EP4072670B1 (en) | Quinazoline derivatives as lpa receptor 2 inhibitors | |
WO2021233394A1 (en) | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | |
WO2023072026A1 (en) | Sarm1 modulators, preparations, and uses thereof | |
WO2021189036A1 (en) | Taf1 inhibitors | |
WO2018045907A1 (en) | Novel 2-acylaminothiazole derivative and preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20878696 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20878696 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20878696 Country of ref document: EP Kind code of ref document: A1 |